

CUMULATIVE
SUPPLEMENT 10
OCTOBER 2003



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23rd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

search

HYMAN, PHELPS
&MCNAMARA, P.C.
WASHINGTON, DC

DEMCO

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23RD EDITION

Cumulative Supplement 10

October 2003

CONTENTS

	PAGE
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Nitroglycerin, Film, Extended Release; Transdermal 23 rd Annual Edition	v
1.4 NDA Patent 30-month Rule	vi
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23rd EDITION

**CUMULATIVE SUPPLEMENT 10
October 2003**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 23rd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)

AAIPHARMA INC
(AAIPHARMA)
BAYER CORP
(BAYER)
BAYER CORP CONSUMER CARE DIV
(BAYER CORP CONSUMER)
BAYER CORP PHARMACEUTICALS DIV
(BAYER)
ESI LEDERLE INC
(ESI LEDERLE)
LEK SERVICES INC
(LEK SVCS)
LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO
(LEK LJUBLJANA)
LEK PHARMACEUTICAL AND CHEMICAL DD
(LEK PHARM)
NEOSAN PHARMACEUTICALS
(NEOSAN PHARMS)
ORGANON INC
(ORGANON INC)
ORGANON INC SUB AKZO INC
(ORGANON)
ORGANON INC SUB AKZO NOBEL INC
(ORGANON INC)
SIDMAK LABORATORIES INC
(SIDMAK LABS)
SYNTEX (USA) INC LLC
(SYNTEX USA INC)
WALLACE LABORATORIES DIV CARTER WALLACE INC
(WALLACE LABS)

WALLACE PHARMACEUTICALS DIV CARTER WALLACE INC
(WALLACE PHARMS)

NEW APPLICANT NAME (NEW ABBREVIATED NAME)

AAIPHARMA LLC
(AAIPHARMA LLC)
BAYER PHARMACEUTICALS CORP
(BAYER PHARMS)
BAYER CORP CONSUMER CARE LLC
(BAYER)
BAYER PHARMACEUTICALS CORP
(BAYER PHARMS)
CLONMEL HEALTHCARE INC
(CLONMEL HEALTHCARE)
LEK PHARMACEUTICALS DD
(LEK PHARM DD)
LEK PHARMACEUTICALS DD
(LEK PHARM DD)
LEK PHARMACEUTICALS DD
(LEK PHARM DD)
AAIPHARMA LLC
(AAIPHARMA LLC)
ORGANON USA INC
(ORGANON USA INC)
ORGANON USA INC
(ORGANON USA INC)
ORGANON USA INC
(ORGANON USA INC)
PLIVA INC
(PLIVA)
ROCHE PALO ALTO LLC
(ROCHE PALO)
MEDPOINTE PHARMACEUTICALS MEDPOINTE
HEALTHCARE INC
(MEDPOINTE PHARM HLC)
MEDPOINTE PHARMACEUTICALS MEDPOINTE
HEALTHCARE INC
(MEDPOINTE PHARM HLC)

1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL 23RD ANNUAL EDITION

The *Approved Drug Products with Therapeutic Equivalence Evaluations 23rd annual edition*, page 3-265 omitted the 3 character Therapeutic Equivalence (TE) Codes for Nitroglycerin, Film, Extended Release; Transdermal products. The correct codes are listed below by product name, applicant holder, TE code, strength, NDA number, and product number.

PRODUCT <u>NAME</u>	APPLICANT	TE CODE	STRENGTH	NDA	PRODUCT
MINITRAN	3M	AB1	0.1MG/HR	N89771	001
MINITRAN	3M	AB1	0.2MG/HR	N89772	001
MINITRAN	3M	AB1	0.4MG/HR	N89773	001
MINITRAN	3M	AB1	0.6MG/HR	N89774	001
NITRO-DUR	KEY PHARMS	AB1	0.1MG/HR	N20145	001
NITRO-DUR	KEY PHARMS	AB1	0.2MG/HR	N20145	002
NITRO-DUR	KEY PHARMS	AB1	0.4MG/HR	N20145	004
NITRO-DUR	KEY PHARMS	AB1	0.6MG/HR	N20145	005
NITROGLYCERIN	HERCON LABS	AB2	0.2MG/HR	N89884	001
NITROGLYCERIN	HERCON LABS	AB2	0.4MG/HR	N89885	001
NITROGLYCERIN	HERCON LABS	AB2	0.6MG/HR	N89886	001

NITROGLYCERIN	MYLAN	AB2	0.1MG/HR	N75033	001
NITROGLYCERIN	MYLAN	AB2	0.2MG/HR	N74609	001
NITROGLYCERIN	MYLAN	AB2	0.4MG/HR	N74607	001

1.4 NDA PATENT 30-MONTH RULE

The Food and Drug Administration has amended its patent submission and listing requirements for new drug applications (NDAs). This final rule became effective on August 18, 2003. The final rule, among other things, limits to one per ANDA or 505(b)(2) application the maximum number of statutory 30-month stays of approval to which an innovator will be entitled when multiple patents are submitted for the same NDA.

Patents listed prior to August 18, 2003 will be designated by a "#" sign and are considered listed under the previous regulations that permitted multiple 30-month stays for an NDA. Patents listed after the effective date of the final rule will not have the # designation displayed and are considered listed under the new rule.

1.5 AVAILABILITY OF THE EDITION

The 23rd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$108.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
<http://www.fda.gov/cder/orange/adp.htm>

The Internet version of the monthly supplement is at
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>

There are ASCII text files of the Orange Book drug product data at
<http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe.

The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 23rd annual edition of the 2002 Orange Book Patent and Exclusivity List is at
<http://www.fda.gov/cder/orange/23bookpub.pdf>

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
<http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
<http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.htm>

The current listing of the Orphan Product Designations and Approvals is available at
<http://www.fda.gov/orphan/designat/list.htm>

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2002) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2002</u>	<u>JUN 2003</u>	<u>SEP 2003</u>	<u>DEC 2003</u>
DRUG PRODUCTS LISTED	10465	10514	10624	
SINGLE SOURCE	2420 (23.1%)	2417 (23.0%)	2406	
MULTISOURCE	7939 (75.9%)	7989 (76.0%)	8110	
THERAPEUTICALLY	7659 (73.2%)	7708 (73.3%)	7830 (73.7%)	
EQUIVALENT				
NOT THERAPEUTICALLY	280 (2.7%)	281 (2.7%)	280 (2.6%)	
EQUIVALENT				
EXCEPTIONS	106 (1.0%)	108 (1.0%)	108 (1.0%)	
NEW MOLECULAR ENTITIES	6	6	6	
APPROVED				
NUMBER OF APPLICANTS	598	604	602	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

- WDAG Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
- WDRP Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION; ORAL
ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE
+ MIKART 325MG/15ML;50MG/15ML;40MG/15ML N40387 001 JAN 31, 2003 JAN NEWA
TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
AB VINTAGE PHARMS 325MG;50MG;40MG N40511 001 AUG 27, 2003 AUG NEWA
AB 500MG;50MG;40MG N40513 001 AUG 25, 2003 AUG NEWA
BUTALBITAL, APAP, AND CAFFEINE
AB AXIOM PHARM 325MG;50MG;40MG N89536 001 FEB 16, 1988 MAY CAHN
ESGIC-PLUS
AB + MIKART 500MG;50MG;40MG N89451 001 MAY 23, 1988 AUG CTNA
FIORICET
AB + WATSON PHARMS 325MG;50MG;40MG N88616 001 NOV 09, 1984 APR CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL; ACETAMINOPHEN; CAFFEINE AND CODEINE PHOSPHATE
AB ABLE 325MG;50MG;40MG;30MG N76528 001 AUG 21, 2003 AUG NEWA
FIORICET W/ CODEINE
AB + WATSON PHARMS 325MG;50MG;40MG;30MG N20232 001 JUL 30, 1992 MAR CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL
PHENAPHEN W/ CODEINE NO. 3
@ ROBINS AH 325MG;30MG N84445 001 JUN DISC
PHENAPHEN W/ CODEINE NO. 4
@ ROBINS AH 325MG;60MG N84446 001 JUN DISC
TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPAHTE
AA ANDRX PHARMS 300MG;15MG N40443 001 JAN 22, 2003 JAN NEWA
AA 300MG;30MG N40443 002 JAN 22, 2003 JAN NEWA
AA 300MG;60MG N40443 003 JAN 22, 2003 JAN NEWA
ACETAMINOPHEN AND CODEINE PHOSPHATE
AA + DURAMED PHARMS BARR 300MG;15MG N40223 001 NOV 18, 1997 AUG CRLD
AA RANBAXY 300MG;60MG N87083 001 JAN CAHN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3
AA RANBAXY 300MG;30MG N85868 001 JAN CAHN
CODRIX
+ ANDRX PHARMS 500MG;30MG N40441 001 MAR 27, 2003 MAR NEWA
+ 500MG;15MG N40447 001 FEB 26, 2003 FEB NEWA
+ 500MG;60MG N40488 001 MAR 28, 2003 MAR NEWA
TYLENOL W/ CODEINE NO. 1
@ ORTHO MCNEIL PHARM 300MG;7.5MG N85055 001 AUG DISC
TYLENOL W/ CODEINE NO. 2
@ ORTHO MCNEIL PHARM 300MG;15MG N85055 002 AUG DISC
TYLENOL W/ CODEINE NO. 4
@ ORTHO MCNEIL PHARM 300MG;60MG N85055 004 AUG DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MALLINCKRODT	500MG/15ML;10MG/15ML	N40508 001	AUG 29, 2003	AUG	NEWA
+ MIKART	325MG/15ML;7.5MG/15ML	N40482 001	SEP 25, 2003	SEP	NEWA
AA	500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992	AUG	CTEC
AA +	500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992	AUG	CTEC
>A> AA VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	N40520 001	OCT 30, 2003	OCT	NEWA
TABLET; ORAL					
>A> ANEXSIA					
>A> AA MALLINCKRODT	750MG;10MG	N40468 001	OCT 31, 2002	OCT	CTNA
HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
AA ABLE	500MG;7.5MG	N40490 001	MAY 21, 2003	MAY	NEWA
AA	650MG;7.5MG	N40474 001	JAN 02, 2003	JAN	NEWA
AA ANDRX PHARMS	500MG;5MG	N40493 001	MAY 28, 2003	MAY	NEWA
AA	660MG;10MG	N40495 001	MAY 28, 2003	MAY	NEWA
AA	750MG;7.5MG	N40494 001	MAY 28, 2003	MAY	NEWA
AA AXIOM PHARM	500MG;5MG	N40236 001	SEP 25, 1997	MAY	CAHN
AA	650MG;10MG	N40240 001	NOV 26, 1997	MAY	CAHN
AA	650MG;7.5MG	N40240 002	NOV 26, 1997	MAY	CAHN
AA	750MG;7.5MG	N40236 002	SEP 25, 1997	MAY	CAHN
>D> AA MALLINCKRODT	750MG;10MG	N40468 001	OCT 31, 2002	OCT	CTNA
AA MIKART	325MG;7.5MG	N40432 001	JAN 22, 2003	JAN	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA AXIOM PHARM	500MG;5MG	N40219 001	JAN 22, 1998	MAY	CAHN
TABLET; ORAL					
AA WATSON LABS	325MG;7.5MG	N40535 001	SEP 05, 2003	SEP	NEWA
AA	325MG;10MG	N40535 002	SEP 05, 2003	SEP	NEWA
PERCOSET					
AA + ENDO PHARMS	325MG;7.5MG	N40434 001	NOV 23, 2001	SEP	CFTG
AA +	325MG;10MG	N40434 002	NOV 23, 2001	SEP	CFTG

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN

AA VINTAGE PHARMS	650MG;65MG	N40507 001	JUL 30, 2003	JUL	NEWA
-------------------	------------	------------	--------------	-----	------

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

+ AAIPHARMA	500MG;100MG	N76429 001	SEP 10, 2003	SEP	NEWA
-------------	-------------	------------	--------------	-----	------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL
DIAMOX

@ DURAMED PHARMS BARR	500MG	N12945 001		JUN	CAHN
+	500MG	N12945 003	APR 25, 1995	JUN	CAHN
TABLET; ORAL					
AB DURAMED PHARMS BARR	125MG	N08943 001		JUN	CAHN

AB +	250MG	N08943 002	JUN CAHN
<u>ACETAZOLAMIDE SODIUM</u>			
	INJECTABLE; INJECTION		
AP + DURAMED PHARMS BARR	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990 JUN CAHN
<u>ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE</u>			
	SUSPENSION/DROPS; OTIC		
	NEO-CORT-DOME		
@ BAYER PHARMS	2%;1%;EQ 0.35% BASE	N50238 001	JUN DISC
<u>ACYCLOVIR</u>			
	CAPSULE; ORAL		
	ACYCLOVIR		
AB AAIPHARMA	200MG	N74833 001	APR 22, 1997 APR CAHN
TABLET; ORAL			
+ CLONMEL HLTHCARE	400MG	N74834 001	APR 24, 1997 JUL DISC
@	800MG	N74834 002	APR 24, 1997 JUL DISC
<u>ACYCLOVIR SODIUM</u>			
	INJECTABLE; INJECTION		
	ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE		
+ BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N74885 001	DEC 19, 1997 AUG CAHN
	EQ 1GM BASE/VIAL	N74885 002	DEC 19, 1997 AUG CAHN
	ACYCLOVIR SODIUM		
AP BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N74913 001	OCT 15, 1997 AUG CAHN
AP	EQ 1GM BASE/VIAL	N74913 002	OCT 15, 1997 AUG CAHN
<u>ALBUMIN HUMAN</u>			
	INJECTABLE; INJECTION		
	OPTISON		
+ AMERSHAM HLTH	10MG/ML	N20899 001	DEC 31, 1997 JUN CAHN
<u>ALBUTEROL SULFATE</u>			
	SOLUTION; INHALATION		
	ALBUTEROL SULFATE		
AN NOVEX	EQ 0.5% BASE	N76391 001	APR 01, 2003 APR NEWA
SYRUP; ORAL			
PROVENTIL			
@ SCHERING	EQ 2MG BASE/5ML	N18062 001	JAN 19, 1983 AUG DISC
TABLET; ORAL			
	ALBUTEROL SULFATE		
@ CLONMEL HLTHCARE	EQ 2MG BASE	N72859 001	DEC 20, 1989 JUN DISC
@	EQ 4MG BASE	N72860 001	DEC 20, 1989 JUN DISC
AB + MYLAN	EQ 2MG BASE	N72893 001	JAN 17, 1991 AUG CRLD
AB +	EQ 4MG BASE	N72894 001	JAN 17, 1991 AUG CRLD
PROVENTIL			
@ SCHERING	EQ 2MG BASE	N17853 001	MAY 07, 1982 AUG DISC
@	EQ 4MG BASE	N17853 002	MAY 07, 1982 AUG DISC
TABLET, EXTENDED RELEASE; ORAL			
>D> BC SCHERING	EQ 4MG BASE	N19383 001	JUL 13, 1987 OCT DISC
>A> @	EQ 4MG BASE	N19383 001	JUL 13, 1987 OCT DISC

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

+ MERCK

EQ 70MG ACID/75ML

N21575 001 SEP 17, 2003 SEP NEWA

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP + AKORN

EQ 0.5MG BASE/ML

N19353 001 DEC 29, 1986 MAR CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

+ SANOFI SYN RES

10MG

N21287 001 JUN 12, 2003 JUN NEWA

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB VINTAGE PHARMS

100MG

N75798 001 JUN 27, 2003 JUN NEWA

AB

300MG

N75798 002 JUN 27, 2003 JUN NEWA

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

JANSSEN ORTHO

EQ 6.25MG BASE

N21001 001 MAY 07, 2001 APR CAHN

+

EQ 12.5MG BASE

N21001 002 MAY 07, 2001 APR CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SABEX 2002

2 IU/ML;40MG/ML;12UGM/ML;40
IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/
ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660
IU/ML;0.03MG/ML

N21163 001 MAY 18, 2000 JUN CPOT

INJECTABLE; IV (INFUSION)

+ SABEX 2002

2 IU/ML;40MG/ML;12UGM/ML;40
IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/
ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660
IU/ML;30UGM/ML

N21559 001 JUN 16, 2003 JUN NEWA

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION

CERNEVIT-12

@ BAXTER HLTHCARE

11.2
IU/VIAL;125MG/VIAL;60UGM/VIAL;200
IU/VIAL;5.5MG/VIAL;414UGM/VIAL;46MG/
VIAL;17.25MG/VIAL;4.53MG/VIAL;4.14
MG/VIAL;3.51MG/VIAL;3,500 IU/VIAL

N20924 001 APR 06, 1999 MAR DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

>D>	@ CLONMEL HLTHCARE	0.25MG	N74174 001	OCT 19, 1993	JUN	DISC
>A>	@	0.5MG	N74174 002	OCT 19, 1993	JUN	DISC
@		1MG	N74174 003	OCT 19, 1993	JUN	DISC
@		2MG	N74174 004	OCT 19, 1993	JUN	DISC

TABLET, EXTENDED RELEASE; ORAL

XANAX XR

PHARMACIA AND UPJOHN	0.5MG	N21434 001	JAN 17, 2003	JAN	NEWA
	1MG	N21434 002	JAN 17, 2003	JAN	NEWA
	2MG	N21434 003	JAN 17, 2003	JAN	NEWA
+	3MG	N21434 004	JAN 17, 2003	JAN	NEWA

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

>D>	PHARMACIA AND UPJOHN	0.01MG/ML	N20755 002	OCT 01, 1997	OCT	DISC
>A>	@	0.01MG/ML	N20755 002	OCT 01, 1997	OCT	DISC
>D>	AP	0.02MG/VIAL	N20379 002	JUL 06, 1995	OCT	CRLD
>A>	AP +	0.02MG/VIAL	N20379 002	JUL 06, 1995	OCT	CRLD
>D>	+	0.02MG/ML	N20755 003	OCT 01, 1997	OCT	DISC
>A>	@	0.02MG/ML	N20755 003	OCT 01, 1997	OCT	DISC

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HCL

AB	GENEVA PHARMS	100MG	N71293 001	FEB 18, 1987	APR	CAHN
----	---------------	-------	------------	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	ALTANA	0.1%	N76065 001	MAY 15, 2003	MAY	NEWA
AB	TARO PHARM INDs	0.1%	N76229 001	MAY 31, 2002	MAY	CTEC
AT		0.1%	N76229 001	MAY 31, 2002	APR	NEWA
	CYCLOCORT					
AT +	FUJISAWA HLTHCARE	0.1%	N18116 002		APR	CFTG
AB +		0.1%	N18116 002		MAY	CTEC
	OINTMENT; TOPICAL					
	AMCINONIDE					
AB	TARO PHARM INDs	0.1%	N76367 001	MAR 19, 2003	MAR	NEWA

AMINO ACIDS

INJECTABLE; INJECTION

PREMASOL 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	10% (10GM/100ML)	N75880 002	JUN 19, 2003	JUN	NEWA
-----------------	------------------	------------	--------------	-----	------

PREMASOL 6% IN PLASTIC CONTAINER

BAXTER HLTHCARE	6% (6GM/100ML)	N75880 001	JUN 19, 2003	JUN	NEWA
-----------------	----------------	------------	--------------	-----	------

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

@ BAXTER HLTHCARE

250MG/ML

N18590 001 OCT 29, 1982 AUG CAHN

@ ELKINS SINK

250MG/ML

N18590 001 OCT 29, 1982 JUN DISC

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP + ABBOTT

25MG/ML

N87601 001 JUL 23, 1982 JUN CRLD

@ ELKINS SINK

25MG/ML

N87239 001 JUN DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP APOTEX

50MG/ML

N76394 001 APR 25, 2003 APR NEWA

AP SICOR PHARMS

50MG/ML

N76163 001 SEP 05, 2003 SEP NEWA

CORDARONE

AP + WYETH PHARMS INC

50MG/ML

N20377 001 AUG 03, 1995 MAR CAHN

TABLET; ORAL

AMIODARONE HCL

AB EON

400MG

N75315 002 JUN 30, 2000 SEP CRLD

TARO

100MG

N75424 002 DEC 18, 2002 SEP CRLD

AB +

400MG

N76362 001 NOV 29, 2002 SEP CRLD

CORDARONE

AB WYETH PHARMS INC

200MG

N18972 001 DEC 24, 1985 MAR CAHN

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

@ ROCHE

40MG/ML

N85749 001 JUN DISC

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10

@ SCHERING

10MG;2MG

N14713 007 MAR DISC

ETRAFON 2-25

@ SCHERING

25MG;2MG

N14713 004 MAR DISC

ETRAFON-FORTE

@ SCHERING

25MG;4MG

N14713 006 MAR DISC

AMLEXANOX

PASTE; DENTAL

APHTHASOL

+ ACCESS PHARMS

5%

N20511 001 DEC 17, 1996 JUL CAHN

>A> AMLODIPINE MALEATE

>A> TABLET; ORAL

>A> AMVAZ

>A> DR REDDYS LABS INC

2.5MG

N21435 001 OCT 31, 2003 OCT NEWA

>A>

5MG

N21435 002 OCT 31, 2003 OCT NEWA

>A> +

10MG

N21435 003 OCT 31, 2003 OCT NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB TARO EQ 12% BASE N75883 001 APR 10, 2003 APR NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXIL

AB GLAXOSMITHKLINE 50MG/ML N62226 005 JUL CRLD

WYMOX

@ WYETH AYERST

125MG/5ML

N62131 001

JUN DISC

@ 250MG/5ML

N62131 002

JUN DISC

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

RANBAXY

200MG

N65080 002 AUG 11, 2003 AUG NEWA

+

400MG

N65080 001 AUG 11, 2003 AUG NEWA

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

PREVPAC

+ TAP PHARM

500MG;500MG;30MG

N50757 001 DEC 02, 1997 MAY CDFR

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB RANBAXY 200MG/5ML;EQ 28.5MG BASE/5ML N65132 001 MAR 19, 2003 MAR NEWA

AB 400MG/5ML;EQ 57MG BASE/5ML N65132 002 MAR 19, 2003 MAR NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

2.5MG;2.5MG;2.5MG;2.5MG

N21303 001 OCT 11, 2001 JAN CAHN

ADDERALL XR 15

3.75MG;3.75MG;3.75MG;3.75MG

N21303 006 MAY 22, 2002 JAN CAHN

ADDERALL XR 20

5MG;5MG;5MG;5MG

N21303 002 OCT 11, 2001 JAN CAHN

ADDERALL XR 25

6.25MG;6.25MG;6.25MG;6.25MG

N21303 004 MAY 22, 2002 JAN CAHN

ADDERALL XR 30

7.5MG;7.5MG;7.5MG;7.5MG

N21303 003 OCT 11, 2001 JAN CAHN

+ SHIRE LABS

1.25MG;1.25MG;1.25MG;1.25MG

N21303 005 MAY 22, 2002 JAN CAHN

ADDERALL XR 5

3.125MG;3.125MG;3.125MG;3.125MG

N11522 012 AUG 31, 2000 MAR CFTG

TABLET; ORAL

ADDERALL 12.5

3.75MG;3.75MG;3.75MG;3.75MG

N11522 013 AUG 31, 2000 MAR CFTG

AB SHIRE LABS

ADDERALL 15

1.875MG;1.875MG;1.875MG;1.875MG

N11522 011 AUG 31, 2000 MAR CFTG

AB SHIRE LABS

ADDERALL 7.5

1.25MG;1.25MG;1.25MG;1.25MG

N40472 001 SEP 30, 2003 SEP NEWA

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB ABRIKA PHARMS

AB		2.5MG;2.5MG;2.5MG;2.5MG	N40472 002	SEP 30, 2003	SEP	NEWA	
AB		5MG;5MG;5MG;5MG	N40472 003	SEP 30, 2003	SEP	NEWA	
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40472 004	SEP 30, 2003	SEP	NEWA	
AB	BARR	1.875MG;1.875MG;1.875MG;1.875MG	N40422 005	MAR 19, 2003	MAR	NEWA	
AB		3.125MG;3.125MG;3.125MG;3.125MG	N40422 006	MAR 19, 2003	MAR	NEWA	
AB		3.75MG;3.75MG;3.75MG;3.75MG	N40422 007	MAR 19, 2003	MAR	NEWA	
>A>	AB	MALLINCKRODT	1.25MG;1.25MG;1.25MG;1.25MG	N40440 001	OCT 07, 2003	OCT	NEWA
>A>	AB		1.875MG;1.875MG;1.875MG;1.875MG	N40440 002	OCT 07, 2003	OCT	NEWA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	N40440 003	OCT 07, 2003	OCT	NEWA
>A>	AB		3.125MG;3.125MG;3.125MG;3.125MG	N40440 004	OCT 07, 2003	OCT	NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	N40440 005	OCT 07, 2003	OCT	NEWA
>A>	AB		5MG;5MG;5MG;5MG	N40440 006	OCT 07, 2003	OCT	NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	N40440 007	OCT 07, 2003	OCT	NEWA
AB	MUTUAL PHARM	1.25MG;1.25MG;1.25MG;1.25MG	N40480 001	SEP 09, 2003	SEP	NEWA	
AB		1.875MG;1.875MG;1.875MG;1.875MG	N40480 002	SEP 09, 2003	SEP	NEWA	
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40480 003	SEP 09, 2003	SEP	NEWA	
AB		3.125MG;3.125MG;3.125MG;3.125MG	N40480 004	SEP 09, 2003	SEP	NEWA	
AB		3.75MG;3.75MG;3.75MG;3.75MG	N40480 005	SEP 09, 2003	SEP	NEWA	
AB		5MG;5MG;5MG;5MG	N40480 006	SEP 09, 2003	SEP	NEWA	
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40480 007	SEP 09, 2003	SEP	NEWA	
AB	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	N40456 001	MAY 06, 2003	MAY	NEWA	
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40456 002	MAY 06, 2003	MAY	NEWA	
AB		5MG;5MG;5MG;5MG	N40456 003	MAY 06, 2003	MAY	NEWA	
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40456 004	MAY 06, 2003	MAY	NEWA	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D>	AP	APOTHECON	EQ 125MG BASE/VIAL	N62860 001	FEB 05, 1988	OCT	WDAG
>A>			EQ 125MG BASE/VIAL	N62860 001	FEB 05, 1988	OCT	WDAG
>D>	AP		EQ 250MG BASE/VIAL	N62860 002	FEB 05, 1988	OCT	WDAG
>A>			EQ 250MG BASE/VIAL	N62860 002	FEB 05, 1988	OCT	WDAG
>D>	AP		EQ 500MG BASE/VIAL	N62860 003	FEB 05, 1988	OCT	WDAG
>A>			EQ 500MG BASE/VIAL	N62860 003	FEB 05, 1988	OCT	WDAG
>D>	AP		EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988	OCT	WDAG
>A>			EQ 1GM BASE/VIAL	N62860 004	FEB 05, 1988	OCT	WDAG
>D>	AP		EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988	OCT	WDAG
>A>			EQ 2GM BASE/VIAL	N62860 005	FEB 05, 1988	OCT	WDAG
			EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	AUG	CAHN
			EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	AUG	CAHN
			EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	AUG	CAHN
			EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	AUG	CAHN
			EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	AUG	CAHN
			EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	AUG	CAHN
		OMNIPEN-N					
			EQ 125MG BASE/VIAL	N60626 001		JUN	DISC
			EQ 250MG BASE/VIAL	N60626 002		JUN	DISC
			EQ 500MG BASE/VIAL	N60626 003		JUN	DISC
			EQ 1GM BASE/VIAL	N60626 004		JUN	DISC
			EQ 2GM BASE/VIAL	N60626 005		JUN	DISC
		TOTACILLIN-N					
AP	+	GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	N60677 001		JUN	CRLD
AP	+		EQ 250MG BASE/VIAL	N60677 002		JUN	CRLD

AP +	EQ 500MG BASE/VIAL	N60677 003	JUN	CRLD
AP +	EQ 1GM BASE/VIAL	N60677 004	JUN	CRLD
AP +	EQ 2GM BASE/VIAL	N60677 005	JUN	CRLD

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

OMNIPEN (AMPICILLIN)

@ WYETH AYERST	250MG	N60624 001	JUN	DISC
@	500MG	N60624 002	JUN	DISC

FOR SUSPENSION; ORAL

@ WYETH AYERST	100MG/ML	N60625 001	JUN	DISC
@	125MG/5ML	N60625 002	JUN	DISC
@	250MG/5ML	N60625 003	JUN	DISC

PRINCIPEN

APOTHECON	EQ 100MG BASE/ML	N61394 001	JUN	CTEC
-----------	------------------	------------	-----	------

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999	MAR	CMFD
+	150MG	N21007 002	APR 15, 1999	MAR	CMFD

SOLUTION; ORAL

+	GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999	MAR	CMFD
---	-----------------	---------	------------	--------------	-----	------

APREPITANT

CAPSULE; ORAL

EMEND

MERCK	80MG	N21549 001	MAR 26, 2003	MAR	NEWA
+	125MG	N21549 002	MAR 26, 2003	MAR	NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

+	ENCYSIVE	100MG/ML	N20883 001	JUN 30, 2000	JUN	CAHN
---	----------	----------	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+	AAIPHARMA	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1IU/ML	N08809 004	AUG 08, 1985	JUN	CTEC
---	-----------	--	------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AB +	WATSON PHARMS	325MG;50MG;40MG	N17534 005	APR 16, 1986	MAR	CAHN
------	---------------	-----------------	------------	--------------	-----	------

TABLET; ORAL

AB +	WATSON PHARMS	325MG;50MG;40MG	N17534 003	APR 16, 1986	MAR	CAHN
------	---------------	-----------------	------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE NO 3

AB + WATSON PHARMS 325MG;50MG;40MG;30MG

N19429 003 OCT 26, 1990 MAR CAHN

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

+ WOMEN FIRST HLTHCARE 325MG;200MG

N11702 003 DEC 29, 1983 JUN CTEC

MICRAININ

@ MEDPOINTE PHARM HLC 325MG;200MG

N84978 001 JUN DISC

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

AB + IVAX PHARMS 325MG;400MG

N87211 001 DEC 22, 1982 JUN CRLD

ROBAXISAL

@ ROBINS AH 325MG;400MG

N12281 001 JUN DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA AXIOM PHARM 325MG;4.5MG;0.38MG

N40260 001 JUL 17, 1998 MAY CAHN

ASPIRIN; PRAVASTATIN SODIUM

TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB 81MG;20MG

N21387 001 JUN 24, 2003 JUN NEWA

81MG;40MG

N21387 002 JUN 24, 2003 JUN NEWA

81MG;80MG

N21387 003 JUN 24, 2003 JUN NEWA

325MG;20MG

N21387 004 JUN 24, 2003 JUN NEWA

325MG;40MG

N21387 005 JUN 24, 2003 JUN NEWA

+ 325MG;80MG

N21387 006 JUN 24, 2003 JUN NEWA

ASPIRIN; PROPOXYPHENINE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

@ AAIPHARMA LLC 325MG;65MG

N10996 005 JUL DISC

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

BRISTOL MYERS SQUIBB EQ 100MG BASE

N21567 001 JUN 20, 2003 JUN NEWA

EQ 150MG BASE

N21567 002 JUN 20, 2003 JUN NEWA

+ EQ 200MG BASE

N21567 003 JUN 20, 2003 JUN NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

@ LILLY 5MG

N21411 001 NOV 26, 2002 MAY DISC

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+ MERIDIAN MEDCL TECHN	EQ 0.5MG SULFATE/0.7ML
+	EQ 1MG SULFATE/0.7ML

N17106 003	JUN 19, 2003	JUL	NEWA
N17106 002	JUN 19, 2003	JUL	NEWA

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

>D> + ABBOTT	0.4MG/ML;75MG/ML	N87847 001	NOV 26, 1982	OCT	WDAG
>A> @	0.4MG/ML;75MG/ML	N87847 001	NOV 26, 1982	OCT	WDAG
>D> +	0.4MG/ML;100MG/ML	N87848 001	NOV 26, 1982	OCT	WDAG
>A> @	0.4MG/ML;100MG/ML	N87848 001	NOV 26, 1982	OCT	WDAG
>D> +	0.4MG/ML;50MG/ML	N87853 001	NOV 26, 1982	OCT	WDAG
>A> @	0.4MG/ML;50MG/ML	N87853 001	NOV 26, 1982	OCT	WDAG

AZATHIOPRINE

TABLET; ORAL

AZASAN

AAIPHARMA LLC	25MG	N75252 002	FEB 03, 2003	FEB	NEWA
AB	50MG	N75252 001	JUN 07, 1999	FEB	NEWA
	75MG	N75252 003	FEB 03, 2003	FEB	NEWA
	100MG	N75252 004	FEB 03, 2003	FEB	NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIVAR

+ MEDPOINTE	0.05%	N21127 001	MAY 22, 2000	APR	CAHN
-------------	-------	------------	--------------	-----	------

AZITHROMYCIN

TABLET; ORAL

ZITHROMAX

PFIZER	EQ 500MG BASE	N50784 001	MAY 24, 2002	AUG	CRLD
--------	---------------	------------	--------------	-----	------

BACLOFEN

>A>	TABLET, ORALLY DISINTEGRATING; ORAL					
>A>	BACLOFEN					
>A>	SCHWARZ PHARMA	10MG	N21589 001	OCT 30, 2003	OCT	NEWA
>A> +	20MG	N21589 002	OCT 30, 2003	OCT	NEWA	

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

@ GLAXOSMITHKLINE	0.042MG/INH	N18153 001	MAR	DISC
-------------------	-------------	------------	-----	------

AEROSOL, METERED; NASAL

BECONASE

@ GLAXOSMITHKLINE	0.042MG/INH	N18584 001	MAR	DISC
-------------------	-------------	------------	-----	------

VANCENASE

@ SCHERING	0.042MG/INH	N18521 001	MAR	DISC
------------	-------------	------------	-----	------

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ HOLLISTER STIER LABS 60UMOLAR

N50114 001

JUL CAHN

BETAMETHASONE

TABLET; ORAL

CELESTONE

@ SCHERING

0.6MG

N12657 003

FEB DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

AB + SAVAGE LABS EQ 0.05% BASE

N19138 001 JUN 26, 1984 MAY CRLD

DIPROSONE

@ SCHERING

EQ 0.05% BASE

N17536 001

MAY DISC

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ALTANA EQ 0.05% BASE

N75276 001 MAY 13, 2003 MAY NEWA

DIPROLENE

AB + SCHERING EQ 0.05% BASE

N19408 002 NOV 22, 1991 MAY CFTG

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA WOCKHARDT 5MG

N40532 001 SEP 29, 2003 SEP NEWA

AA 10MG

N40533 001 SEP 29, 2003 SEP NEWA

AA 25MG

N40534 001 SEP 29, 2003 SEP NEWA

AA 50MG

N40518 001 SEP 29, 2003 SEP NEWA

URECHOLINE

AA + ODYSSEY PHARMS 5MG

N89095 001 DEC 19, 1985 SEP CFTG

AA + 10MG

N88440 001 MAY 29, 1984 SEP CFTG

AA + 25MG

N88441 001 MAY 29, 1984 SEP CFTG

AA + 50MG

N89096 001 DEC 19, 1985 SEP CFTG

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB DURAMED PHARMS BARR 5MG

N19982 002 JUL 31, 1992 JUN CAHN

AB + 10MG

N19982 001 JUL 31, 1992 JUN CAHN

AB WYETH PHARMS INC 5MG

N19982 002 JUL 31, 1992 MAR CAHN

AB + 10MG

N19982 001 JUL 31, 1992 MAR CAHN

BISOPROLOL FUMARATE; HYDROCHLORTHIAZIDE

TABLET; ORAL

ZIAC

AB DURAMED PHARMS BARR 2.5MG;6.25MG

N20186 003 MAR 26, 1993 JUN CAHN

AB 5MG;6.25MG

N20186 001 MAR 26, 1993 JUN CAHN

AB + 10MG;6.25MG

N20186 002 MAR 26, 1993 JUN CAHN

AB WYETH PHARMS INC 2.5MG;6.25MG

N20186 003 MAR 26, 1993 MAR CAHN

AB 5MG;6.25MG

N20186 001 MAR 26, 1993 MAR CAHN

AB + 10MG;6.25MG

N20186 002 MAR 26, 1993 MAR CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS
ANGIOMAX

>A>	+	MEDICINES CO	250MG/VIAL	N20873 001 DEC 15, 2000 OCT CAHN
>D>	+	MEDS (TMC)	250MG/VIAL	N20873 001 DEC 15, 2000 OCT CAHN

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP	GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N64084 001 JUN 01, 1996 AUG CAHN
AP		EQ 30 UNITS BASE/VIAL	N64084 002 JUN 01, 1996 AUG CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS
VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL

N21602 001 MAY 13, 2003 MAY NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

Q BAXTER HLTHCARE	50MG/ML	N70545 001 MAY 14, 1986 AUG CAHN
Q	50MG/ML	N70546 001 MAY 14, 1986 AUG CAHN
Q ELKINS SINK	50MG/ML	N70545 001 MAY 14, 1986 JUN DISC
Q	50MG/ML	N70546 001 MAY 14, 1986 JUN DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT	ALCON	0.2%	N76254 001 SEP 16, 2003 SEP NEWA
AT	BAUSCH AND LOMB	0.2%	N76260 001 MAY 28, 2003 SEP CFTG
	+	0.2%	N76260 001 MAY 28, 2003 MAY NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

DIMETANE-DX

Q ROBINS AH 2MG/5ML;10MG/5ML;30MG/5ML

N19279 001 AUG 24, 1984 MAR DISC

MYPHETANE DX

AA	+	MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML	N88811 001 JUN 07, 1985 MAR CTEC
----	---	--------------	---------------------------	----------------------------------

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

Q ASTRazeneca 0.032MG/INH

N20233 001 FEB 14, 1994 SEP DISC

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAIN

+	AMPHASTAR	0.375% (37.5MG/10ML);1% (100MG/10ML)	N21496 001 MAY 23, 2003 MAY NEWA
---	-----------	---	----------------------------------

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 WELLBUTRIN SR

>D>	GLAXOSMITHKLINE	150MG	N20358 003	OCT 04, 1996	OCT	CRLD
>A>	+	150MG	N20358 003	OCT 04, 1996	OCT	CRLD
>D>	+	200MG	N20358 004	JUN 14, 2002	OCT	CRLD
>A>		200MG	N20358 004	JUN 14, 2002	OCT	CRLD
	WELLBUTRIN XL					
	SMITHKLINE BEECHAM	150MG	N21515 001	AUG 28, 2003	AUG	NEWA
	+	300MG	N21515 002	AUG 28, 2003	AUG	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
 BUSPIRONE HCL

AB	EGIS	15MG	N75119 003	JAN 23, 2003	JAN	NEWA
----	------	------	------------	--------------	-----	------

BUSULFAN

INJECTABLE; INJECTION
 BUSULFEX

+ ESP PHARMA	6MG/ML	N20954 001	FEB 04, 1999	JUN	CAHN
--------------	--------	------------	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL
 CAFCIT

+ MEAD JOHNSON	EQ 10MG BASE/ML	N20793 001	SEP 21, 1999	JUN	CAHN
----------------	-----------------	------------	--------------	-----	------

CALCITRIOL

INJECTABLE; INJECTION
 CALCITRIOL

AP	AAIPHARMA	0.001MG/ML	N75766 001	FEB 20, 2003	FEB	NEWA
AP		0.002MG/ML	N75766 002	FEB 20, 2003	FEB	NEWA
AP	GENSIA SICOR PHARMS	0.001MG/ML	N75823 001	MAR 31, 2003	MAR	NEWA
AP		0.002MG/ML	N75823 002	MAR 31, 2003	MAR	NEWA
AP	LUITPOLD	0.001MG/ML	N75746 001	SEP 26, 2003	SEP	NEWA
AP		0.002MG/ML	N75746 002	SEP 26, 2003	SEP	NEWA
AP	LYNE	0.001MG/ML	N76206 001	SEP 17, 2003	SEP	NEWA
	SOLUTION; ORAL					
AA	ROXANE	1UGM/ML	N76242 001	JUL 18, 2003	JUL	NEWA
	ROCALTROL					
AA +	ROCHE	1UGM/ML	N21068 001	NOV 20, 1998	JUL	CFTG

CALCIUM ACETATE

CAPSULE; ORAL
 PHOSLO

@ NABI	EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	AUG	CAHN
@	EQ 169MG CALCIUM	N21160 002	APR 02, 2001	AUG	CAHN
	PHOSLO GELCAPS				
+ NABI	EQ 169MG CALCIUM	N21160 003	APR 02, 2001	AUG	CAHN

TABLET; ORAL
 PHOSLO

+ NABI	EQ 169MG CALCIUM	N19976 001	DEC 10, 1990	AUG	CAHN
--------	------------------	------------	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE;
SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+ QOL MEDCL 0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML
;1.9MG/ML;7.3MG/ML;0.2MG/ML N20577 001 SEP 27, 1996 MAY CAHN

CARBAMAZEPINE

TABLET; ORAL

TERIL

AB TARO 200MG N76525 001 SEP 26, 2003 SEP NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

STALEVO 100

ORION PHARMA INC 25MG;200MG;100MG N21485 002 JUN 11, 2003 JUN NEWA

STALEVO 150

+ ORION PHARMA INC 37.5MG;200MG;150MG N21485 003 JUN 11, 2003 JUN NEWA

STALEVO 50

ORION PHARMA INC 12.5MG;200MG;50MG N21485 001 JUN 11, 2003 JUN NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

+ MIKART 4MG/5ML N40458 001 APR 25, 2003 APR NEWA

TABLET; ORAL

+ MIKART 4MG N40442 001 MAR 19, 2003 MAR NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)

PARAPLATIN

+ BRISTOL MYERS SQUIBB EQ 50MG /5ML(10MG/ML) N20452 001 JUL 14, 2003 JUL NEWA

+ EQ 150MG /15ML(10MG/ML) N20452 002 JUL 14, 2003 JUL NEWA

+ EQ 450MG /45ML(10MG/ML) N20452 003 JUL 14, 2003 JUL NEWA

CARVEDILOL

TABLET; ORAL

COREG

+ GLAXOSMITHKLINE 12.5MG N20297 002 SEP 14, 1995 APR CRLD
25MG N20297 001 SEP 14, 1995 APR CRLD

CEFACLOR

CAPSULE; ORAL

CECLOR

>D> AB CEPH INTL EQ 250MG BASE N62205 001 OCT CTNA
>D> AB EQ 500MG BASE N62205 002 OCT CTNA

CEFACLOR

>A> AB CEPH INTL EQ 250MG BASE N62205 001 OCT CTNA
>A> AB EQ 500MG BASE N62205 002 OCT CTNA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL			
CEFADROXIL			
>D>	AB	BARR	EQ 500MG BASE
>A>	AB	RANBAXY	EQ 500MG BASE
FOR SUSPENSION; ORAL			
	AB	RANBAXY	EQ 125MG BASE/5ML
	AB		EQ 250MG BASE/5ML
	AB		EQ 500MG BASE/5ML
DURICEF			
	AB	WARNER CHILCOTT	EQ 125MG BASE/5ML
	AB		EQ 250MG BASE/5ML
	AB +		EQ 500MG BASE/5ML

N65015 001	JUN 22, 1999	OCT	CAHN
N65015 001	JUN 22, 1999	OCT	CAHN
N65115 001	MAR 26, 2003	MAR	NEWA
N65115 002	MAR 26, 2003	MAR	NEWA
N65115 003	MAR 26, 2003	MAR	NEWA
N50527 002		MAR	CFTG
N50527 003		MAR	CFTG
N50527 001		MAR	CFTG

CEFAZOLIN SODIUM

INJECTABLE; INJECTION			
CEFAZOLIN SODIUM			
>A>	AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL
>A>	AP		EQ 1GM BASE/VIAL
>D>	AP	WESTWARD	EQ 500MG BASE/VIAL
>D>	AP		EQ 1GM BASE/VIAL

N65047 001	SEP 18, 2001	OCT	CAHN
N65047 002	SEP 18, 2001	OCT	CAHN
N65047 001	SEP 18, 2001	OCT	CAHN
N65047 002	SEP 18, 2001	OCT	CAHN

CEFDITOREN PIVOXIL

TABLET; ORAL			
SPECTRACEF			
+ +	PURDUE PHARMA LP	200MG	

N21222 001	AUG 29, 2001	MAY	CAHN
------------	--------------	-----	------

CEFIXIME

FOR SUSPENSION; ORAL			
SUPRAX			
@	LEDERLE	100MG/5ML	
TABLET; ORAL			
@	LEDERLE	200MG	
@		400MG	

N50622 001	APR 28, 1989	APR	DISC
N50621 001	APR 28, 1989	APR	DISC
N50621 002	APR 28, 1989	APR	DISC

CEFOTAXIME SODIUM

INJECTABLE; INJECTION			
CEFOTAXIME SODIUM			
AP	LUPIN	EQ 500MG BASE/VIAL	
AP		EQ 1GM BASE/VIAL	
AP		EQ 2GM BASE/VIAL	
CLAFORAN			
AP	AVENTIS PHARMS	EQ 1GM BASE/VIAL	
AP		EQ 2GM BASE/VIAL	

N65124 001	SEP 24, 2003	SEP	NEWA
N65124 002	SEP 24, 2003	SEP	NEWA
N65124 003	SEP 24, 2003	SEP	NEWA
N62659 001	JAN 13, 1987	SEP	CTEC
N62659 002	JAN 13, 1987	SEP	CTEC

CEFOXITIN SODIUM

INJECTABLE; INJECTION			
CEFOXITIN			
AP	BAXTER HLTHCARE	EQ 10GM BASE/VIAL	
MEFOXIN IN PLASTIC CONTAINER			
+	MERCK	EQ 20MG BASE/ML	
+		EQ 40MG BASE/ML	

N65050 001	SEP 11, 2000	AUG	CAHN
N63182 001	JAN 25, 1993	MAR	CRLD
N63182 002	JAN 25, 1993	MAR	CRLD

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	RANBAXY	EQ 100MG BASE	N65083 001	AUG 20, 2003	AUG	NEWA
AB		EQ 200MG BASE	N65083 002	AUG 20, 2003	AUG	NEWA
	VANTIN					
AB	PHARMACIA AND UPJOHN	EQ 100MG BASE	N50674 001	AUG 07, 1992	AUG	CFTG
AB +		EQ 200MG BASE	N50674 002	AUG 07, 1992	AUG	CFTG

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

FUJISAWA HLTHCARE	EQ 1GM BASE/VIAL	N63294 002	MAR 31, 1994	AUG	CAHN
	EQ 2GM BASE/VIAL	N63294 003	MAR 31, 1994	AUG	CAHN

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP	LUPIN	EQ 250MG BASE/VIAL	N65125 001	SEP 30, 2003	SEP	NEWA
AP		EQ 500MG BASE/VIAL	N65125 002	SEP 30, 2003	SEP	NEWA
AP		EQ 1GM BASE/VIAL	N65125 003	SEP 30, 2003	SEP	NEWA
AP		EQ 2GM BASE/VIAL	N65125 004	SEP 30, 2003	SEP	NEWA
	ROCEPHIN					
AP +	HLR	EQ 250MG BASE/VIAL	N50585 001	DEC 21, 1984	SEP	CFTG
AP +		EQ 500MG BASE/VIAL	N50585 002	DEC 21, 1984	SEP	CFTG
AP +		EQ 1GM BASE/VIAL	N50585 003	DEC 21, 1984	SEP	CFTG
AP +		EQ 2GM BASE/VIAL	N50585 004	DEC 21, 1984	SEP	CFTG

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

>A>	AB	BIOCHEMIE US	EQ 250MG BASE	N65126 001	OCT 28, 2003	OCT	NEWA
>A>	AB		EQ 500MG BASE	N65126 002	OCT 28, 2003	OCT	NEWA
	AB	LUPIN	EQ 250MG BASE	N65135 001	JUL 25, 2003	JUL	NEWA
	AB		EQ 500MG BASE	N65135 002	JUL 25, 2003	JUL	NEWA
	AB	RANBAXY	EQ 125MG BASE	N65118 001	APR 25, 2003	APR	NEWA
	AB		EQ 250MG BASE	N65118 002	APR 25, 2003	APR	NEWA
	AB		EQ 500MG BASE	N65118 003	APR 25, 2003	APR	NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

>A>	AB	CEPH INTL	EQ 250MG BASE	N62118 001		OCT	CTNA
>A>	AB		EQ 500MG BASE	N62118 002		OCT	CTNA
>D>	AB	TEVA	EQ 250MG BASE	N62821 001	FEB 05, 1988	OCT	WDAG
>A>	@		EQ 250MG BASE	N62821 001	FEB 05, 1988	OCT	WDAG
	KEFLEX						
>D>	AB		EQ 250MG BASE	N62118 001		OCT	CTNA
>D>	AB		EQ 500MG BASE	N62118 002		OCT	CTNA
	FOR SUSPENSION; ORAL						
	CEPHALEXIN						
>A>	+	CEPH INTL	EQ 100MG BASE/ML	N62117 001		OCT	CTNA
>A>	AB		EQ 125MG BASE/5ML	N62117 002		OCT	CTNA
	KEFLEX						
>D>	+		EQ 100MG BASE/ML	N62117 001		OCT	CTNA

>D>	AB	EQ 125MG BASE/5ML	N62117 002	OCT	CTNA
		TABLET, FOR SUSPENSION; ORAL			
		PANIXINE DISPERDOSE			
	RANBAXY	EQ 125MG BASE	N65100 002	SEP 11, 2003	SEP NEWA
	+	EQ 250MG BASE	N65100 001	SEP 11, 2003	SEP NEWA

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM

+ BRISTOL	EQ 1GM BASE/VIAL	N62464 001	MAY 07, 1984	MAR	CRLD
+	EQ 2GM BASE/VIAL	N62464 002	MAY 07, 1984	MAR	CRLD
+	EQ 4GM BASE/VIAL	N62464 003	MAY 07, 1984	MAR	CRLD
KEFLIN					
@ LILLY	EQ 1GM BASE/VIAL	N50482 001		MAR	DISC
@	EQ 2GM BASE/VIAL	N50482 002		MAR	DISC
@	EQ 4GM BASE/VIAL	N50482 003		MAR	DISC

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

@ BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62720 001	JUL 02, 1987	AUG	CAHN
@	EQ 1GM BASE/VIAL	N62720 002	JUL 02, 1987	AUG	CAHN
@	EQ 2GM BASE/VIAL	N62720 003	JUL 02, 1987	AUG	CAHN
@	EQ 20GM BASE/VIAL	N62720 004	JUL 02, 1987	AUG	CAHN

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

>D>	+	GLAXOSMITHKLINE	2MG	N10669 002	OCT	CAHN
>A>	+	SMITHKLINE BEECHAM	2MG	N10669 002	OCT	CAHN

CHLORAMPHENICOL

CAPSULE; ORAL

MYCHEL

@ ARMENPHARM	250MG	N60851 001	JUL	DISC	>D>
OINTMENT; OPHTHALMIC					>A>
CHLORAMPHENICOL					>D>
AT + ALTANA	1%	N60133 001	MAY	CRLD	>D>
CHLOROMYCETIN					>A>
@ PARKEDALE	1%	N50156 001	MAY	DISC	>D>
CHLOROPTIC S.O.P.					>A>
@ ALLERGAN	1%	N61187 001	JUN	DISC	
SOLUTION/DROPS; OPHTHALMIC					
CHLOROPTIC					
@ ALLERGAN	0.5%	N50091 001	JUN	DISC	
SOLUTION/DROPS; OTIC					
CHLOROMYCETIN					
@ PARKEDALE	0.5%	N50205 001	MAY	DISC	

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

@ GRUPPO LEPESTIT	EQ 1GM BASE/VIAL	N62278 001	JUL	DISC	>D>
					>A>

OCT CTNA

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HCL

@ SANOFI SYNTHELABO

EQ 40MG BASE/ML

N06002 002

JUN DISC

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA IMPAX LABS

EQ 300MG BASE

N40516 001 AUG 29, 2003 AUG NEWA

@ WATSON LABS

EQ 150MG BASE

N87979 001 DEC 21, 1982 SEP DISC

@

EQ 300MG BASE

N88030 001 DEC 21, 1982 SEP DISC

AA + WEST WARD

EQ 150MG BASE

N83082 001 SEP CRLD

CHLORTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

@ MERCK

150MG;250MG

N16016 001 MAY DISC

ALDOCLOR-250

@ MERCK

250MG;250MG

N16016 002 MAY DISC

AUG CAHN

AUG CAHN

AUG CAHN

AUG CAHN

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

AP BAXTER HLTHCARE

25MG/ML

N83329 001

JUN CAHN

TABLET; ORAL

@ LEDERLE

10MG

N84803 001

JUN DISC

OCT CAHN

OCT CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@ CLONMEL HLTHCARE

25MG

N87451 001

JUL CAHN

@

50MG

N87450 001

JUL CAHN

JUL DISC

>D AB MYLAN

50MG

N86831 001

OCT CRLD

>A AB +

50MG

N86831 001

OCT CRLD

>D HYGROTON

MAY CRLD

>D AB AVENTIS PHARMS

25MG

N12283 004

OCT DISC

>A @

25MG

N12283 004

OCT DISC

>D AB +

50MG

N12283 003

OCT DISC

>A @

50MG

N12283 003

OCT DISC

MAY DISC

THALITONE

@ MONARCH PHARMS

25MG

N19574 002

FEB 12, 1992 MAY DISC

JUN DISC

CICLOPIROX

SHAMPOO; TOPICAL

LOPROX

+ MEDICIS

1%

N21159 001 FEB 28, 2003 FEB NEWA

MAY DISC

CILOSTAZOL

TABLET; ORAL

PLETAL

JUL DISC

>D OTSUKA

50MG

N20863 001

JAN 15, 1999 OCT CRLD

>A +

50MG

N20863 001

JAN 15, 1999 OCT CRLD

CIMETIDINE

SOLUTION; ORAL

CIMETIDINE HCL

AA DURAMED PHARM BARR 300MG/5ML

N75110 001 JUN 18, 1998 AUG CAIN

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

AA + ALPHARMA EQ 300MG BASE/5ML

N74176 001 JUN 01, 1994 AUG CRLD

AA DURAMED PHARMS BARR EQ 300MG BASE/5ML

N75110 001 JUN 18, 1998 AUG CAIN

TAGAMET

@ GLAXOSMITHKLINE EQ 300MG BASE/5ML

N17924 001 AUG DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPRO XR

+ BAYER PHARMS 425.2MG;EQ 574.9MG BASE

N21473 002 AUG 28, 2003 AUG NEWA

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPRODEX

+ ALCON 0.3%;0.1%

N21537 001 JUL 18, 2003 JUL NEWA

CITRIC ACID; UREA, C-13

FOR SOLUTION; TABLET, FOR SOLUTION; ORAL

IDKIT:HP

@ ORIDION 4GM;75MG

N21314 001 DEC 17, 2002 JUL DISC

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

AP + ORTHO BIOTECH 1MG/ML

N20229 001 FEB 26, 1993 APR CTEC

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

AA + TEVA EQ 0.5MG BASE/5ML

N73399 001 JUN 30, 1994 JUN CRLD

TAVIST

@ NOVARTIS EQ 0.5MG BASE/5ML

N18675 001 JUN 28, 1985 JUN DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HCL

AB WATSON LABS EQ 300MG BASE

N63083 002 MAR 18, 2003 MAR NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP @ BAXTER HLTHCARE EQ 150MG BASE/ML

N62806 001 OCT 15, 1987 AUG CAHN

@

EQ 150MG BASE/ML

N62889 001 APR 25, 1988 AUG CAHN

@

EQ 150MG BASE/ML

N63068 001 AUG 28, 1989 AUG CAHN

CLOBETASOL PROPIONATE

LOTION; TOPICAL

CLOBEX

+ GALDERMA LABS LP 0.05%

N21535 001 JUL 24, 2003 JUL NEWA

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

@ WYETH AYERST 500MG

N16099 002 JUN DISC

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL

KLOPIN RAPIDLY DISINTEGRATING

ROCHE	0.125MG	N20813 001	DEC 23, 1997	APR	CMFD
	0.25MG	N20813 002	DEC 23, 1997	APR	CMFD
	0.5MG	N20813 003	DEC 23, 1997	APR	CMFD
+	1MG	N20813 004	DEC 23, 1997	APR	CMFD
	2MG	N20813 005	DEC 23, 1997	APR	CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ CLONMEL HLTHCARE	3.75MG	N71742 001	DEC 14, 1987	JUN	DISC
@	7.5MG	N71743 001	DEC 14, 1987	JUN	DISC
@	15MG	N71744 001	DEC 14, 1987	JUN	DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

IVAX PHARMS	12.5MG	N74949 003	JUL 31, 2003	JUL	NEWA
AB +	100MG	N74949 002	NOV 26, 1997	SEP	CRLD
CLOZARIL					
AB NOVARTIS	100MG	N19758 002	SEP 26, 1989	SEP	CRLD

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC W/ CODEINE

@ WYETH AYERST	10MG/5ML;5MG/5ML;6.25MG/5ML	N08306 005	APR 02, 1984	JUN	DISC
PROMETH VC W/ CODEINE					
AA + ALPHARMA	10MG/5ML;5MG/5ML;6.25MG/5ML	N88764 001	OCT 31, 1984	JUN	CRLD

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ CODEINE

@ WYETH AYERST	10MG/5ML;6.25MG/5ML	N08306 004	APR 02, 1984	JUN	DISC
PROMETH W/ CODEINE					
AA + ALPHARMA	10MG/5ML;6.25MG/5ML	N88763 001	OCT 31, 1984	JUN	CRLD

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL

COLESTID

+ PHARMACIA AND UPJOHN 1GM

N20222 001 JUL 19, 1994 MAY CRLD

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

COPPER T MODEL TCU 380A

+ FEI 309MG/COPPER

N18680 001 NOV 15, 1984 MAR CAHN

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

BP + PHARMACIA AND UPJOHN 25MG
CORTONE
@ MERCK 25MG

N08126 001

APR CRLD

N07750 003

APR DISC

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

+ AMPHASTAR 0.25MG/VIAL

N16750 001

JUN CAHN

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

CROMOPTIC

@ KING PHARMS 4%

N75088 001 APR 27, 1999 MAY DISC

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

+ QUESTCOR PHARMS 0.5MG/INH

N19722 001 NOV 05, 1996 JUN CAHN

INJECTABLE; INJECTION

CYANOCOBALAMIN

@ BAXTER HLTHCARE 1MG/ML

N80515 002

AUG CAHN

@ ELKINS SINK 1MG/ML

N80515 002

JUN DISC

AP PHARMAFORCE 1MG/ML

N40451 001 SEP 23, 2003 SEP NEWA

@ WYETH AYERST 0.1MG/ML

N80554 001

JUN DISC

@ 1MG/ML

N80554 002

JUN DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL

AA MCNEIL CONS SPECLT 5MG

N17821 001

MAR CMFD

5MG

N17821 001

APR CTEC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

NEOSAR

@ GENESIA SICOR PHARMS 100MG/VIAL

N40015 001 APR 29, 1993 AUG DISC

AP @ 100MG/VIAL

N87442 001 FEB 16, 1982 AUG CAHN

@ 200MG/VIAL

N40015 002 APR 29, 1993 AUG DISC

AP @ 200MG/VIAL

N87442 002 FEB 16, 1982 AUG CAHN

@ 500MG/VIAL

N40015 003 APR 29, 1993 AUG DISC

AP @ 500MG/VIAL

N87442 003 FEB 16, 1982 AUG CAHN

@ 1GM/VIAL

N40015 004 APR 29, 1993 AUG DISC

AP @ 1GM/VIAL

N87442 004 JUL 08, 1983 AUG CAHN

@ 2GM/VIAL

N40015 005 APR 29, 1993 AUG DISC

AP		2GM/VIAL	N87442 005	MAR 30, 1989	AUG CAHN
<u>CYCLOSPORINE</u>					
CAPSULE; ORAL					
GENGRAF					
AB1	ABBOTT	25MG	N65003 001	MAY 12, 2000	FEB CTNA
BX		50MG	N65003 002	MAY 12, 2000	FEB CTNA
AB1		100MG	N65003 003	MAY 12, 2000	FEB CTNA
EMULSION; OPHTHALMIC					
RESTASIS					
+ ALLERGAN		0.05%	N50790 001	DEC 23, 2002	MAR CMS1
INJECTABLE; INJECTION					
CYCLOSPORINE					
>A>	AP PHARMAFORCE	50MG/ML	N65151 001	OCT 07, 2003	OCT NEWA
<u>CYPROHEPTADINE HYDROCHLORIDE</u>					
TABLET; ORAL					
CYPROHEPTADINE HCL					
AA	COREPHARMA	4MG	N40537 001	SEP 30, 2003	SEP NEWA
<u>CYTARABINE</u>					
INJECTABLE; INJECTION					
CYTARABINE					
AP	SICOR PHARMS	100MG/VIAL	N75206 001	DEC 30, 1998	JUL CAHN
AP +		500MG/VIAL	N75206 002	DEC 30, 1998	JUL CAHN
AP		1GM/VIAL	N75206 004	DEC 30, 1998	JUL CAHN
AP		2GM/VIAL	N75206 003	DEC 30, 1998	JUL CAHN
CYTOSAR-U					
AP +	GENSIA SICOR PHARMS	100MG/VIAL	N16793 001		JUN CAHN
AP +		500MG/VIAL	N16793 002		JUN CAHN
AP +		1GM/VIAL	N16793 003	DEC 21, 1987	JUN CAHN
AP +		2GM/VIAL	N16793 004	DEC 21, 1987	JUN CAHN
<u>DALFORPRISTIN; QUINUPRISTIN</u>					
INJECTABLE; IV (INFUSION)					
SYNERCID					
+ KING PHARMS		350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	FEB CAHN
@		420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	FEB CAHN
<u>DAPTOMYCIN</u>					
INJECTABLE; IV (INFUSION)					
CUBICIN					
CUBIST		250MG/VIAL	N21572 001	SEP 12, 2003	SEP NEWA
+		500MG/VIAL	N21572 002	SEP 12, 2003	SEP NEWA
<u>DEMECLOCYCLINE HYDROCHLORIDE</u>					
TABLET; ORAL					
DECLOMYCIN					
>A>	@ ESP PHARMA	75MG	N50261 001		OCT CAHN
>A>		150MG	N50261 002		OCT CAHN
>A>	+	300MG	N50261 003		OCT CAHN
>D>	@ WYETH PHARMS INC	75MG	N50261 001		OCT CAHN
@		75MG	N50261 001		MAR CAHN

>D>		150MG	N50261 002	OCT	CAHN
		150MG	N50261 002	MAR	CAHN
>D>	+	300MG	N50261 003	OCT	CAHN
	+	300MG	N50261 003	MAR	CAHN
<u>DESIRUDIN</u>					
INJECTABLE; SUBCUTANEOUS					
IPRIVASK					
+ AVENTIS PHARMS	15MG/VIAL	N21271 001 APR 04, 2003 APR NEWA			
<u>DESMOPRESSIN ACETATE</u>					
SPRAY, METERED; NASAL					
DESMOPRESSIN ACETATE					
AB + FERRING	0.01MG/SPRAY	N21333 001 SEP 16, 2002 MAY CMS1			
MINIRIN					
AB + FERRING	0.01MG/SPRAY	N21333 001 SEP 16, 2002 JUN CTNA			
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>					
TABLET; ORAL-21					
ORTHO-CEPT					
@ ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 001 DEC 14, 1992 MAR DISC			
TABLET; ORAL-28					
AB + ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 002 DEC 14, 1992 MAR CRLD			
<u>DESOXIMETASONE</u>					
CREAM; TOPICAL					
DESOXIMETASONE					
AB CLAY PARK	0.25%	N76510 001 JUL 01, 2003 JUL NEWA			
<u>DEXAMETHASONE</u>					
ELIXIR; ORAL					
DECADRON					
@ MERCK	0.5MG/5ML	N12376 002 APR DISC			
HEXADROL					
AA + ORGANON	0.5MG/5ML	N12674 001 APR CRLD			
<u>DEXAMETHASONE SODIUM PHOSPHATE</u>					
INJECTABLE; INJECTION					
DEXAMETHASONE					
AP BAXTER HLTHCARE	EQ 4MG PHOSPHATE/ML	N84282 001 AUG CAHN			
DEXAMETHASONE SODIUM PHOSPHATE					
AP AM PHARM	EQ 10MG PHOSPHATE/ML	N40491 001 APR 11, 2003 APR NEWA			
<u>DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE</u>					
SOLUTION/DROPS; OPHTHALMIC					
NEODECADRON					
@ MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001 MAY DISC			
<u>DEXCHLORPHENIRAMINE MALEATE</u>					
SYRUP; ORAL					
MYLARAMINE					
>D> AA MORTON GROVE	2MG/5ML	N88251 001 MAR 23, 1984 OCT CRLD			
>A> +	2MG/5ML	N88251 001 MAR 23, 1984 OCT CRLD			

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

>D>	POLARAMINE						
>D>	AA SCHERING	2MG/5ML		N86837	001	JUL 19, 1982	OCT DISC
>A>	@	2MG/5ML		N86837	001	JUL 19, 1982	OCT DISC
	TABLET; ORAL						
	DEXCHLORPHENIRAMINE MALEATE						
>D>	AA PLIVA	2MG		N88682	001	JAN 17, 1986	OCT CRLD
>A>	+	2MG		N88682	001	JAN 17, 1986	OCT CRLD
>D>	POLARAMINE						
>D>	AA + SCHERING	2MG		N86835	001		OCT DISC
>A>	@	2MG		N86835	001		OCT DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	GLAXOSMITHKLINE	5MG		N17078	001		JUL CRLD
AB		10MG		N17078	002		JUL CRLD
	DEXTROAMPHETAMINE SULFATE						
AB	MALLINCKRODT	5MG		N76353	001	MAY 06, 2003	MAY NEWA
AB		10MG		N76353	002	MAY 06, 2003	MAY NEWA
AB		15MG		N76353	003	MAY 06, 2003	MAY NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ DEXTROMETHORPHAN

@ WYETH AYERST 15MG/5ML;6.25MG/5ML

N11265 002 APR 02, 1984 JUN DISC

PROMETH W/ DEXTROMETHORPHAN

AA + ALPHARMA 15MG/5ML;6.25MG/5ML

N88762 001 OCT 31, 1984 JUN CRLD

DIAZEPAM

GEL; RECTAL

DIASTAT

>D>	+ XCEL PHARMS	2.5MG/0.5ML		N20648	001	JUL 29, 1997	OCT CRLD
>A>		2.5MG/0.5ML		N20648	001	JUL 29, 1997	OCT CRLD
	INJECTABLE; INJECTION						
	DIAZEPAM						
	@ BAXTER HLTHCARE	5MG/ML		N71308	001	JUL 17, 1987	AUG CAHN
AP		5MG/ML		N71309	001	JUL 17, 1987	AUG CAHN
AP		5MG/ML		N71310	001	JUL 17, 1987	AUG CAHN
	@ ELKINS SINK	5MG/ML		N70311	001	DEC 16, 1985	JUN DISC
	@	5MG/ML		N70312	001	DEC 16, 1985	JUN DISC
	@	5MG/ML		N70313	001	DEC 16, 1985	JUN DISC
	TABLET; ORAL						
	@ CLONMEL HLTHCARE	5MG		N70227	001	SEP 26, 1985	AUG DISC
	@	10MG		N70228	001	SEP 26, 1985	AUG DISC

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

@ MERCK 50MG

N11366 001 MAY DISC

DICLOXA**CILLIN** SODIUM

CAPSULE; ORAL

PATHOCIL

@ WYETH AYERST	EQ 250MG BASE	N50011 002	JUN	DISC
@	EQ 500MG BASE	N50011 003	MAR 28, 1983	JUN DISC
FOR SUSPENSION; ORAL				
DICLOXA CILLIN SODIUM				
+ APOTHECON	EQ 62.5MG BASE/5ML	N61455 001	JUN	CTEC
PATHOCIL				
@ WYETH AYERST	EQ 62.5MG BASE/5ML	N50092 001	JUN	DISC

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DICYCLOMINE HCL (PRESERVATIVE-FREE)

AP	BEDFORD	10MG/ML	N40465 001	JUN 30, 2003	JUN	NEWA
----	---------	---------	------------	--------------	-----	------

DIENESTROL

CREAM; VAGINAL

DIENESTROL

@ ORTHO MCNEIL	0.01%	N06110 005	AUG	DISC
----------------	-------	------------	-----	------

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP	SABEX 2002	0.25MG/ML	N40481 001	AUG 21, 2003	AUG	NEWA
@	WYETH AYERST	0.25MG/ML	N84386 001		JUN	DISC
TABLET; ORAL						
AB	CARACO	0.125MG	N76363 001	JAN 31, 2003	JAN	NEWA
AB		0.25MG	N76363 002	JAN 31, 2003	JAN	NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP	+ XCEL PHARMS	1MG/ML	N05929 001		APR	CFTG
DIHYDROERGOTAMINE MESYLATE						
AP	BEDFORD	1MG/ML	N40453 001	JUN 09, 2003	JUN	NEWA

AP	PADDOCK	1MG/ML	N40475 001	APR 28, 2003	APR	NEWA
----	---------	--------	------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

>A>	BC	+ AVENTIS PHARMS	360MG	N20062 005	AUG 24, 1999	OCT	NEWA
		TAZTIA XT					
AB4	ANDRX PHARMS	120MG		N75401 001	APR 10, 2003	APR	NEWA
AB4		180MG		N75401 002	APR 10, 2003	APR	NEWA
AB4		240MG		N75401 003	APR 10, 2003	APR	NEWA
AB4		300MG		N75401 004	APR 10, 2003	APR	NEWA
AB4		360MG		N75401 005	APR 10, 2003	APR	NEWA
	TIAZAC						
AB4	+ BIOVAIL	120MG		N20401 001	SEP 11, 1995	APR	CFTG
AB4		120MG		N20401 001	SEP 11, 1995	AUG	CRLD
AB4	+	180MG		N20401 002	SEP 11, 1995	APR	CFTG

JUN	DISC	AB4	180MG	N20401 002	SEP 11, 1995	AUG	CRLD
JUN	DISC	AB4 +	240MG	N20401 003	SEP 11, 1995	APR	CFTG
JUN	DISC	AB4	240MG	N20401 003	SEP 11, 1995	AUG	CRLD
JUN	DISC	AB4 +	300MG	N20401 004	SEP 11, 1995	APR	CFTG
JUN	DISC	AB4	300MG	N20401 004	SEP 11, 1995	AUG	CRLD
JUN	DISC	AB4 +	360MG	N20401 005	SEP 11, 1995	APR	CFTG
JUN	DISC	AB4	360MG	N20401 005	SEP 11, 1995	AUG	CRLD
JUN	CTEC	INJECTABLE; INJECTION					
JUN	DISC	DILTIAZEM HCL					
AP	+ BEDFORD	5MG/ML		N74617 001	FEB 28, 1996	AUG	CRLD
JUN	DISC	TABLET, EXTENDED RELEASE; ORAL					
	CARDIZEM LA						
	+ BIOVAIL	120MG		N21392 001	FEB 06, 2003	FEB	NEWA
	+	180MG		N21392 002	FEB 06, 2003	FEB	NEWA
	+	240MG		N21392 003	FEB 06, 2003	FEB	NEWA
JUN	NEWA	+	300MG	N21392 004	FEB 06, 2003	FEB	NEWA
	+	360MG		N21392 005	FEB 06, 2003	FEB	NEWA
	+	420MG		N21392 006	FEB 06, 2003	FEB	NEWA
AUG	DISC	<u>DILTIAZEM MALATE</u>					
	TABLET, EXTENDED RELEASE; ORAL						
	TIAMATE						
	@ MERCK	EQ 120MG HCL		N20506 001	OCT 04, 1996	MAY	DISC
	@	EQ 180MG HCL		N20506 002	OCT 04, 1996	MAY	DISC
	@	EQ 240MG HCL		N20506 003	OCT 04, 1996	MAY	DISC
AUG	NEWA						
JUN	DISC	<u>DIMENHYDRINATE</u>					
	INJECTABLE; INJECTION						
JAN	NEWA	DIMENHYDRINATE					
JAN	NEWA	@ BAXTER HLTHCARE	50MG/ML	N84767 001		AUG	CAHN
	+ STERIS	50MG/ML		N80615 001		JUN	CTEC
	@ WYETH AYERST	50MG/ML		N84316 001		JUN	DISC
APR	CFTG	<u>DIMETHYL SULFOXIDE</u>					
	SOLUTION; INTRAVESICAL						
	RIMSO-50						
JUN	NEWA	AT + EDWARDS LIFESCIENCES	50%	N17788 001		JUL	CAHN
APR	NEWA						
	<u>DIMYRISTOYL LECITHIN; PERFLUXANE</u>						
	INJECTABLE; INTRAVENOUS						
	IMAGENT						
	+ IMCOR	0.92MG/VIAL; 0.092MG/VIAL		N21191 001	MAY 31, 2002	AUG	CAHN
OCT	NEWA						
APR	NEWA	<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>					
	INJECTABLE; INJECTION						
APR	NEWA	DIPHENHYDRAMINE HCL					
APR	NEWA	AP BAXTER HLTHCARE	50MG/ML	N80817 002		JUN	CAHN
APR	NEWA	@	50MG/ML	N83183 001		AUG	CAHN
APR	NEWA	@ WYETH AYERST	50MG/ML	N80577 001		JUN	DISC
APR	CFTG						
AUG	CRLD						
APR	CFTG						

	<u>DIPYRIDAMOLE</u>						
	TABLET; ORAL						
	DIPYRIDAMOLE						
AB	CLONMEL HLTHCARE	25MG		N88999 001	FEB 05, 1991	JUL CAHN	
	@	25MG		N88999 001	FEB 05, 1991	AUG DISC	
AB		50MG		N89000 001	FEB 05, 1991	JUL CAHN	
AB		75MG		N89001 001	FEB 05, 1991	JUL CAHN	
	@	75MG		N89001 001	FEB 05, 1991	AUG DISC	
	<u>DOBUTAMINE HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	DOBUTAMINE HCL						
	@ BAXTER HLTHCARE	EQ 12.5MG BASE/ML		N74381 001	SEP 26, 1996	AUG CAHN	
	@ ELKINS SINK	EQ 12.5MG BASE/ML		N74381 001	SEP 26, 1996	JUN DISC	
	<u>DOLASETRON MESYLATE MONOHYDRATE</u>						
	INJECTABLE; INJECTION						
	ANZEMET						
	AVENTIS PHARMS	EQ 12.5MG BASE/0.625ML		N20624 002	SEP 11, 1997	JUL CPOT	
		EQ 12.5MG BASE/0.625ML		N20624 002	SEP 11, 1997	SEP CPOT	
+		EQ 100MG BASE/5ML		N20624 001	SEP 11, 1997	SEP CPOT	
+		EQ 500MG BASE/25ML		N20624 003	DEC 11, 2001	SEP NEWA	
	<u>DOPAMINE HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	DOPAMINE HCL						
	@ BAXTER HLTHCARE	40MG/ML		N18398 001		JUN DISC	
	@	80MG/ML		N18398 002	MAR 22, 1982	JUN DISC	
	<u>DOXAPRAM HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	DOPRAM						
AP +	BAXTER HLTHCARE CORP	20MG/ML		N14879 001		JAN CAHN	
	DOXAPRAM HCL						
AP	BEDFORD	20MG/ML		N76266 001	JAN 10, 2003	JAN NEWA	
	<u>DOXORUBICIN HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	ADRIAMYCIN RDF						
	@ PHARMACIA AND UPJOHN	150MG/VIAL		N50467 004	JUL 22, 1987	JUL DISC	
	<u>DOXYCYCLINE</u>						
	CAPSULE; ORAL						
	DOXYCYCLINE						
AB	AXIOM PHARM	EQ 50MG BASE		N65041 001	APR 28, 2000	MAY CAHN	
AB		EQ 100MG BASE		N65041 002	APR 28, 2000	MAY CAHN	
>A>	+ RANBAXY	EQ 75MG BASE		N65053 003	SEP 10, 2003	OCT NEWA	
	<u>DOXYCYCLINE HYCLATE</u>						
	CAPSULE; ORAL						
	DOXYCYCLINE HYCLATE						
AB	AXIOM PHARM	EQ 50MG BASE		N61717 001		MAY CAHN	

AB		EQ 100MG BASE	N61717 002	MAY	CAHN
	CAPSULE, COATED PELLETS; ORAL				
DORYX					
FAULDING	EQ 75MG BASE		N50582 002	AUG 13, 2001	FEB NEWA
INJECTABLE; INJECTION					
DOXY 100					
+ AM PHARM PARTNERS	EQ 100MG BASE/VIAL		N62475 001	DEC 09, 1983	MAR CRLD
DOXY 200					
+ AM PHARM PARTNERS	EQ 200MG BASE/VIAL		N62475 002	DEC 09, 1983	MAR CRLD
DOXYCYCLINE					
@ BAXTER HLTHCARE	EQ 100MG BASE/VIAL		N62450 001	OCT 27, 1983	AUG CAHN
@	EQ 200MG BASE/VIAL		N62450 002	OCT 27, 1983	AUG CAHN
DOXYCYCLINE HYCLATE					
@ BAXTER HLTHCARE	EQ 100MG BASE/VIAL		N62992 001	FEB 16, 1989	AUG CAHN
@	EQ 200MG BASE/VIAL		N62992 002	FEB 16, 1989	AUG CAHN
VIBRAMYCIN					
@ PFIZER	EQ 100MG BASE/VIAL		N50442 002		MAR DISC
@	EQ 200MG BASE/VIAL		N50442 001		MAR DISC
TABLET; ORAL					
DOXYCYCLINE HYCLATE					
AB AXIOM PHARM	EQ 100MG BASE		N62269 002	NOV 08, 1982	MAY CAHN
AB WEST WARD	EQ 100MG BASE		N65095 001	JUL 02, 2003	JUL NEWA
DOXYCYCLINE HYLATE					
@ AXIOM PHARM	EQ 50MG BASE		N62269 003		MAY CAHN
<u>EDROPHONIUM CHLORIDE</u>					
INJECTABLE; INJECTION					
REVERSOL					
@ ORGANON	10MG/ML		N89624 001	MAY 13, 1988	MAY DISC
<u>ELETRIPTAN HYDROBROMIDE</u>					
TABLET; ORAL					
RELPAX					
PFIZER IRELAND	EQ 20MG BASE		N21016 001	DEC 26, 2002	MAR CAHN
+	EQ 40MG BASE		N21016 002	DEC 26, 2002	MAR CAHN
<u>EMTRICITABINE</u>					
CAPSULE; ORAL					
EMTRIVA					
+ GILEAD	200MG		N21500 001	JUL 02, 2003	JUL NEWA
<u>ENALAPRIL MALEATE; HYDROCHLORTHIAZIDE</u>					
TABLET; ORAL					
ENALAPRIL MALEATE AND HYDROCHLORTHIAZIDE					
AB IVAX PHARMS	5MG;12.5MG		N75736 001	MAR 25, 2003	MAR NEWA
AB	10MG;25MG		N75736 002	MAR 25, 2003	MAR NEWA
<u>ENFUVIRTIDE</u>					
INJECTABLE; SUBCUTANEOUS					
FUZEON					
+ ROCHE	90MG/VIAL		N21481 001	MAR 13, 2003	MAR NEWA

<u>ENOXAPARIN SODIUM</u>			
INJECTABLE; SUBCUTANEOUS			
LOVENOX	300MG/3ML	N20164 009	JAN 23, 2003 JAN NEWA
+ AVENTIS			
>A>			
<u>EPINASTINE HYDROCHLORIDE</u>			
SOLUTION/DROPS; OPHTHALMIC		N21565 001	OCT 16, 2003 OCT NEWA
>A>			
ELESTAT	0.05%		
>A>			
+ ALLERGAN			
<u>EPINEPHRINE</u>			
INJECTABLE; IM-SC		N20800 001	MAY 30, 2003 MAY NEWA
TWINJECT	0.3MG /DELIVERY		
+ HOLLISTER STIER LABS			
<u>EPINEPHRINE BITARTRATE; ETIDOCAINe HYDROCHLORIDE</u>			
INJECTABLE; INJECTION			
DURANEST	0.005MG/ML;1%	N17751 006	OCT WDAG
+ ASTRazeneca	0.005MG/ML;1%	N17751 006	OCT WDAG
@ DENTSPHY PHARM	0.005MG/ML;1.5%	N21384 001	MAR DISC
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE</u>			
INJECTABLE; INJECTION			
LIDOCAINE HCL AND EPINEPHRINE		N80406 001	JUN DISC
@ ELKINS SINK	0.01MG/ML;1%	N80406 002	JUN DISC
@	0.01MG/ML;2%		
<u>EROSARTAN MESYLATE</u>			
TABLET; ORAL			
TEVETEN	EQ 300MG BASE	N20738 004	DEC 22, 1997 JUL CAHN
BIOVAIL	EQ 400MG BASE	N20738 005	DEC 22, 1997 JUL CAHN
	EQ 600MG BASE	N20738 006	MAY 27, 1999 JUL CAHN
+ EPROSARTAN MESYLATE; HYDROCHLORTIAZIDE			
TABLET; ORAL			
TEVETEN HCT	600MG;12.5MG	N21268 001	NOV 01, 2001 JUL CAHN
BIOVAIL	600MG;25MG	N21268 002	NOV 01, 2001 JUL CAHN
+ ERGOTAMINE TARTRATE			
TABLET; SUBLINGUAL			
ERGOMAR	2MG	N87693 001	FEB 24, 1983 MAR CAHN
+ HARVEST PHARMS			
<u>ERYTHROMYCIN</u>			
SOLUTION; TOPICAL			
STATICIN	1.5%	N50526 001	APR CTEC
+ WESTWOOD SQUIBB			

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROMYCIN
⑧ ELKINS SINK EQ 500MG BASE/VIAL N62563 001 MAR 28, 1985 JUN DISC
⑧ EQ 1GM BASE/VIAL N62563 002 MAR 28, 1985 JUN DISC
ERYTHROMYCIN LACTOBIONATE
AP BAXTER HLTHCARE EQ 500MG BASE/VIAL N62993 001 MAY 09, 1989 AUG CAHN
AP EQ 1GM BASE/VIAL N62993 002 MAY 09, 1989 AUG CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC
+ BAXTER HLTHCARE CORP 10MG/ML N19386 006 FEB 25, 2003 JUN NEWA
+ 20MG/ML N19386 007 MAY 28, 2003 JUN NEWA
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
+ BAXTER HLTHCARE CORP 2GM/100ML N19386 005 JAN 27, 2003 MAR NEWA
BREVIBLOC IN PLASTIC CONTAINER
+ BAXTER HLTHCARE CORP 1GM/100ML N19386 004 FEB 16, 2001 MAR NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA
BX + BERLEX LABS 0.0375MG/24HR N20375 005 MAY 27, 2003 JUN NEWA
+ 0.06MG/24HR N20375 006 MAY 27, 2003 JUN NEWA
TABLET; ORAL
ESTRADIOL
⑧ CLONMEL HLTHCARE 0.5MG N40275 001 DEC 29, 1998 AUG DISC
⑧ 1MG N40275 002 DEC 29, 1998 AUG DISC
⑧ 2MG N40275 003 DEC 29, 1998 AUG DISC

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL
FEMRING
GALEN LTD 0.05MG/24HR N21367 001 MAR 20, 2003 MAR NEWA
+ 0.1MG/24HR N21367 002 MAR 20, 2003 MAR NEWA

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR
LUNELLE
⑧ PHARMACIA AND UPJOHN 5MG/0.5ML;25MG/0.5ML N20874 001 OCT 05, 2000 AUG DISC

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
DEPO-TESTADIOL
⑧ PHARMACIA AND UPJOHN 2MG/ML;50MG/ML N17968 001 MAY WDAG

ESTRADIOL HEMIHYDRATE

>A> EMULSION; TOPICAL
>A> ESTRASORB
>A> + NOVAVAX 0.25% N21371 001 OCT 09, 2003 OCT NEWA

ESTRADIOL; NORGESTIMATE

TABLET; ORAL
PREFEST
+ KING PHARMS 1MG;1MG;0.09MG

N21040 001 OCT 22, 1999 MAY CTNA

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN
+ WYETH PHARMS INC 0.625MG/GM N20216 001 MAR CAHN
INJECTABLE; INJECTION
+ WYETH PHARMS INC 25MG/VIAL N10402 001 MAR CAHN
TABLET; ORAL
WYETH PHARMS INC 0.3MG N04782 003 MAR CAHN
0.45MG N04782 006 JUL 16, 2003 JUL NEWA
+ 0.625MG N04782 004 MAR CAHN
0.9MG N04782 005 JAN 26, 1984 MAR CAHN
+ 1.25MG N04782 001 MAR CAHN
2.5MG N04782 002 MAR CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

@ WYETH PHARMS INC 0.625MG;0.625MG;5MG

N20303 002 DEC 30, 1994 MAR CAHN

PREMPHASE 14/14

+ WYETH PHARMS INC 0.625MG;0.625MG;5MG

N20527 002 NOV 17, 1995 MAR CAHN

PREMPRO

+ WYETH PHARMS INC 0.3MG;1.5MG

N20527 005 JUN 04, 2003 JUN NEWA

+ WYETH PHARMS INC 0.45MG;1.5MG

N20527 004 MAR 12, 2003 MAR NEWA

+ WYETH PHARMS INC 0.625MG;0.625MG;2.5MG;2.5MG

N20527 001 NOV 17, 1995 MAR CAHN

+ WYETH PHARMS INC 0.625MG;0.625MG;5MG;5MG

N20527 003 JAN 09, 1998 MAR CAHN

PREMPRO (PREMARIN;CYCRIN)

@ WYETH PHARMS INC 0.625MG;0.625MG;2.5MG;2.5MG

N20303 001 DEC 30, 1994 MAR CAHN

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS 0.3MG

N84951 001 JAN CRLD

ETHACRYNIC ACID

TABLET; ORAL

EDECрин

+ MERCK 25MG

N16092 001 MAY CRLD

@ 50MG

N16092 002 MAY DISC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HCL

AB + WEST WARD 400MG

N75095 002 NOV 30, 1999 JUN CRLD

MYAMBUTOL

AB LEDERLE 100MG

N16320 001 JUN DISC

AB 400MG

N16320 003 JUN DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28
DEMULEN 1/35-28
AB + GD SEARLE LLC 0.035MG;1MG N18160 001 JUL CRLD

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL
NUVARING
+ ORGANON USA INC 0.015MG;0.12MG N21187 001 OCT 03, 2001 JUN CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL
SEASONALE
+ BARR 0.03MG;0.15MG N21544 001 SEP 05, 2003 SEP NEWA
TABLET; ORAL-21
ALESSE
AB1 + WYETH PHARMS INC 0.02MG;0.1MG N20683 001 MAR 27, 1997 MAR CAHN
LEVONORGESTREL AND ETHINYL ESTRADIOL
AB1 BARR 0.02MG;0.1MG N75862 001 APR 29, 2003 APR NEWA
NORDETTE-21
AB + WYETH PHARMS INC 0.03MG;0.15MG N18668 001 MAY 10, 1982 MAR CAHN
TRIPHASIC-21
AB + WYETH PHARMS INC 0.03MG;0.04MG;0.03MG;0.05MG;0.125MG N19192 001 NOV 01, 1984 MAR CAHN
;0.075MG
TABLET; ORAL-28
ALESSE
AB1 WYETH PHARMS INC 0.02MG;0.1MG N20683 002 MAR 27, 1997 MAR CAHN
LEVONORGESTREL AND ETHINYL ESTRADIOL
AB1 BARR 0.02MG;0.1MG N75862 002 APR 29, 2003 APR NEWA
NORDETTE-28
AB WYETH PHARMS INC 0.03MG;0.15MG N18782 001 JUL 21, 1982 MAR CAHN
TRIPHASIC-28
AB WYETH PHARMS INC 0.03MG;0.04MG;0.03MG;0.05MG;0.125MG N19190 001 NOV 01, 1984 MAR CAHN
;0.075MG

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
BREVICON 21-DAY
AB + WATSON LABS 0.035MG;0.5MG N17566 001 AUG CRLD
MODICON 21
@ ORTHO MCNEIL PHARM 0.035MG;0.5MG N17488 001 AUG DISC
ORTHO-NOVUM 1/35-21
@ ORTHO MCNEIL PHARM 0.035MG;1MG N17489 002 AUG DISC
ORTHO-NOVUM 10/11-21
@ ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG N18354 001 JAN 11, 1982 AUG DISC
ORTHO-NOVUM 7/7-21
@ ORTHO MCNEIL PHARM 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 N18985 001 APR 04, 1984 AUG DISC
.75MG
TRI-NORINYL 21-DAY
@ WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 N18977 001 APR 13, 1984 MAR CPOT
.5MG
@ 0.035MG,0.035MG;0.5MG,1MG N18977 001 APR 13, 1984 FEB DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28
ORTHO-NOVUM 7/7/7-28

AB + ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N18985 002 APR 04, 1984 FEB CRLD
+ WARNER CHILCOTT	0.035MG;0.4MG	N17716 001 JAN CRLD
+ OVCON-50	0.05MG;1MG	N17576 001 JAN CRLD
+ WARNER CHILCOTT	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .5MG	N18977 002 APR 13, 1984 MAR CPOT
+ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 002 APR 13, 1984 JAN CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
FEMHRT

+ GALEN CHEM	0.005MG;1MG	N21065 002 OCT 15, 1999 MAY CAHN
--------------	-------------	----------------------------------

TABLET; ORAL-21
ESTROSTEP 21

@ GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 001 OCT 09, 1996 APR CAHN
JUNEL 1.5/30		

AB BARR 0.03MG;1.5MG N76381 001 MAY 30, 2003 MAY NEWA

JUNEL 1/20

AB BARR 0.02MG;1MG N76380 001 MAY 30, 2003 MAY NEWA

LOESTRIN 21 1.5/30

+ GALEN CHEM	0.03MG;1.5MG	N17875 001 APR CAHN
--------------	--------------	---------------------

AB + 0.03MG;1.5MG N17875 001 MAY CFTG

LOESTRIN 21 1/20

+ GALEN CHEM	0.02MG;1MG	N17876 001 APR CAHN
--------------	------------	---------------------

AB + 0.02MG;1MG N17876 001 MAY CFTG

TABLET; ORAL-28
ESTROSTEP FE

+ GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 002 OCT 09, 1996 APR CAHN
--------------	-----------------------------------	----------------------------------

JUNEL FE 1.5/30

AB BARR 0.03MG;1.5MG N76064 001 SEP 18, 2003 SEP NEWA

JUNEL FE 1/20

AB BARR 0.02MG;1MG N76081 001 SEP 18, 2003 SEP NEWA

LOESTRIN FE 1.5/30

AB + GALEN CHEM	0.03MG;1.5MG	N17355 001 APR CAHN
-----------------	--------------	---------------------

LOESTRIN FE 1/20

AB + GALEN CHEM	0.02MG;1MG	N17354 001 APR CAHN
-----------------	------------	---------------------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21
LO/OVRAL

AB + WYETH PHARMS INC	0.03MG;0.3MG	N17612 001 MAR CAHN
-----------------------	--------------	---------------------

OGESTREL 0.5/50-21

AB WATSON LABS	0.05MG;0.5MG	N75406 001 DEC 15, 1999 FEB CAHN
----------------	--------------	----------------------------------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

OVRAL

AB +	WYETH PHARMS INC	0.05MG;0.5MG	N16672 001	MAR	CAHN
	TABLET; ORAL-28				
	LO/OVRAL-28				
AB	WYETH PHARMS INC	0.03MG;0.3MG	N17802 001	MAR	CAHN
	OGESTREL 0.5/50-28				
AB	WATSON LABS	0.05MG;0.5MG	N75406 002	DEC 15, 1999	FEB CAHN
	OVRAL-28				
AB	WYETH PHARMS INC	0.05MG;0.5MG	N16806 001	MAR	CAHN

ETHIONAMIDE

TABLET; ORAL

TRECATOR-SC

+ AB	WYETH PHARMS INC	250MG	N13026 002	MAR	CAHN
------	------------------	-------	------------	-----	------

ETHOTOIN

TABLET; ORAL

PEGANONE

+ AB	OVATION PHARMS	250MG	N10841 001	MAR	CAHN
	@	500MG	N10841 003	MAR	CAHN

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

AB	PROCTER AND GAMBLE	200MG	N17831 001	JUL	CTEC
AB +		400MG	N17831 002	JUL	CTEC
	ETIDRONATE DISODIUM				
AB	GENPHARM	200MG	N75800 001	JAN 24, 2003	JAN NEWA
AB		400MG	N75800 002	JAN 24, 2003	JAN NEWA

ETODOLAC

CAPSULE; ORAL

LODINE

AB	WYETH PHARMS INC	200MG	N18922 002	JAN 31, 1991	MAR	CAHN
AB +		300MG	N18922 003	JAN 31, 1991	MAR	CAHN
	TABLET; ORAL					
AB	WYETH PHARMS INC	400MG	N18922 004	JUL 29, 1993	MAR	CAHN
AB +		500MG	N18922 005	JUN 28, 1996	MAR	CAHN

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

AB	TARO	400MG	N76174 001	MAR 13, 2003	MAR	NEWA
AB		500MG	N76174 002	MAR 13, 2003	MAR	NEWA
AB		600MG	N76174 003	MAR 13, 2003	MAR	NEWA
	LODINE XL					
AB +	WYETH PHARMS INC	400MG	N20584 001	OCT 25, 1996	MAR	CAHN
AB +		500MG	N20584 003	JAN 20, 1998	MAR	CAHN
AB +		600MG	N20584 002	OCT 25, 1996	MAR	CAHN

ETOPOSIDE

INJECTABLE; INJECTION
 ETOPOSIDE

AP	SICOR PHARMS	20MG/ML	N74284 001	FEB 10, 1994	JUL	CAHN
AP		20MG/ML	N74529 001	JUL 24, 1996	JUL	CAHN
	TOPOSAR					
AP	GENSIA SICOR PHARMS	20MG/ML	N74166 001	FEB 27, 1995	JUL	CAHN

FAMOTIDINE

INJECTABLE; INJECTION
 FAMOTIDINE

AP	BAXTER HLTHCARE	10MG/ML	N75488 001	APR 16, 2001	AUG	CAHN
	FAMOTIDINE PRESERVATIVE FREE					
AP	BAXTER HLTHCARE	10MG/ML	N75486 001	APR 16, 2001	JUN	CAHN

FELBAMATE

SUSPENSION; ORAL
 FELBATOL

+ MEDPOINTE	600MG/5ML	N20189 003	JUL 29, 1993	MAR	CAHN
TABLET; ORAL					
MEDPOINTE	400MG	N20189 001	JUL 29, 1993	MAR	CAHN
+	600MG	N20189 002	JUL 29, 1993	MAR	CAHN

FENOFIBRATE

CAPSULE; ORAL
 >A> FENOFIBRATE (MICRONIZED)

>A> AB	IMPAK LABS	67MG	N75868 001	OCT 27, 2003	OCT	NEWA
>A> AB		134MG	N75868 002	OCT 27, 2003	OCT	NEWA
>A> AB		200MG	N75868 003	OCT 27, 2003	OCT	NEWA
>D>	TEVA	67MG	N75753 001	SEP 03, 2002	OCT	CFTG
>A> AB		67MG	N75753 001	SEP 03, 2002	OCT	CFTG
		67MG	N75753 001	SEP 03, 2002	MAR	CTEC
>D>		134MG	N75753 002	APR 09, 2002	OCT	CFTG
>A> AB		134MG	N75753 002	APR 09, 2002	OCT	CFTG
		134MG	N75753 002	APR 09, 2002	MAR	CTEC
>D>	+	200MG	N75753 003	APR 09, 2002	OCT	CFTG
>A> AB	+	200MG	N75753 003	APR 09, 2002	OCT	CFTG
	+	200MG	N75753 003	APR 09, 2002	MAR	CRLD
	TRICOR (MICRONIZED)					
@ ABBOTT		67MG	N19304 002	FEB 09, 1998	MAR	DISC
@		134MG	N19304 003	JUN 30, 1999	MAR	DISC
@		200MG	N19304 004	JUN 30, 1999	MAR	DISC

FENTANYL CITRATE

INJECTABLE; INJECTION
 FENTANYL CITRATE PRESERVATIVE FREE

AP + BAXTER HLTHCARE	EQ 0.05MG BASE/ML	N19101 001	JUL 11, 1984	AUG	CAHN
----------------------	-------------------	------------	--------------	-----	------

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL
 FERRISELTZ

@ OTSUKA	600MG/PACKET	N20292 001	OCT 14, 1997	AUG	CAHN
----------	--------------	------------	--------------	-----	------

>A> FERRIC HEXACYANOFERRATE(II)

>A> CAPSULE; ORAL
 >A> RADIOGARDASE (PRUSSIAN BLUE)
 >A> + HEYDT 500MG

N21626 001 OCT 02, 2003 OCT NEWA

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL
 FLAVOXATE HCL
 AB IMPAX PHARMS 100MG
 URISPAS
 + ORTHO MCNEIL PHARM 100MG
 AB + 100MG

N76234 001 AUG 28, 2003 AUG NEWA
 N16769 001 MAR CAHN
 N16769 001 AUG CFTG

FLECAINIDE ACETATE

TABLET; ORAL
 FLECAINIDE ACETATE
 AB GENEVA PHARMS 50MG
 AB 100MG
 AB 150MG
 AB RANBAXY 50MG
 AB 100MG
 AB 150MG
 AB ROXANE 50MG
 AB 100MG
 AB 150MG

N76030 001 OCT 28, 2002 JUN CAHN
 N76030 002 OCT 28, 2002 JUN CAHN
 N76030 003 OCT 28, 2002 JUN CAHN
 N76421 001 MAR 28, 2003 MAR NEWA
 N76421 002 MAR 28, 2003 MAR NEWA
 N76421 003 MAR 28, 2003 MAR NEWA
 N76278 001 JAN 14, 2003 JAN NEWA
 N76278 002 JAN 14, 2003 JAN NEWA
 N76278 003 JAN 14, 2003 JAN NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
 FLUDARA
 AP + BERLEX 50MG/VIAL
 FLUDARABINE PHOSPHATE
 AP GENESIA SICOR PHARMS 50MG/VIAL

N20038 001 APR 18, 1991 AUG CFTG
 N76349 001 AUG 28, 2003 AUG NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL
 FLUDROCORTISONE ACETATE
 AB BARR 0.1MG

N40425 001 JAN 21, 2003 JAN NEWA

FLUNISOLIDE

SPRAY, METERED; NASAL
 NASAREL
 + IVAX RES 0.029MG/SPRAY

N20409 001 MAR 08, 1995 JUL CPOT

FLUOCINONIDE

CREAM; TOPICAL
 FLUOCINONIDE
 AB1 ALPHARMA US PHARM 0.05%
 AB1 FOUGERA 0.05%
 AB1 TARO 0.05%
 AB1 0.05%
 AB1 TEVA 0.05%

N73085 001 FEB 14, 1992 MAY CTEC
 N73030 001 OCT 17, 1994 MAY CTEC
 N19117 001 JUN 26, 1984 MAY CTEC
 N71500 001 JUN 10, 1987 MAY CTEC
 N72488 001 FEB 06, 1989 MAY CTEC

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

AB2	ALPHARMA US PHARM	0.05%	N74204 001	JUN 13, 1995	MAY	CTEC
AB2	DRAKIS HLTH	0.05%	N72494 001	JAN 19, 1989	MAY	CTEC
AB2	TARO	0.05%	N72494 001	JAN 19, 1989	JUN	CAHN
AB2	TEVA	0.05%	N72490 001	FEB 07, 1989	MAY	CTEC
	LIDEX					
AB1 +	MEDICIS	0.05%	N16908 002		MAY	CTEC
	LIDEX-E					
AB2 +	MEDICIS	0.05%	N16908 003		MAY	CRLD

FLUORESCIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

@ NOVARTIS 25%

N17869 001

JAN DISC

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

AP GENSIA SICOR PHARMS 50MG/ML

N40023 001 OCT 18, 1991 JUL CAHN

AP + 50MG/ML

N81225 001 AUG 28, 1991 JUL CAHN

FLUOROURACIL

AP SICOR PHARMS 50MG/ML

N40333 001 JAN 27, 2000 JUL CAHN

AP 50MG/ML

N40334 001 FEB 25, 2000 JUL CAHN

SOLUTION; TOPICAL

FLUOROPLEX

@ ALLERGAN HERBERT 1%

N16765 001

JUN DISC

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

@ KING PHARMS 25MG/ML

N74966 001 APR 16, 1998 MAY DISC

FLURANDRENOLIDE

LOTION; TOPICAL

CORDRAN

>D>	+ OCLASSEN	0.05%	N13790 001	OCT	CAHN
	+	0.05%	N13790 001	MAY	CTEC
>A>	+ WATSON LABS	0.05%	N13790 001	OCT	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB GENPHARM 125MG

N76224 001 MAY 09, 2003 MAY NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB GENEVA PHARMS 25MG

N75887 001 JAN 05, 2001 APR CAHN

AB 50MG

N75887 002 JAN 05, 2001 APR CAHN

<u>GANCICLOVIR</u>	
CAPSULE; ORAL	
CYTOVENE	
AB	ROCHE PALO 250MG
AB +	500MG
GANCICLOVIR	
AB	RANBAXY 250MG
AB	500MG
N20460 001 DEC 22, 1994 JUN CFTG	
N20460 002 DEC 12, 1997 JUN CFTG	
N76457 001 JUN 27, 2003 JUN NEWA	
N76457 002 JUN 27, 2003 JUN NEWA	
<u>GANCICLOVIR SODIUM</u>	
INJECTABLE; INJECTION	
CYTOVENE IV	
AP +	ROCHE PALO EQ 500MG BASE/VIAL
GANCICLOVIR SODIUM	
AP	BEDFORD EQ 500MG BASE/VIAL
N19661 001 JUN 23, 1989 JUL CFTG	
N76222 001 JUL 16, 2003 JUL NEWA	
<u>GATIFLOXACIN</u>	
INJECTABLE; INJECTION	
TEQUIN	
+ +	BRISTOL MYERS SQUIBB EQ 2MG /ML(200MG/100ML)
+ +	EQ 2MG /ML(400MG/200ML)
+ +	EQ 10MG /ML(200MG)
N21062 001 DEC 17, 1999 APR CRLD	
N21062 002 DEC 17, 1999 APR CRLD	
N21062 003 DEC 17, 1999 APR CRLD	
SOLUTION/DROPS; OPHTHALMIC	
ZYMAR	
+ +	ALLERGAN 0.3%
N21493 001 MAR 28, 2003 MAR NEWA	
<u>GEFITINIB</u>	
TABLET; ORAL	
IRESSA	
+ +	ASTRAZENECA 250MG
N21399 001 MAY 05, 2003 MAY NEWA	
<u>GEMFIBROZIL</u>	
TABLET; ORAL	
GEMFIBROZIL	
+ +	CLONNELL HLTHCARE 600MG
N74270 001 SEP 27, 1993 AUG DISC	
<u>GEMIFLOXACIN MESYLATE</u>	
TABLET; ORAL	
FACTIVE	
+ +	GENESOFT PHARMS EQ 320MG BASE
+ +	LG LIFE EQ 320MG BASE
N21158 001 APR 04, 2003 MAY CAHN	
N21158 001 APR 04, 2003 APR NEWA	
<u>GEMTUZUMAB OZOGAMICIN</u>	
INJECTABLE; INJECTION	
MYLOTARG	
+ +	WYETH PHARMS INC 5MG/VIAL
N21174 001 MAY 17, 2000 MAR CAHN	
<u>GENTAMICIN SULFATE</u>	
CREAM; TOPICAL	
GARAMYCIN	
@ SCHERING	EQ 0.1% BASE
N60462 001 FEB DISC	

GENTAMICIN SULFATE

CREAM; TOPICAL					
GENTAMICIN SULFATE					
AT + FOUGERA	EQ 0.1% BASE	N62531	001	JUL 05, 1984	FEB CRLD
INJECTABLE; INJECTION					
AP + AM PHARM PARTNERS	EQ 10MG BASE/ML	N62356	001	MAR 04, 1982	JUN CRLD
@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N62251	002		JUN DISC
@	EQ 40MG BASE/ML	N62251	001		JUN DISC
OINTMENT; OPHTHALMIC					
GARAMYCIN					
@ SCHERING	EQ 0.3% BASE	N50425	001		APR DISC
GENTAMICIN SULFATE					
+ AKORN	EQ 0.3% BASE	N64093	001	AUG 31, 1995	APR CRLD

GLIMEPIRIDE

TABLET; ORAL					
AMARYL					
+ AVENTIS PHARMS	1MG	N20496	001	NOV 30, 1995	JAN CRLD
	4MG	N20496	003	NOV 30, 1995	JAN CRLD

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL					
GLIPIZIDE					
AB WATSON LABS	5MG	N76467	001	SEP 08, 2003	SEP NEWA
GLUCOTROL XL					
AB PFIZER	5MG	N20329	001	APR 26, 1994	SEP CFTG

GLYBURIDE

TABLET; ORAL					
GLYBURIDE (MICRONIZED)					
>D> AB AVENTIS PHARMS	1.5MG	N20055	001	APR 17, 1992	OCT DISC
>A> @	1.5MG	N20055	001	APR 17, 1992	OCT DISC
>D> AB	3MG	N20055	002	APR 17, 1992	OCT DISC
>A> @	3MG	N20055	002	APR 17, 1992	OCT DISC
>D> AB	6MG	N20055	003	MAR 08, 2000	OCT DISC
>A> @	6MG	N20055	003	MAR 08, 2000	OCT DISC
AB HIKMA	1.5MG	N75890	001	JUL 31, 2003	JUL NEWA
AB	3MG	N75890	002	JUL 31, 2003	JUL NEWA
AB	6MG	N75890	003	JUL 31, 2003	JUL NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION					
ROBINUL					
AP + BAXTER HLTHCARE CORP	0.2MG/ML	N17558	001		AUG CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION					
FACTREL					
+ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123	001	SEP 30, 1982	MAY CAHN
@	EQ 0.2MG BASE/VIAL	N18123	002	SEP 30, 1982	MAY CAHN
@	EQ 0.5MG BASE/VIAL	N18123	003	SEP 30, 1982	MAY CAHN

GONADOTROPIN, CHORIONIC
INJECTABLE; INJECTION

A.P.L.

@ FERRING

5,000 UNITS/VIAL

N17055 001

JUL CAHN

@

10,000 UNITS/VIAL

N17055 002

JUL CAHN

@

20,000 UNITS/VIAL

N17055 003

JUL CAHN

@ WYETH AYERST

5,000 UNITS/VIAL

N17055 001

JUN DISC

@

10,000 UNITS/VIAL

N17055 002

JUN DISC

CHORIONIC GONADOTROPIN

@ STERIS

5,000 UNITS/VIAL

N17016 006

SEP DISC

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

>D> AT BAUSCH AND LOMB

0.025MG/ML;EQ 1.75MG BASE/ML;10,000

UNITS/ML

N64047 001 JAN 31, 1996 OCT CRLD

>A> AT +

0.025MG/ML;EQ 1.75MG BASE/ML;10,000

UNITS/ML

N64047 001 JAN 31, 1996 OCT CRLD

GRANisetron Hydrochloride

SOLUTION; ORAL

KYTRIL

+ ROCHE

EQ 2MG BASE/10ML

N21238 001 JUN 27, 2001 JUL CMFD

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

@ OTSUKA

EQ 200MG BASE

N20695 001 NOV 06, 1997 MAY DISC

@

EQ 400MG BASE

N20695 002 MAY 14, 1998 MAY DISC

@

EQ 600MG BASE

N20695 003 MAY 14, 1998 MAY DISC

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

AB + WATSON LABS

EQ 8MG BASE

N74025 002 FEB 28, 1994 JUN CRLD

WYTENSIN

@ WYETH AYERST

EQ 4MG BASE

N18587 001 SEP 07, 1982 JUN DISC

@

EQ 8MG BASE

N18587 002 SEP 07, 1982 JUN DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ KING PHARMS

EQ 50MG BASE/ML

N75176 001 FEB 09, 2000 MAY DISC

@

EQ 100MG BASE/ML

N75176 002 FEB 09, 2000 MAY DISC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP-LOCK

AP + BAXTER HLTHCARE

10 UNITS/ML

N17037 007

JUN CAHN

AP +

100 UNITS/ML

N17037 006

JUN CAHN

HEP-LOCK U/P

AP + BAXTER HLTHCARE

10 UNITS/ML

N17037 010

JUN CAHN

AP +

AP		100 UNITS/ML	N17037 011	JUN 10, 1983	JUN	CAHN
HEPARIN LOCK FLUSH						
BAXTER HLTHCARE CORP	10 UNITS/ML	N17007 008		MAY	CAHN	
B	100 UNITS/ML	N17007 009		MAY	CAHN	
HEPARIN SODIUM						
AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17037 001		JUN	CAHN
AP		5,000 UNITS/ML	N17037 002		JUN	CAHN
AP		5,000 UNITS/0.5ML	N17037 013	APR 07, 1986	JUN	CAHN
AP		10,000 UNITS/ML	N17037 003		JUN	CAHN
BAXTER HLTHCARE CORP	1,000 UNITS/ML	N17007 001		MAY	CAHN	
B	2,500 UNITS/ML	N17007 007		MAY	CAHN	
B	5,000 UNITS/ML	N17007 002		MAY	CAHN	
B	5,000 UNITS/0.5ML	N17007 010		MAY	CAHN	
B	7,500 UNITS/ML	N17007 003		MAY	CAHN	
B	10,000 UNITS/ML	N17007 004		MAY	CAHN	
B	15,000 UNITS/ML	N17007 005		MAY	CAHN	
B	20,000 UNITS/ML	N17007 006		MAY	CAHN	
>D>	SODIUM HEPARIN					
>D> AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17036 001	MAR 04, 1988	OCT	DISC
>A>	B	1,000 UNITS/ML	N17036 001	MAR 04, 1988	OCT	DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	AXIOM PHARM	1.5MG/5ML;5MG/5ML	N40285 001	JUL 19, 1999	MAY	CAHN
----	-------------	-------------------	------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

WYDASE

BAXTER HLTHCARE	150 UNITS/ML	N06343 002	AUG	CAHN
B	150 UNITS/VIAL	N06343 006	AUG	CAHN
B	1,500 UNITS/VIAL	N06343 005	AUG	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

CLONMEL HLTHCARE	25MG	N86243 001	AUG	DISC
B	50MG	N86242 002	AUG	DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	CLONMEL HLTHCARE	25MG	N87059 001	JUL	CAHN
AB		50MG	N87068 001	JUL	CAHN
B		100MG	N87060 001	JUL	CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

CLONMEL HLTHCARE	15MG;250MG	N72507 001	JUN 02, 1989	JUL	DISC
B	25MG;250MG	N72508 001	JUN 02, 1989	JUL	DISC
B	30MG;500MG	N72509 001	JUN 02, 1989	JUL	DISC
B	50MG;500MG	N72510 001	JUN 02, 1989	JUL	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL
 BENICAR HCT
 SANKYO 12.5MG;20MG N21532 002 JUN 05, 2003 JUN NEWA
 12.5MG;40MG N21532 003 JUN 05, 2003 JUN NEWA
 + 25MG;40MG N21532 005 JUN 05, 2003 JUN NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
 INDERIDE-40/25
 AB WYETH PHARMS INC 25MG;40MG N18031 001 MAR CAHN
 INDERIDE-80/25
 AB + WYETH PHARMS INC 25MG;80MG N18031 002 MAR CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
 DIOVAN HCT
 NOVARTIS 25MG;160MG N20818 003 JAN 17, 2002 JUL NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL
 HYDROCODONE BITARTRATE AND IBUPROFEN
 AB TEVA 7.5MG;200MG N76023 001 APR 11, 2003 APR NEWA
 VICOPROFEN
 AB + ABBOTT 7.5MG;200MG N20716 001 SEP 23, 1997 APR CFTG

HYDROCORTISONE

LOTION; TOPICAL
 HYDROCORTISONE
 AT VINTAGE PHARMS 2.5% N40417 001 JUL 30, 2003 JUL NEWA

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL
 CORTEF
 @ PHARMACIA AND UPJOHN EQ 10MG BASE/5ML N09900 001 AUG DISC

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
 HYDROCORTONE
 @ MERCK EQ 50MG BASE/ML N12052 001 APR DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
 HYDROCORTISONE SODIUM SUCCINATE
 @ BAXTER HLTHCARE EQ 100MG BASE/VIAL N86619 001 AUG CAHN
 @ EQ 250MG BASE/VIAL N87567 001 AUG CAHN
 @ EQ 500MG BASE/VIAL N87568 001 AUG CAHN
 @ EQ 1GM BASE/VIAL N87569 001 AUG CAHN

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

@ BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N50237 006	JUN 05, 1984	JUN	DISC
@	1%;EQ 3.5MG BASE/GM	N50237 005	JUN 05, 1984	JUN	DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423 001	AUG 25, 1983	FEB	CMFD
SUSPENSION/DROPS; OPHTHALMIC					
AT ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001	MAY 11, 1988	FEB	CMFD
SUSPENSION/DROPS; OTIC					
AT ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488 001	NOV 06, 1985	FEB	CMFD

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOBIOPTIC

>D> + SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	N62302 001	OCT	WDAG
>A> @	5MG/ML;EQ 10,000 UNITS BASE/ML	N62302 001	OCT	WDAG

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

@ WYETH AYERST	50MG	N83383 001	JUN	DISC
----------------	------	------------	-----	------

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

SALUTENSIN

@ SHIRE LABS	50MG;0.125MG	N12359 003	JUL	DISC
--------------	--------------	------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HCL

AP FAULDING	10MG/ML	N76444 001	APR 25, 2003	APR	NEWA
-------------	---------	------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

@ ELKINS SINK	50MG/ML	N85551 002	JUN	DISC
---------------	---------	------------	-----	------

HYDROXYZINE HCL

@ ELKINS SINK	25MG/ML	N85551 001	JUN	DISC
---------------	---------	------------	-----	------

TABLET; ORAL

ATARAX

@ PFIZER	10MG	N10392 001	FEB	DISC
----------	------	------------	-----	------

@	25MG	N10392 004	FEB	DISC
---	------	------------	-----	------

@	50MG	N10392 006	FEB	DISC
---	------	------------	-----	------

@	100MG	N10392 005	FEB	DISC
---	-------	------------	-----	------

HYDROXYZINE HCL

AB + SIDMAK LABS NJ	10MG	N88617 001	JAN 10, 1986	FEB	CRLD
---------------------	------	------------	--------------	-----	------

AB +	25MG	N88618 001	JAN 10, 1986	FEB	CRLD
------	------	------------	--------------	-----	------

AB +	50MG	N88619 001	JAN 10, 1986	FEB	CRLD
------	------	------------	--------------	-----	------

@ 100MG

N81054 001 SEP 25, 1995 FEB DISC

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL

>D>	PFIZER	EQ 25MG HCL/5ML	N11795 001	OCT	CRLD
>A>	+	EQ 25MG HCL/5ML	N11795 001	OCT	CRLD

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

@ ROCHE

EQ 2.5MG BASE

+ EQ 2.5MG BASE

N21455 001 MAY 16, 2003 JUL DISC

N21455 001 MAY 16, 2003 MAY NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

+ AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	SEP	CTNA
+	3GM/VIAL	N76078 002	MAY 28, 2002	SEP	CTNA

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

@ NOVARTIS

50MG

N21335 001 MAY 10, 2001 JUN DISC

TABLET; ORAL

NOVARTIS

100MG

N21588 001 APR 18, 2003 APR NEWA

+

400MG

N21588 002 APR 18, 2003 APR NEWA

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

@ QUESTCOR PHARMS 100MG/ML

N02282 001 SEP DISC

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

@ BAXTER HLTHCARE	41%	N74629 001	NOV 06, 1996	AUG	CAHN
@	51%	N74629 004	MAR 31, 1998	AUG	CAHN
@	61%	N74629 002	NOV 06, 1996	AUG	CAHN
@	76%	N74629 003	NOV 06, 1996	AUG	CAHN
@ ELKINS SINK PHARM	41%	N74629 001	NOV 06, 1996	JUN	DISC
@	51%	N74629 004	MAR 31, 1998	JUN	DISC
@	61%	N74629 002	NOV 06, 1996	JUN	DISC
@	76%	N74629 003	NOV 06, 1996	JUN	DISC

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

@ MALLINCKRODT

51%

N20923 001 MAY 28, 1998 JUN DISC

OPTIRAY 300

+ MALLINCKRODT

64%

N20923 004 MAY 13, 1999 JUN NEWA

OPTIRAY 320

@ MALLINCKRODT

68%

N20923 002 MAY 29, 1998 JUN DISC

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL

ATROVENT

AB +	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N20393 001	OCT 20, 1995	MAR	CFTG
AB +		0.042MG/SPRAY	N20394 001	OCT 20, 1995	MAR	CFTG
	IPRATROPIUM BROMIDE					
AB	BAUSCH AND LOMB	0.021MG/SPRAY	N76025 001	MAR 31, 2003	MAR	NEWA
AB		0.042MG/SPRAY	N76103 001	MAR 31, 2003	MAR	NEWA
AB	DEY	0.021MG/SPRAY	N75552 001	MAR 31, 2003	MAR	NEWA
AB		0.042MG/SPRAY	N75553 001	MAR 31, 2003	MAR	NEWA
AB	NOVEX	0.021MG/SPRAY	N76156 001	APR 18, 2003	APR	NEWA
AB		0.042MG/SPRAY	N76155 001	APR 18, 2003	APR	NEWA

ISONIAZID

TABLET; ORAL

ISONIAZID

AA	@ AXIOM PHARM	100MG	N80136 001	MAY	CAHN
	AA	300MG	N83633 001	MAY	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HCL

	@ BAXTER HLTHCARE	0.2MG/ML	N83486 001	JUN	DISC
--	-------------------	----------	------------	-----	------

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

BC +	SCHWARZ PHARMA	40MG	N19790 001	SEP 02, 1988	JUN	CRLD
+		40MG	N19790 001	SEP 02, 1988	JUL	CTEC

ISORDIL

@ WYETH AYERST 40MG

N12882 002 JUL 29, 1988 JUN DISC

TABLET; ORAL

AB	BIOVAI	5MG	N12093 007	JUL 29, 1988	JUN	CAHN
AB		10MG	N12093 002	JUL 29, 1988	JUN	CAHN
AB		20MG	N12093 006	JUL 29, 1988	JUN	CAHN

AB + 30MG

N12093 005 JUL 29, 1988 JUN CAHN

>D>	AB	40MG	N12093 001	JUL 29, 1988	OCT	CRLD
>A>	+	40MG	N12093 001	JUL 29, 1988	OCT	CRLD

AB		40MG	N12093 001	JUL 29, 1988	JUN	CAHN
AB	WYETH PHARMS INC	5MG	N12093 007	JUL 29, 1988	MAR	CAHN
AB		10MG	N12093 002	JUL 29, 1988	MAR	CAHN

AB		20MG	N12093 006	JUL 29, 1988	MAR	CAHN
AB +		30MG	N12093 005	JUL 29, 1988	MAR	CAHN
AB		40MG	N12093 001	JUL 29, 1988	MAR	CAHN

SORBITRATE

>D>	AB	ASTRAZENECA	20MG	N86405 002	AUG 21, 1990	OCT	WDAG
>A>	@		20MG	N86405 002	AUG 21, 1990	OCT	WDAG

>D>	AB		40MG	N88125 001	AUG 21, 1990	OCT	WDAG
>A>	@		40MG	N88125 001	AUG 21, 1990	OCT	WDAG

	TABLET; SUBLINGUAL						
	ISORDIL						

AB	BIOVAI	2.5MG	N12940 004	JUL 29, 1988	JUN	CAHN
----	--------	-------	------------	--------------	-----	------

AB		5MG	N12940 003	JUL 29, 1988	JUN	CAHN
	+	10MG	N12940 005	JUL 29, 1988	JUN	CAHN
AB	WYETH PHARMS INC	2.5MG	N12940 004	JUL 29, 1988	MAR	CAHN
AB		5MG	N12940 003	JUL 29, 1988	MAR	CAHN
	+	10MG	N12940 005	JUL 29, 1988	MAR	CAHN
TABLET, CHEWABLE; ORAL SORBITRATE						
>D>	+ ASTRAZENECA	10MG	N16776 003	APR 01, 1996	OCT	WDAG
>A>	@	10MG	N16776 003	APR 01, 1996	OCT	WDAG

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
IMDUR

>D>	AB + SCHERING	30MG	N20225 001	AUG 12, 1993	OCT	CAHN
>D>	AB +	60MG	N20225 002	AUG 12, 1993	OCT	CAHN
>D>	AB +	120MG	N20225 003	MAR 30, 1995	OCT	CAHN
>A>	AB + SCHERING PLOUGH	30MG	N20225 001	AUG 12, 1993	OCT	CAHN
>A>	AB +	60MG	N20225 002	AUG 12, 1993	OCT	CAHN
>A>	AB +	120MG	N20225 003	MAR 30, 1995	OCT	CAHN

ISOTRETINOIN

CAPSULE; ORAL
CLARAVIS

AB	BARR	10MG	N76356 001	APR 11, 2003	APR	NEWA
AB		20MG	N76135 002	APR 11, 2003	APR	NEWA
AB		40MG	N76135 001	APR 11, 2003	APR	NEWA
SOTRET						
	RANBAXY	30MG	N76503 001	JUN 20, 2003	JUN	NEWA

ISRADIPINE

CAPSULE; ORAL
DYNACIRC

AB	RELIANT PHARMS	2.5MG	N19546 001	DEC 20, 1990	MAY	CAHN
	+	5MG	N19546 002	DEC 20, 1990	MAY	CAHN
TABLET, EXTENDED RELEASE; ORAL						
DYNACIRC CR						
	+ RELIANT PHARMS	5MG	N20336 001	JUN 01, 1994	MAY	CAHN
	+	10MG	N20336 002	JUN 01, 1994	MAY	CAHN

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN

AB	@ BAXTER HLTHCARE	EQ 75MG BASE/2ML	N62324 001		AUG	CAHN
	@	EQ 500MG BASE/2ML	N62324 002		AUG	CAHN
	@	EQ 1GM BASE/3ML	N62324 003		AUG	CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AB	CLONMEL HLTHCARE	75MG	N74014 003	JAN 29, 1993	JUN	CAHN
AB +	TEVA	75MG	N73517 001	DEC 22, 1992	JUN	CRLD
ORUDIS						
	@ WYETH AYERST	25MG	N18754 001	JUL 31, 1987	JUN	DISC

⑧	50MG	N18754 002	JAN 09, 1986	JUN	DISC	
⑧	75MG	N18754 003	JAN 09, 1986	JUN	DISC	
CAPSULE, EXTENDED RELEASE; ORAL						
ORUVAIL						
AB	WYETH PHARMS INC	100MG	N19816 003	FEB 08, 1995	MAR	CAHN
AB		150MG	N19816 002	FEB 08, 1995	MAR	CAHN
AB +		200MG	N19816 001	SEP 24, 1993	MAR	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>D>	AP	ABBOTT	15MG/ML	N74801 001	JUN 05, 1997	OCT	DISC
>A>	⑧		15MG/ML	N74801 001	JUN 05, 1997	OCT	DISC
>D>	AP		30MG/ML	N74801 002	JUN 05, 1997	OCT	DISC
>A>	⑧		30MG/ML	N74801 002	JUN 05, 1997	OCT	DISC
>D>	AP	BEDFORD	30MG/ML	N75228 001	APR 26, 1999	OCT	CRLD
>A>	AP +		30MG/ML	N75228 001	APR 26, 1999	OCT	CRLD
SOLUTION/DROPS; OPHTHALMIC							
ACULAR LS							
+ ALLERGAN		0.4%		N21528 001	MAY 30, 2003	MAY	NEWA

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HCL

>D>	AB	APOTHECON	100MG	N75223 001	NOV 20, 1998	OCT	WDAG
>A>	⑧		100MG	N75223 001	NOV 20, 1998	OCT	WDAG
>D>	AB		200MG	N75223 002	NOV 20, 1998	OCT	WDAG
>A>	⑧		200MG	N75223 002	NOV 20, 1998	OCT	WDAG
>D>	AB		300MG	N75223 003	NOV 20, 1998	OCT	WDAG
>A>	⑧		300MG	N75223 003	NOV 20, 1998	OCT	WDAG

LACTULOSE

SOLUTION; ORAL

CHRONULAC

⑧ AVENTIS PHARMS

10GM/15ML

N17884 001

AUG DISC

CONSTULOSE

AA + ALPHARMA

10GM/15ML

N70288 001

AUG CRLD

LACTULOSE

AA VISTAPHARM

10GM/15ML

N74138 001

SEP 30, 1992 MAR CAHN

SOLUTION; ORAL, RECTAL

AA NOVEX

10GM/15ML

N76645 001

JUL 28, 2003 JUL NEWA

LAMIVUDINE

TABLET; ORAL

EPIVIR

GLAXOSMITHKLINE

300MG

N20564 003

JUN 24, 2002 SEP NEWA

LEFLUNOMIDE

TABLET; ORAL

ARAVA

+ AVENTIS PHARMS

20MG

N20905 002

SEP 10, 1998 MAR CRLD

⑧

100MG

N20905 003

SEP 10, 1998 MAR DISC

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL					
LEUCOVORIN CALCIUM					
>A> @ FAULDING	EQ 60MG BASE/VIAL	N08107 003	JAN 30, 1987	OCT	CAHN
>D> @ XANODYNE PHARM	EQ 60MG BASE/VIAL	N08107 003	JAN 30, 1987	OCT	CAHN
INJECTABLE; INJECTION					
@ ELKINS SINK	EQ 50MG BASE/VIAL	N70480 001	JAN 02, 1987	JUN	DISC
@	EQ 100MG BASE/VIAL	N81224 001	JUN 03, 1994	JUN	DISC
>A> @ FAULDING	EQ 3MG BASE/ML	N08107 001		OCT	CAHN
>A> AP +	EQ 50MG BASE/VIAL	N08107 002		OCT	CAHN
>A> AP +	EQ 100MG BASE/VIAL	N08107 004	MAY 23, 1988	OCT	CAHN
>A> AP +	EQ 350MG BASE/VIAL	N08107 005	APR 05, 1989	OCT	CAHN
>D> @ XANODYNE PHARM	EQ 3MG BASE/ML	N08107 001		OCT	CAHN
>D> AP +	EQ 50MG BASE/VIAL	N08107 002		OCT	CAHN
>D> AP +	EQ 100MG BASE/VIAL	N08107 004	MAY 23, 1988	OCT	CAHN
>D> AP +	EQ 350MG BASE/VIAL	N08107 005	APR 05, 1989	OCT	CAHN

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

+ ATRIX

30MG/VIAL

N21488 001 FEB 13, 2003 FEB NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

+ SEPRACOR

EQ 0.0103% BASE

N20837 003 JAN 30, 2002 JUL CPOT

+

EQ 0.25% BASE

N20837 004 JUL 18, 2003 JUL NEWA

LEVETIRACETAM

SOLUTION; ORAL

KEPPRA

+ UCB

100MG/ML

N21505 001 JUL 15, 2003 JUL NEWA

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

@ ALCON

EQ 0.5% BASE

N21114 001 FEB 23, 2000 JUL CAHN

+ MEDPOINTE

EQ 0.5% BASE

N21114 001 FEB 23, 2000 MAR CAHN

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

>D> + ORTHO MCNEIL PHARM

25MG/ML

N20635 001 DEC 20, 1996 OCT CPOT

>A>

+

500MG /20ML(25MG/ML)

N20635 001 DEC 20, 1996 OCT CPOT

>A>

+

750MG /30ML(25MG/ML)

N20635 004 DEC 20, 1996 OCT NEWA

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> + ORTHO MCNEIL PHARM

5MG/ML

N20635 002 DEC 20, 1996 OCT CPOT

>A>

+

250MG /50ML(5MG/ML)

N20635 002 DEC 20, 1996 OCT CPOT

>D>

+

500MG 100ML

N20635 003 DEC 20, 1996 OCT CPOT

>A>

+

500MG 100ML/(5MG/ML)

N20635 003 DEC 20, 1996 OCT CPOT

>A>

+

750MG /150ML(5MG/ML)

N20635 005 DEC 20, 1996 OCT NEWA

LEVONORGESTREL

IMPLANT; IMPLANTATION

LEVONORGESTREL

BX +	WYETH PHARMS INC	75MG/IMPLANT	N20627 001	AUG 15, 1996	MAR	CAHN
@		75MG/IMPLANT	N20627 001	AUG 15, 1996	JUN	DISC
	NORPLANT II					
BX +	POPULATION COUNCIL	75MG/IMPLANT	N20544 001	NOV 01, 1996	JUN	CRLD
	NORPLANT SYSTEM IN PLASTIC CONTAINER					
+ WYETH PHARMS INC	36MG/IMPLANT		N20088 001	DEC 10, 1990	MAR	CAHN
@	36MG/IMPLANT		N20088 001	DEC 10, 1990	JUN	DISC

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ ICN	2MG	N08720 001	DEC 19, 1991	FEB	DISC
		N74278 001	MAR 31, 2000	FEB	CRLD

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

BX ALARA PHARM	0.025MG	N21342 001	MAR 01, 2002	APR	CAHN
BX	0.05MG	N21342 002	MAR 01, 2002	APR	CAHN
BX	0.075MG	N21342 003	MAR 01, 2002	APR	CAHN
BX	0.088MG	N21342 004	MAR 01, 2002	APR	CAHN
BX	0.1MG	N21342 005	MAR 01, 2002	APR	CAHN
BX	0.112MG	N21342 006	MAR 01, 2002	APR	CAHN
BX	0.125MG	N21342 007	MAR 01, 2002	APR	CAHN
BX	0.15MG	N21342 008	MAR 01, 2002	APR	CAHN
BX	0.175MG	N21342 009	MAR 01, 2002	APR	CAHN
BX	0.2MG	N21342 010	MAR 01, 2002	APR	CAHN
BX +	0.3MG	N21342 011	MAR 01, 2002	APR	CAHN

LEVOLET

BX VINTAGE PHARMS	0.025MG	N21137 001	JUN 06, 2003	JUN	NEWA
BX	0.05MG	N21137 002	JUN 06, 2003	JUN	NEWA
BX	0.075MG	N21137 003	JUN 06, 2003	JUN	NEWA
BX	0.088MG	N21137 004	JUN 06, 2003	JUN	NEWA
BX	0.1MG	N21137 005	JUN 06, 2003	JUN	NEWA
BX	0.112MG	N21137 006	JUN 06, 2003	JUN	NEWA
BX	0.125MG	N21137 007	JUN 06, 2003	JUN	NEWA
BX	0.137MG	N21137 008	JUN 06, 2003	JUN	NEWA
BX	0.15MG	N21137 009	JUN 06, 2003	JUN	NEWA
BX	0.175MG	N21137 010	JUN 06, 2003	JUN	NEWA
BX	0.2MG	N21137 011	JUN 06, 2003	JUN	NEWA
BX	0.3MG	N21137 012	JUN 06, 2003	JUN	NEWA

LIDOCAINE

SOLUTION; TOPICAL

XYLOCAINE

@ ASTRazeneca

5%

N14127 001

AUG DISC

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

⑧ ELKINS SINK	1%	N80407 001
⑧	2%	N80407 002
⑧ WYETH AYERST	1%	N83083 001
⑧	2%	N83083 002
LIDOCAINE HCL PRESERVATIVE FREE		
⑧ ELKINS SINK	1%	N84625 001
⑧	2%	N84625 002

JELLY; TOPICAL

LIDOCAINE HCL

AT	AKORN	2%	N40433 001	FEB 12, 2003	FEB	NEWA
----	-------	----	------------	--------------	-----	------

LIDOCAINE; PRILOCaine

CREAM; TOPICAL

EMLA

AB	+ ASTRAZENECA	2.5%;2.5%	N19941 001	DEC 30, 1992	AUG	CFTG
	LIDOCAINE AND PRILOCaine					
AB	ALTANA	2.5%;2.5%	N76453 001	AUG 18, 2003	AUG	NEWA
AB	ATRIX	2.5%;2.5%	N76320 001	AUG 27, 2003	AUG	NEWA
AB	HI TECH PHARMA	2.5%;2.5%	N76290 001	SEP 25, 2003	SEP	NEWA

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	RANBAXY	30MG	N75944 006	FEB 11, 2003	FEB	NEWA
AB	WEST WARD	30MG	N76063 006	JUN 27, 2003	JUN	NEWA
	ZESTRIL					
AB	ASTRAZENECA	30MG	N19777 006	JAN 20, 1999	APR	CRLD

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	ROXANE	150MG	N17812 002	JAN 28, 1987	FEB	CTEC
AB	WEST WARD	150MG	N76243 002	FEB 24, 2003	FEB	NEWA
	TABLET, EXTENDED RELEASE; ORAL					
AB	+ GLAXOSMITHKLINE	450MG	N18152 001	MAR 29, 1982	JUN	CFTG
	LITHIUM CARBONATE					
AB	ABLE	300MG	N76382 001	APR 21, 2003	APR	NEWA
AB	BARR	450MG	N76366 001	AUG 21, 2003	AUG	NEWA
AB	WEST WARD	450MG	N76490 001	JUN 17, 2003	JUN	NEWA

LORATADINE

SYRUP; ORAL

CLARITIN

⑧ SCHERING	1MG/ML	N20641 001	OCT 10, 1996	MAY	DISC
TABLET; ORAL					
⑧ SCHERING	10MG	N19658 001	APR 12, 1993	MAY	DISC

LORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL
CLARITIN REDITABS
© SCHERING 10MG

N20704 001 DEC 23, 1996 MAY DISC

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM INTENSOL
+ ROXANE 2MG/ML
INJECTABLE; INJECTION
ATIVAN
AP + BAXTER HLTHCARE CORP 2MG/ML
AP + 4MG/ML
TABLET; ORAL
AB BIOVAIL 0.5MG
AB 1MG
AB + 2MG

N72755 001 JUN 28, 1991 MAY CRLD
N18140 001 FEB CAHN
N18140 002 FEB CAHN
N17794 001 JUN CAHN
N17794 002 JUN CAHN
N17794 003 JUN CAHN

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE
+ TARGACEPT 2.5MG

N10251 001 APR CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM
AB + MYLAN EQ 100MG BASE
MECLOMEN
© PARKE DAVIS EQ 50MG BASE
© EQ 100MG BASE

N71081 001 SEP 03, 1986 MAY CRLD
N18006 001 MAY DISC
N18006 002 MAY DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL
MEFLOQUINE HCL
AB GENEVA PHARMS 250MG

N76175 001 FEB 20, 2002 APR CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE
AB COPLEY PHARM 40MG/ML

N75681 001 MAY 05, 2003 MAY NEWA

>A> MEMANTINE HYDROCHLORIDE

TABLET; ORAL
NAMENDA
© FOREST LABS 5MG
+ 10MG
© 15MG
© 20MG
15MG
20MG

N21487 001 OCT 16, 2003 OCT NEWA
N21487 002 OCT 16, 2003 OCT NEWA
N21487 003 OCT 16, 2003 OCT DISC
N21487 004 OCT 16, 2003 OCT DISC
N21487 003 OCT 16, 2003 OCT DISC
N21487 004 OCT 16, 2003 OCT DISC

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
REPRONEX

BX + FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001 AUG 27, 1999 MAY CRLD
@	150 IU/VIAL;150 IU/VIAL	N21047 002 AUG 27, 1999 MAY DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

@ BAXTER HLTHCARE	25MG/ML	N88279 001 JUN 15, 1984 AUG CAHN
@	50MG/ML	N88280 001 JUN 15, 1984 AUG CAHN
@	75MG/ML	N88281 001 JUN 15, 1984 AUG CAHN
@	100MG/ML	N88282 001 JUN 15, 1984 AUG CAHN
AP BAXTER HLTHCARE CORP	25MG/ML	N80455 007 MAY CAHN
AP	50MG/ML	N80455 008 MAY CAHN
AP	75MG/ML	N80455 009 MAY CAHN
AP	100MG/ML	N80455 010 MAY CAHN
TABLET; ORAL		
AA AXIOM PHARM	50MG	N80448 001 MAY CAHN
AA	100MG	N80448 002 MAY CAHN
@ WYETH AYERST	50MG	N80454 001 JUN DISC

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERGAN

@ BAXTER HLTHCARE CORP	25MG/ML;25MG/ML	N11730 001 MAY CAHN
------------------------	-----------------	---------------------

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION
WYAMINE SULFATE

@ BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N08248 002 FEB CAHN
@	EQ 30MG BASE/ML	N08248 001 FEB CAHN

MEPROBAMATE

TABLET; ORAL

EQUANIL		
@ WYETH AYERST	200MG	N10028 005 JUN DISC
@	400MG	N10028 004 JUN DISC

MEPROBAMATE		
-------------	--	--

+ ROXANE	600MG	N84332 001 JUN CRLD
----------	-------	---------------------

MILTON		
--------	--	--

AA + MEDPOINTE	600MG	N83919 001 APR CAHN
@ MEDPOINTE PHARM HLC	600MG	N83919 001 JUN DISC

MERCAPTOPURINE

TABLET; ORAL

PURINETHOL		
------------	--	--

+ TEVA	50MG	N09053 002 AUG CAHN
--------	------	---------------------

MESORIDAZINE BESYLATE

TABLET; ORAL

SERENTIL

@ NOVARTIS

EQ 10MG BASE

N16774 001

JUN DISC

@

EQ 50MG BASE

N16774 003

JUN DISC

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+50 21-DAY

AB + WATSON LABS 0.05MG;1MG N13625 002 AUG CRLD
 ORTHO-NOVUM 1/50 21
 @ ORTHO MCNEIL PHARM 0.05MG;1MG N12728 004 AUG DISC

METAXALONE

TABLET; ORAL

SKELAXIN

JONES PHARMA INC

400MG

N13217 001

JUN CAHN

+

800MG

N13217 003 AUG 30, 2002

JUN CAHN

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+ RANBAXY

500MG/5ML

N21591 001 SEP 11, 2003 SEP NEWA

TABLET; ORAL

METFORMIN HCL

AB PUREPAC PHARM 1GM

N76033 003 JAN 24, 2002 FEB CMS1

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

BRISTOL MYERS SQUIBB 500MG

N21202 001 OCT 13, 2000 AUG CRLD

+

750MG

N21202 004 APR 11, 2003 APR NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

SB PHARMCO

500MG;EQ 1MG BASE

N21410 001 OCT 10, 2002 APR CAHN

500MG;EQ 2MG BASE

N21410 002 OCT 10, 2002 APR CAHN

+

500MG;EQ 4MG BASE

N21410 003 OCT 10, 2002 APR CAHN

500MG;EQ 4MG BASE

N21410 003 OCT 10, 2002 AUG CRLD

1GM;EQ 2MG BASE

N21410 004 AUG 25, 2003 AUG NEWA

+

1GM;EQ 4MG BASE

N21410 005 AUG 25, 2003 AUG NEWA

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

>D>

METHAPHARM

100MG/VIAL

N19193 001 OCT 31, 1986 OCT CRLD

>A>

+

100MG/VIAL

N19193 001 OCT 31, 1986 OCT CRLD

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

DOLOPHINE HCL

+ AAIPHARMA

10MG/ML

N21624 001

APR CAHN

+ ROXANE

10MG/ML

N21624 001

FEB CMS1

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE

AB + MIKART	50MG	N40062 002 JAN 27, 1994 JUN CRLD
NEPTAZANE		
⑧ LEDERLE	25MG	N11721 002 NOV 25, 1991 JUN DISC
⑧	50MG	N11721 001 JUN DISC

METHENAMINE HIPPURATE

TABLET; ORAL
METHENAMINE HIPPURATE

AB COREPHARMA	1GM	N76411 001 JUN 20, 2003 JUN NEWA
---------------	-----	----------------------------------

METHIMAZOLE

TABLET; ORAL
TAPAZOLE

AB LILLY	10MG	N07517 004 JUN CRLD
----------	------	---------------------

METHOCARBAMOL

INJECTABLE; INJECTION
ROBAXIN

AP + BAXTER HLTHCARE CORP	100MG/ML	N11790 001 AUG CAHN
TABLET; ORAL		
METHOCARBAMOL		
AA ABLE	500MG	N40413 001 MAR 17, 2003 MAR NEWA
AA	750MG	N40413 002 MAR 17, 2003 MAR NEWA
⑧ CLONMEL HLTHCARE	500MG	N85961 001 JUN DISC
⑧	750MG	N85963 001 JUN DISC
AA LANNETT	500MG	N84756 002 MAR 31, 2003 MAR NEWA
AA VINTAGE PHARMS	500MG	N40489 001 JAN 29, 2003 JAN NEWA
AA	750MG	N40489 002 JAN 29, 2003 JAN NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE LPF

>A> AP + FAULDING	EQ 25MG BASE/ML	N11719 007 MAR 31, 1982 OCT CAHN
>D> AP + WYETH PHARMS INC	EQ 25MG BASE/ML	N11719 007 MAR 31, 1982 OCT CAHN
AP +	EQ 25MG BASE/ML	N11719 007 MAR 31, 1982 MAR CAHN
METHOTREXATE SODIUM		
>A> ⑧ FAULDING	EQ 2.5MG BASE/ML	N11719 004 OCT CAHN
>A> +	EQ 20MG BASE/VIAL	N11719 001 OCT CAHN
>A> AP +	EQ 25MG BASE/ML	N11719 005 OCT CAHN
>A> ⑧	EQ 50MG BASE/VIAL	N11719 003 OCT CAHN
>A> ⑧	EQ 100MG BASE/VIAL	N11719 006 OCT CAHN
>D> ⑧ WYETH PHARMS INC	EQ 2.5MG BASE/ML	N11719 004 OCT CAHN
>D> ⑧	EQ 2.5MG BASE/ML	N11719 004 MAR CAHN
>D> +	EQ 20MG BASE/VIAL	N11719 001 OCT CAHN
>D> +	EQ 20MG BASE/VIAL	N11719 001 MAR CAHN
>D> AP +	EQ 25MG BASE/ML	N11719 005 OCT CAHN
AP +	EQ 25MG BASE/ML	N11719 005 MAR CAHN
>D> ⑧ ⑧	EQ 50MG BASE/VIAL	N11719 003 OCT CAHN
>D> ⑧ ⑧	EQ 50MG BASE/VIAL	N11719 003 MAR CAHN

>D>	EQ	EQ 100MG BASE/VIAL	N11719 006	OCT	CAHN
	EQ	EQ 100MG BASE/VIAL	N11719 006	MAR	CAHN
	METHOTREXATE SODIUM PRESERVATIVE FREE				
>A>	AP + FAULDING	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	OCT CAHN
>D>	AP + WYETH PHARMS INC	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	OCT CAHN
	AP +	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	MAR CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL					
PAMINE FORTE					
+ BRADLEY PHARMS	5MG		N08848 002	MAR 25, 2003	MAR NEWA

METHYCLOTHIAZIDE

TABLET; ORAL					
AQUATENSEN					
@ MEDPOINTE PHARM HLC	5MG		N17364 001		JUN DISC

METHYLDOPA

TABLET; ORAL					
ALDOMET					
@ MERCK	125MG		N13400 003		MAY DISC
EQ	250MG		N13400 001		MAY DISC
METHYLDOPA					
@ CLONMEL HLTHCARE	125MG		N70070 003	OCT 15, 1985	JUN DISC

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION					
METHYLDOPATE HCL					
@ BAXTER HLTHCARE	50MG/ML		N70291 001	JUL 01, 1986	AUG CAHN
@ ELKINS SINK	50MG/ML		N70291 001	JUL 01, 1986	JUN DISC

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
METADATE CD					
CELLTECH PHARMS	10MG		N21259 003	MAY 27, 2003	JUL NEWA
BX	20MG		N21259 001	APR 03, 2001	JUL CRLD
BX +	30MG		N21259 002	JUN 19, 2003	JUL CTEC
+	30MG		N21259 002	JUN 19, 2003	JUN NEWA
RITALIN LA					
BX NOVARTIS	30MG		N21284 002	JUN 05, 2002	JUL CTEC
TABLET, CHEWABLE; ORAL					
METHYLIN					
MALLINCKRODT	2.5MG		N21475 001	APR 15, 2003	APR NEWA
	5MG		N21475 002	APR 15, 2003	APR NEWA
+	10MG		N21475 003	APR 15, 2003	APR NEWA
TABLET, EXTENDED RELEASE; ORAL					
CONCERTA					
>D>	+ MCNEIL CONS SPECLT	18MG	N21121 001	AUG 01, 2000	OCT CRLD
>A>		18MG	N21121 001	AUG 01, 2000	OCT CRLD
	+	18MG	N21121 001	AUG 01, 2000	MAY CAHN
>D>	+	27MG	N21121 004	APR 01, 2002	OCT CRLD
>A>		27MG	N21121 004	APR 01, 2002	OCT CRLD
	+	27MG	N21121 004	APR 01, 2002	MAY CAHN

>D>	+	36MG	N21121 002	AUG 01, 2000	OCT	CRLD
>A>		36MG	N21121 002	AUG 01, 2000	OCT	CRLD
	+	36MG	N21121 002	AUG 01, 2000	MAY	CAHN
	+	54MG	N21121 003	DEC 08, 2000	MAY	CAHN

METHYLPREDNISOLONE

TABLET; ORAL
MEDROL
@ PHARMACIA AND UPJOHN 2MG

N11153 002

JUL DISC

METHYLPREDNISOLONE ACETATE

OINTMENT; TOPICAL
MEDROL ACETATE
@ PHARMACIA AND UPJOHN 0.25%

N12421 001

JUN DISC

METHYSERGIDE MALEATE

TABLET; ORAL
SANsert
@ NOVARTIS 2MG

N12516 001

JUN DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
REGLAN
AP + BAXTER HLTHCARE CORP EQ 5MG BASE/ML N17862 001 AUG CAHN
@ EQ 10MG BASE/ML N17862 004 MAY 28, 1987 AUG CAHN
SOLUTION; ORAL
METOCLOPRAMIDE
AA VISTAPHARM EQ 5MG BASE/5ML N75051 001 JAN 26, 2001 APR CAHN
TABLET; ORAL
METOCLOPRAMIDE HCL
@ CLONMEL HLTHCARE EQ 10MG BASE N72639 001 MAY 09, 1991 JUN DISC

METOLAZONE

TABLET; ORAL
ZAROXOLYN
CELLTECH PHARMS 2.5MG N17386 001 JUL CRLD
+ 5MG N17386 002 JUL CRLD

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE
AP BEDFORD LABS 1MG/ML N76495 001 JUL 07, 2003 JUL NEWA

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE
AB ABLE 250MG N76519 001 JUN 27, 2003 JUN NEWA
AB 500MG N76519 002 JUN 27, 2003 JUN NEWA
TABLET, EXTENDED RELEASE; ORAL
FLAGYL ER
AB + GD SEARLE LLC 750MG N20868 001 NOV 26, 1997 JUN CFTG
METRONIDAZOLE
AB ABLE 750MG N76462 001 JUN 25, 2003 JUN NEWA

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

AB	BAYER PHARMS	EQ 1GM BASE/VIAL	N50549 001	JUN	DISC	
AB		EQ 2GM BASE/VIAL	N50549 002	JUN	DISC	
AB		EQ 3GM BASE/VIAL	N50549 003	JUN	DISC	
AB		EQ 4GM BASE/VIAL	N50549 004	JUN	DISC	
AB		EQ 20GM BASE/VIAL	N50549 005	MAR 02, 1988	JUN	DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	N75243 001	JUN 20, 2000	JUN	CAHN
AP		EQ 5MG BASE/ML	N75243 002	JUN 20, 2000	JUN	CAHN
	SYRUP; ORAL					

AA	HI TECH PHARMA	EQ 2MG BASE/ML	N75958 001	SEP 04, 2003	SEP	NEWA
----	----------------	----------------	------------	--------------	-----	------

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HCL

AB	EON	2.5MG	N76514 001	SEP 11, 2003	SEP	NEWA
AB		5MG	N76514 002	SEP 11, 2003	SEP	NEWA
AB	MYLAN	2.5MG	N76577 001	SEP 10, 2003	SEP	NEWA
AB		5MG	N76577 002	SEP 10, 2003	SEP	NEWA
AB		10MG	N76577 003	SEP 10, 2003	SEP	NEWA
	PROAMATINE					
AB	SHIRE PHARM	2.5MG	N19815 001	SEP 06, 1996	SEP	CFTG
AB +		5MG	N19815 002	SEP 06, 1996	SEP	CFTG
AB		10MG	N19815 003	MAR 20, 2002	SEP	CFTG

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

+ ACTELION PHARMS	100MG	N21348 001	JUL 31, 2003	JUL	NEWA
-------------------	-------	------------	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	JUN	CAHN
AP	BIONICHE (CANADA)	EQ 1MG BASE/ML	N76428 001	JUN 16, 2003	JUN	NEWA
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	AUG	CAHN
	MILRINONE LACTOSE IN 5% DEXTROSE					
AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002	AUG	CAHN
	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP + SANOFI SYNTHELABO	EQ 20MG BASE/100ML		N20343 003	AUG 09, 1994	MAY	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	WYETH PHARMS INC	EQ 50MG BASE	N50649 001	MAY 31, 1990	MAR	CAHN
AB		EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	CAHN

AB	+		EQ 100MG BASE	N50649	002	MAY 31, 1990	MAR	CAHN
		MINOCYCLINE HCL						
AB	TEVA	VECTRIN	EQ 75MG BASE	N63009	002	AUG 12, 2003	AUG	NEWA
>D>	@ MEDICIS		EQ 75MG BASE	N63067	002	SEP 15, 1999	OCT	CMFD
>A>	AB		EQ 75MG BASE	N63067	002	SEP 15, 1999	OCT	CMFD
>D>	@		EQ 100MG BASE	N63067	001	JUL 31, 1990	OCT	CMFD
>A>	AB		EQ 100MG BASE	N63067	001	JUL 31, 1990	OCT	CMFD
		INJECTABLE; INJECTION						
		MINOCIN						
	+ WYETH PHARMS INC	TABLET; ORAL	EQ 100MG BASE/VIAL	N50444	001		MAR	CAHN
		MINOCYCLINE HCL						
	MEDICIS		EQ 50MG BASE	N65131	001	APR 16, 2003	AUG	CAHN
			EQ 75MG BASE	N65131	002	APR 16, 2003	AUG	CAHN
	+ PAR PHARM		EQ 100MG BASE	N65131	003	APR 16, 2003	AUG	CAHN
			EQ 50MG BASE	N65131	001	APR 16, 2003	APR	NEWA
			EQ 75MG BASE	N65131	002	APR 16, 2003	APR	NEWA
			EQ 100MG BASE	N65131	003	APR 16, 2003	APR	NEWA
		<u>MIRTAZAPINE</u>						
		TABLET; ORAL						
		MIRTAZAPINE						
AB	ALPHAPHARM		15MG	N76176	001	JUN 19, 2003	JUN	NEWA
AB			30MG	N76176	002	JUN 19, 2003	JUN	NEWA
AB			45MG	N76176	003	JUN 19, 2003	JUN	NEWA
AB	AMIDE PHARM		15MG	N76241	001	JUN 25, 2003	JUN	NEWA
AB			30MG	N76241	002	JUN 25, 2003	JUN	NEWA
AB			45MG	N76241	003	JUN 25, 2003	JUN	NEWA
AB	ANDRX PHARMS		15MG	N76336	001	JUN 20, 2003	JUN	NEWA
AB			30MG	N76336	002	JUN 20, 2003	JUN	NEWA
AB			45MG	N76336	003	JUN 20, 2003	JUN	NEWA
AB	EON		15MG	N76219	001	JUN 19, 2003	JUN	NEWA
AB			30MG	N76219	002	JUN 19, 2003	JUN	NEWA
AB			45MG	N76219	003	JUN 19, 2003	JUN	NEWA
AB	GENEVA PHARMS		15MG	N76189	001	JUN 19, 2003	JUN	NEWA
AB			30MG	N76189	002	JUN 19, 2003	JUN	NEWA
AB			45MG	N76189	003	JUN 19, 2003	JUN	NEWA
AB	MYLAN		15MG	N76122	001	JUN 19, 2003	JUN	NEWA
AB			30MG	N76122	002	JUN 19, 2003	JUN	NEWA
AB			45MG	N76122	003	JUN 19, 2003	JUN	NEWA
AB	PUREPAC PHARM		15MG	N76308	001	JUN 20, 2003	JUN	NEWA
AB			30MG	N76308	002	JUN 20, 2003	JUN	NEWA
AB			45MG	N76308	003	JUN 20, 2003	JUN	NEWA
AB	ROXANE		15MG	N76270	001	JUN 19, 2003	JUN	NEWA
AB			30MG	N76270	002	JUN 19, 2003	JUN	NEWA
AB			45MG	N76270	003	JUN 19, 2003	JUN	NEWA
AB	TEVA		15MG	N76119	001	JAN 24, 2003	JAN	NEWA
AB			30MG	N76119	002	JAN 24, 2003	JAN	NEWA
AB			45MG	N76119	003	JUN 19, 2003	JUN	NEWA
AB	WATSON LABS		15MG	N76312	001	JUN 19, 2003	JUN	NEWA
AB			30MG	N76312	002	JUN 19, 2003	JUN	NEWA
AB			45MG	N76312	003	JUN 19, 2003	JUN	NEWA

MIRTAZAPINE

TABLET; ORAL

REMERON

AB + ORGANON	15MG	N20415 001	JUN 14, 1996	JAN	CFTG
AB	30MG	N20415 002	JUN 14, 1996	JAN	CFTG

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP BAXTER HLTHCARE	5MG/VIAL	N64180 001	DEC 23, 1999	AUG	CAHN
AP	20MG/VIAL	N64180 002	DEC 23, 1999	AUG	CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HCL

AB TEVA	7.5MG	N76204 001	MAY 08, 2003	MAY	NEWA
AB	15MG	N76204 002	MAY 08, 2003	MAY	NEWA
UNIVASC					
AB SCHWARZ PHARMA	7.5MG	N20312 001	APR 19, 1995	MAY	CFTG
AB +	15MG	N20312 002	APR 19, 1995	MAY	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX + LIGAND	30MG	N21260 001	MAR 20, 2002	JUN	CAHN
BX +	60MG	N21260 002	MAR 20, 2002	JUN	CAHN
+	90MG	N21260 003	MAR 20, 2002	JUN	CAHN
+	120MG	N21260 004	MAR 20, 2002	JUN	CAHN

INJECTABLE; INJECTION

DURAMORPH PF

AP + BAXTER HLTHCARE	1MG/ML	N18565 002	SEP 18, 1984	AUG	CAHN
INFUMORPH					
+ BAXTER HLTHCARE	10MG/ML	N18565 003	JUL 19, 1991	AUG	CAHN
+	25MG/ML	N18565 004	JUL 19, 1991	AUG	CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

@ CLONMEL HLTHCARE	15MG	N75407 001	JAN 28, 2000	JUL	DISC
AB MALLINCKRODT	15MG	N76412 001	JUL 31, 2003	JUL	NEWA
AB	30MG	N76412 002	JUL 31, 2003	JUL	NEWA
AB	60MG	N76412 003	JUL 31, 2003	JUL	NEWA
AB	100MG	N76438 001	JUL 03, 2003	JUL	NEWA
AB	200MG	N76438 002	JUL 03, 2003	JUL	NEWA

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VIGAMOX

+ ALCON	0.5%	N21598 001	APR 15, 2003	APR	NEWA
---------	------	------------	--------------	-----	------

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

BX	CLAY PARK LABS	2%	N50788 001 DEC 04, 2002 JAN CTEC
BX	JOHNSON AND JOHNSON	2%	N50788 001 DEC 04, 2002 APR CAHN

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPT

+ ROCHE PALO	250MG	N50722 001 MAY 03, 1995 FEB CAHN
SUSPENSION; ORAL		
+ ROCHE PALO	200MG/ML	N50759 001 OCT 01, 1998 FEB CAHN
TABLET; ORAL		
+ ROCHE PALO	500MG	N50723 001 JUN 19, 1997 FEB CAHN

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

+ ROCHE PALO	500MG/VIAL	N50758 001 AUG 12, 1998 FEB CAHN
--------------	------------	----------------------------------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	IVAX PHARMS	500MG	N76009 001 JAN 24, 2003 JAN NEWA
AB		750MG	N76009 002 JAN 24, 2003 JAN NEWA

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

>D>	@ ALLERGAN HERBERT	1%	N19599 001 FEB 29, 1988 OCT CMFD
>A>		1%	N19599 001 FEB 29, 1988 OCT CMFD
	@	1%	N19599 001 FEB 29, 1988 JUN DISC
GEL; TOPICAL			
>D>	@ ALLERGAN HERBERT	1%	N19356 001 JUN 18, 1990 OCT CMFD
>A>	+	1%	N19356 001 JUN 18, 1990 OCT CMFD
	@	1%	N19356 001 JUN 18, 1990 JUN DISC

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

@ KING PHARMS	10MG/ML	N74471 001 MAR 19, 1998 MAY DISC
@	20MG/ML	N74471 002 MAR 19, 1998 MAY DISC

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@ BAXTER HLTHCARE	0.4MG/ML	N70496 001 SEP 24, 1986 AUG CAHN
@ ELKINS SINK	0.4MG/ML	N70299 001 SEP 24, 1986 JUN DISC
@ ELKINS SINK PHARM	0.4MG/ML	N70298 001 SEP 24, 1986 JUN DISC
NALOXONE HCL		
@ BAXTER HLTHCARE	0.02MG/ML	N71272 001 MAY 24, 1988 AUG CAHN
@	1MG/ML	N71273 001 MAY 24, 1988 AUG CAHN
@	1MG/ML	N71274 001 MAY 24, 1988 AUG CAHN

⑥		1MG/ML	N71287 001	MAY 24, 1988	AUG	CAHN
⑥ ELKINS SINK		0.02MG/ML	N71272 001	MAY 24, 1988	JUN	DISC
⑥		1MG/ML	N71273 001	MAY 24, 1988	JUN	DISC
⑥		1MG/ML	N71274 001	MAY 24, 1988	JUN	DISC
⑥		1MG/ML	N71287 001	MAY 24, 1988	JUN	DISC

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

⑥ ORGANON USA INC		50MG/ML	N13132 001	JUN 12, 1986	MAY	DISC
⑥		100MG/ML	N13132 002	JUN 12, 1986	MAY	DISC
⑥		200MG/ML	N13132 003	JUN 12, 1986	MAY	DISC
NANDROLONE DECANOATE						
+ STERIS		50MG/ML	N86385 001	JAN 13, 1984	MAY	CRLD
+		100MG/ML	N86598 001	JAN 13, 1984	MAY	CRLD
+		200MG/ML	N88128 001	DEC 05, 1983	MAY	CRLD

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB	ABLE	EQ 250MG BASE	N76544 001	AUG 22, 2003	AUG	NEWA	
AB		EQ 500MG BASE	N76544 002	AUG 22, 2003	AUG	NEWA	
>D>	AB	AL HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998	OCT	CAHN
>D>	AB		EQ 500MG BASE	N74480 001	MAY 14, 1996	OCT	CAHN
>A>	AB	HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998	OCT	CAHN
>A>	AB		EQ 500MG BASE	N74480 001	MAY 14, 1996	OCT	CAHN

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

AB	+ ELAN PHARM	EQ 375MG BASE	N20353 001	JAN 05, 1996	APR	CFTG
AB	+	EQ 500MG BASE	N20353 002	JAN 05, 1996	MAR	CFTG
AB	+ ELAN PHARMA	EQ 375MG BASE	N20353 001	JAN 05, 1996	JUN	CAHN
AB	+	EQ 500MG BASE	N20353 002	JAN 05, 1996	JUN	CAHN
⑥		EQ 750MG BASE	N20353 003	JAN 05, 1996	JUN	CAHN
NAPROXEN SODIUM						
AB	ANDRX PHARMS	EQ 375MG BASE	N75416 002	APR 23, 2003	APR	NEWA
AB		EQ 500MG BASE	N75416 001	AUG 27, 2002	MAR	NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HCL

AB	DR REDDYS LABS INC	50MG	N76309 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76309 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76309 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76309 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76309 005	SEP 16, 2003	SEP	NEWA
AB	EON	50MG	N76302 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76302 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76302 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76302 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76302 005	SEP 16, 2003	SEP	NEWA
AB	GENEVA PHARMS	50MG	N76072 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76072 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76072 003	SEP 16, 2003	SEP	NEWA

AB		200MG	N76072 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76072 005	SEP 16, 2003	SEP	NEWA
AB	IVAX PHARMS	50MG	N75763 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N75763 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N75763 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N75763 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N75763 005	SEP 16, 2003	SEP	NEWA
AB	MYLAN	100MG	N76129 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76129 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76129 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76129 005	SEP 16, 2003	SEP	NEWA
AB	RANBAXY	50MG	N76409 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76409 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76409 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76409 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76409 005	SEP 16, 2003	SEP	NEWA
AB	ROXANE	50MG	N76196 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76196 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76196 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76196 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76196 005	SEP 16, 2003	SEP	NEWA
AB	TEVA	50MG	N76037 001	SEP 16, 2003	SEP	NEWA
AB		100MG	N76037 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76037 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76037 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76037 005	SEP 16, 2003	SEP	NEWA
AB	WATSON LABS	100MG	N76073 002	SEP 16, 2003	SEP	NEWA
AB		150MG	N76073 003	SEP 16, 2003	SEP	NEWA
AB		200MG	N76073 004	SEP 16, 2003	SEP	NEWA
AB		250MG	N76073 005	SEP 16, 2003	SEP	NEWA
SERZONE						
AB	BRISTOL MYERS SQUIBB	50MG	N20152 001	DEC 22, 1994	SEP	CFTG
AB		100MG	N20152 002	DEC 22, 1994	SEP	CFTG
AB		150MG	N20152 003	DEC 22, 1994	SEP	CFTG
AB		200MG	N20152 004	DEC 22, 1994	SEP	CFTG
AB	+	250MG	N20152 005	DEC 22, 1994	SEP	CFTG

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+ AGOURON

EQ 625MG BASE

N21503 001 APR 30, 2003 APR NEWA

NIFEDIPINE

CAPSULE; ORAL

ADALAT

@ BAYER PHARMS

10MG

N19478 001 NOV 27, 1985 JUN DISC

@

20MG

N19478 002 SEP 17, 1986 JUN DISC

TABLET, EXTENDED RELEASE; ORAL

PROCARDIA XL

AB2 PFIZER

30MG

N19684 001 SEP 06, 1989 JUL CRLD

AB2

60MG

N19684 002 SEP 06, 1989 JUL CRLD

NITROFURANTOIN

TABLET; ORAL				
FURADANTIN				
@ PROCTER AND GAMBLE	50MG	N08693 001	APR	DISC
@	100MG	N08693 002	APR	DISC
NITROFURANTOIN				
@ WATSON LAB	50MG	N80447 001	APR	DISC
@ WHITEWORTH TOWN PLSN	100MG	N84085 002	APR	DISC

NITROFURAZONE

OINTMENT; TOPICAL				
FURACIN				
@ SHIRE PHARM	0.2%	N05795 001	MAR	DISC

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL*

NITROGLYCERIN

AB2 MYLAN TECHNOLOGIES	0.1MG/HR	N75033 001	FEB 06, 1998	APR	CAHN
AB2 +	0.1MG/HR	N75033 001	FEB 06, 1998	AUG	CRLD
AB2	0.2MG/HR	N74609 001	AUG 30, 1996	APR	CAHN
AB2 +	0.2MG/HR	N74609 001	AUG 30, 1996	AUG	CRLD
AB2	0.4MG/HR	N74607 001	AUG 30, 1996	APR	CAHN
AB2 +	0.4MG/HR	N74607 001	AUG 30, 1996	AUG	CRLD
AB2	0.6MG/HR	N74559 001	AUG 30, 1996	APR	CAHN
AB2 +	0.6MG/HR	N74559 001	AUG 30, 1996	AUG	CRLD
TRANSDERM-NITRO					
@ NOVARTIS	0.1MG/HR	N20144 001	FEB 27, 1996	AUG	DISC
@	0.2MG/HR	N20144 002	FEB 27, 1996	AUG	DISC
@	0.4MG/HR	N20144 003	FEB 27, 1996	AUG	DISC
@	0.6MG/HR	N20144 004	FEB 27, 1996	AUG	DISC
@	0.8MG/HR	N20144 005	FEB 27, 1996	AUG	DISC
INJECTABLE; INJECTION					
TRIDIL					
@ FAULDING	0.5MG/ML	N18537 002	JUN 16, 1983	MAY	DISC
@	5MG/ML	N18537 001		MAY	DISC
OINTMENT; TRANSDERMAL					
NITROGLYCERIN					
+ FOUGERA	2%	N87355 001	JUL 08, 1988	APR	CAHN

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB TORPHARM	150MG	N76383 001	JAN 23, 2003	JAN	NEWA
AB	300MG	N76383 002	JAN 23, 2003	JAN	NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP + ABBOTT	EQ 1MG BASE/ML	N07513 001		MAR	CFTG
NOREPINEPHRINE BITARTRATE					
>A> AP BEDFORD	EQ 1MG BASE/ML	N40462 001	OCT 31, 2003	OCT	NEWA
AP GENESIA SICOR PHARMS	EQ 1MG BASE/ML	N40455 001	MAR 03, 2003	MAR	NEWA

*SEE SECTION 1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE;TRANSDERMAL

NORETHINDRONE ACETATE

TABLET; ORAL
AYGESTIN
AB + DURAMED PHARMS BARR 5MG N18405 001 APR 21, 1982 JUN CAHN
AB + WYETH PHARMS INC 5MG N18405 001 APR 21, 1982 MAR CAHN

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
CHIBROXIN
@ MERCK 0.3% N19757 001 JUN 17, 1991 MAY DISC

NORGESTREL

TABLET; ORAL
OVRETTE
+ WYETH PHARMS INC 0.075MG N17031 001 MAR CAHN

NYSTATIN

POWDER; ORAL
NILSTAT
@ CLONMEL HLTHCARE 100% N50576 001 DEC 22, 1983 JUL DISC
NYSTATIN
+ PADDOCK 100% N62613 001 NOV 26, 1985 JUL CRLD

OFLOXACIN

TABLET; ORAL
FLOXIN
AB ORTHO MCNEIL PHARM 200MG N19735 001 DEC 28, 1990 SEP CFTG
AB 300MG N19735 002 DEC 28, 1990 SEP CFTG
AB + 400MG N19735 003 DEC 28, 1990 SEP CFTG
OFLOXACIN
AB PAR PHARM 200MG N76093 001 SEP 02, 2003 SEP NEWA
AB 300MG N76093 002 SEP 02, 2003 SEP NEWA
AB 400MG N76093 003 SEP 02, 2003 SEP NEWA
AB RANBAXY 200MG N76220 001 SEP 02, 2003 SEP NEWA
AB 300MG N76220 002 SEP 02, 2003 SEP NEWA
AB 400MG N76220 003 SEP 02, 2003 SEP NEWA
AB TEVA 200MG N76182 001 SEP 02, 2003 SEP NEWA
AB 300MG N76182 002 SEP 02, 2003 SEP NEWA
AB 400MG N76182 003 SEP 02, 2003 SEP NEWA

OLANZAPINE

TABLET; ORAL
ZYPREXA
+ LILLY 5MG N20592 002 SEP 30, 1996 MAY CRLD
20MG N20592 006 SEP 09, 1997 MAY CRLD
TABLET, ORALLY DISINTEGRATING; ORAL
ZYPREXA ZYDIS
+ LILLY 5MG N21086 001 APR 06, 2000 AUG CRLD
20MG N21086 004 APR 06, 2000 AUG CRLD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

AB	LEK SVCS	10MG	N75757 001	JAN 28, 2003	JAN	NEWA
AB		20MG	N75757 002	JAN 28, 2003	JAN	NEWA
AB	MYLAN	10MG	N75876 001	MAY 29, 2003	MAY	NEWA
AB		20MG	N75876 002	MAY 29, 2003	MAY	NEWA
>A>	AB	TORPHARM	N76048 001	OCT 06, 2003	OCT	NEWA
>A>	AB		N76048 002	OCT 06, 2003	OCT	NEWA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION
ORPHENADRINE CITRATE

AP	BEDFORD LABS	30MG/ML	N40463 001	MAR 04, 2003	MAR	NEWA
----	--------------	---------	------------	--------------	-----	------

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL
OXYTROL
+ WATSON LABS (UTAH) 3.9MG/24HR

N21351 002	FEB 26, 2003	FEB	NEWA
------------	--------------	-----	------

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
ALZA 5MG
10MG

N20897 001	DEC 16, 1998	MAY	CRLD
N20897 002	DEC 16, 1998	MAY	CRLD

OXYCODONE HYDROCHLORIDE

TABLET; ORAL
ROXICODONE
>D> ELAN PHARMS 15MG
>A> + 15MG
>D> + 30MG
>A> + 30MG

N21011 001	AUG 31, 2000	OCT	CRLD
N21011 001	AUG 31, 2000	OCT	CRLD
N21011 002	AUG 31, 2000	OCT	CRLD
N21011 002	AUG 31, 2000	OCT	CRLD

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN
@ BAXTER HLTHCARE CORP 10USP UNITS/ML

N18243 001		MAY	CAHN
------------	--	-----	------

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS
ALOXI
+ HELSINN HLTHCARE EQ 0.25MG BASE/5ML(EQ 0.05MG BASE/ML)

N21372 001	JUL 25, 2003	JUL	NEWA
------------	--------------	-----	------

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE
AP + GENSIA SICOR PHARMS 1MG/ML
AP + 2MG/ML
PAVULON
@ ORGANON 1MG/ML
@ 2MG/ML

N72759 001	JUL 31, 1990	MAY	CRLD
N72760 001	JUL 31, 1990	MAY	CRLD
N17015 002		MAY	DISC
N17015 001		MAY	DISC

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PROTONIX IV

+ WYETH PHARMS INC EQ 40MG BASE/VIAL
TABLET, DELAYED RELEASE; ORAL

PROTONIX

+ WYETH PHARMS INC EQ 20MG BASE
EQ 20MG BASE
+ EQ 40MG BASEN20988 001 MAR 22, 2001 MAR CAHN
N20987 002 JUN 12, 2001 MAR CAHN
N20987 002 JUN 12, 2001 APR CRLD
N20987 001 FEB 02, 2000 MAR CAHNPAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

AA + KING PHARMS EQ 250MG BASE

N62310 001 MAY CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HCL

AB TORPHARM EQ 10MG BASE
AB EQ 20MG BASE
AB EQ 30MG BASE
AB EQ 40MG BASE

PAXIL
AB GLAXOSMITHKLINE EQ 10MG BASE
AB EQ 20MG BASE
AB EQ 30MG BASE
AB + EQ 40MG BASEN75356 001 JUL 30, 2003 JUL NEWA
N75356 002 JUL 30, 2003 JUL NEWA
N75356 003 JUL 30, 2003 JUL NEWA
N75356 004 JUL 30, 2003 JUL NEWA

N20031 001 DEC 29, 1992 JUL CFTG
N20031 002 DEC 29, 1992 JUL CFTG
N20031 003 DEC 29, 1992 JUL CFTG
N20031 005 DEC 29, 1992 JUL CFTGPAROXETINE MESYLATE

TABLET; ORAL

PAROXETINE MESYLATE

SYNTON PHARMS EQ 10MG BASE
EQ 20MG BASE
EQ 30MG BASE
+ EQ 40MG BASEN21299 001 JUL 03, 2003 JUL NEWA
N21299 002 JUL 03, 2003 JUL NEWA
N21299 003 JUL 03, 2003 JUL NEWA
N21299 004 JUL 03, 2003 JUL NEWAPEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+ PHARMACIA AND UPJOHN 10MG/VIAL
+ 15MG/VIAL
+ 20MG/VIALN21106 001 MAR 25, 2003 MAR NEWA
N21106 002 MAR 25, 2003 MAR NEWA
N21106 003 MAR 25, 2003 MAR NEWAPENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

@ MARSAM PHARMS LLC 1,000,000 UNITS/VIAL
@ 5,000,000 UNITS/VIAL
@ 10,000,000 UNITS/VIAL
@ 20,000,000 UNITS/VIALN62991 001 SEP 13, 1988 JUL DISC
N62991 002 SEP 13, 1988 JUL DISC
N62991 003 SEP 13, 1988 JUL DISC
N62991 004 SEP 13, 1988 JUL DISC

TABLET; ORAL

@ WYETH AYERST 200,000 UNITS

N60413 001 JUN DISC

⑧	250,000 UNITS	N60413 002	JUN DISC
⑧	400,000 UNITS	N60413 003	JUN DISC

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

LEDERCILLIN VK

⑧ LEDERLE	EQ 125MG BASE/5ML	N60136 001	JUN DISC
⑧	EQ 250MG BASE/5ML	N60136 002	JUN DISC
TABLET; ORAL			
⑧ LEDERLE	EQ 250MG BASE	N60134 001	JUN DISC
⑧	EQ 500MG BASE	N60134 002	JUN DISC
PEN-VEE K			
⑧ WYETH AYERST	EQ 250MG BASE	N60006 002	JUN DISC
⑧	EQ 500MG BASE	N60006 003	JUN DISC

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

⑧ BAXTER HLTHCARE	300MG/VIAL	N73617 001	DEC 18, 1995	AUG CAHN
⑧ ELKINS SINK	300MG/VIAL	N73617 001	DEC 18, 1995	JUN DISC

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+ ABBOTT	50MG/ML	N83246 001	JUN CTEC
SODIUM PENTOBARBITAL			
⑧ WYETH AYERST	50MG/ML	N83261 001	JUN DISC

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

AB IVAX PHARMS	EQ 0.05MG BASE	N76094 001	SEP 04, 2003	SEP NEWA
AB	EQ 0.25MG BASE	N76094 002	SEP 04, 2003	SEP NEWA
AB	EQ 1MG BASE	N76094 003	SEP 04, 2003	SEP NEWA

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

AB CLAY PARK	5%	N76369 001	APR 21, 2003	APR NEWA
--------------	----	------------	--------------	----------

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB + IVAX PHARMS	16MG	N89457 001	SEP 10, 1987	FEB CRLD
TRILAFON				
⑧ SCHERING	2MG	N10775 001	FEB	DISC
⑧	4MG	N10775 002	FEB	DISC
⑧	8MG	N10775 003	FEB	DISC
⑧	16MG	N10775 004	FEB	DISC

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL					
PHENTERMINE HCL					
AA ABLE	15MG	N40497 001	MAR 13, 2003	MAR	NEWA
AA AMBI PHARMS	30MG	N40083 001	MAR 07, 1997	MAY	CAHN
AA AMIDE PHARM	15MG	N40460 001	JAN 14, 2003	JAN	NEWA
AA	30MG	N40448 001	JAN 22, 2003	JAN	NEWA
>A> AA MUTUAL PHARM	30MG	N40525 001	OCT 23, 2003	OCT	NEWA
>A> AA	37.5MG	N40527 001	OCT 23, 2003	OCT	NEWA
TABLET; ORAL					
AA + EON	30MG	N88605 001	SEP 28, 1987	JAN	CFTG
>A> AA MUTUAL PHARM	37.5MG	N40526 001	OCT 23, 2003	OCT	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL					
PHENERGAN VC					
@ WYETH AYERST	5MG/5ML;6.25MG/5ML	N08604 003	APR 02, 1984	APR	DISC
PROMETH VC PLAIN					
AA + ALPHARMA	5MG/5ML;6.25MG/5ML	N88761 001	NOV 08, 1984	APR	CRLD

PHENYTOIN

SUSPENSION; ORAL					
PHENYTOIN					
AB VISTAPHARM	125MG/5ML	N40342 001	JAN 31, 2001	MAR	CAHN

PHENYTOIN SODIUM

INJECTABLE; INJECTION					
DILANTIN					
@ PARKE DAVIS	50MG/ML	N10151 001		MAR	DISC
PHENYTOIN					
+ ELKINS SINK	50MG/ML	N84307 001		MAR	CRLD
PHENYTOIN SODIUM					
@ ABBOTT	50MG/ML	N89521 001	MAR 17, 1987	MAR	DISC
@	50MG/ML	N89744 001	DEC 18, 1987	MAR	DISC

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL					
DILANTIN					
PARKE DAVIS	30MG	N84349 001		FEB	CRLD
+	30MG	N84349 001		JUN	CRLD
EXTENDED PHENYTOIN SODIUM					
AB BARR	100MG	N40435 001	JUN 20, 2003	JUN	NEWA

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL					
SALAGEN					
MGI PHARMA INC	5MG	N20237 001	MAR 22, 1994	APR	CRLD
+	7.5MG	N20237 002	APR 18, 2003	APR	NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

+ WYETH PHARMS INC	EQ 2GM BASE/VIAL	N50545 002	MAR	CAHN	
@	EQ 2GM BASE/VIAL	N50545 002	JUN	DISC	
@	EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	MAR	CAHN
@	EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	JUN	DISC
+	EQ 3GM BASE/VIAL	N50545 003	MAR	CAHN	
@	EQ 3GM BASE/VIAL	N50545 003	JUN	DISC	
@	EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	MAR	CAHN
@	EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	JUN	DISC
+	EQ 4GM BASE/VIAL	N50545 004	MAR	CAHN	
@	EQ 4GM BASE/VIAL	N50545 004	JUN	DISC	
@	EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	MAR	CAHN
@	EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	JUN	DISC
@	EQ 40GM BASE/VIAL	N50545 006	SEP 30, 1985	MAR	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

ZOSYN

+ WYETH PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N50684 001	OCT 22, 1993	MAR	CAHN
+	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N50684 002	OCT 22, 1993	MAR	CAHN
+	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993	MAR	CAHN
+	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N50684 004	OCT 22, 1993	MAR	CAHN
ZOSYN IN PLASTIC CONTAINER					
+ WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N50750 001	FEB 24, 1998	MAR	CAHN
+	EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998	MAR	CAHN
+	EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998	MAR	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

@ 3M

EQ 0.2MG BASE/INH

N19009 001 DEC 30, 1986 MAY DISC

PIROXICAM

CAPSULE; ORAL

PIROXICAM

>D> AB	SCS	10MG	N74036 001	MAY 29, 1992	OCT	WDAG
>A>	@	10MG	N74036 001	MAY 29, 1992	OCT	WDAG
>D> AB		20MG	N74036 002	MAY 29, 1992	OCT	WDAG
>A>	@	20MG	N74036 002	MAY 29, 1992	OCT	WDAG

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

@ BAXTER HLTHCARE 2MEQ/ML

N80203 001

AUG CAHN

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M15

UPSHER SMITH 15MEQ

N74726 003 JUN 06, 2003 JUN NEWA

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

@ BAXTER HLTHCARE CORP	300MG/ML	N18799 001 DEC 13, 1982 MAR CAHN
PROTOPAM CHLORIDE		
+ BAXTER HLTHCARE CORP	1GM/VIAL	N14134 001 JUL CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

>D>	PHARMACIA AND UPJOHN	0.25MG	N20667 002 JUL 01, 1997 OCT CRLD
>A>	+	0.25MG	N20667 002 JUL 01, 1997 OCT CRLD
>D>	+	1.5MG	N20667 005 JUL 01, 1997 OCT CRLD
>A>	+	1.5MG	N20667 005 JUL 01, 1997 OCT CRLD

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HCL

@ CLONMEL HLTHCARE	EQ 2MG BASE	N72706 001 MAY 16, 1989 JUL DISC
--------------------	-------------	----------------------------------

PREDNICKARBATE

CREAM; TOPICAL

DERMATOP E EMOLlient

+ DERMIK LABS	0.1%	N20279 001 OCT 29, 1993 APR CTNA
---------------	------	----------------------------------

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA AXIOM PHARM	15MG/5ML	N40287 001 MAY 28, 1999 MAY CAHN
AA HI TECH PHARMA	15MG/5ML	N40401 001 FEB 27, 2003 FEB NEWA
+ KV PHARM	5MG/5ML	N40423 001 OCT 22, 2001 JUL CRLD
AA +	15MG/5ML	N40364 001 APR 10, 2002 JUL CRLD
AA MORTON GROVE	15MG/5ML	N40313 001 SEP 10, 2003 SEP NEWA
AA PHARM ASSOC	15MG/5ML	N40399 001 MAR 05, 2003 MAR NEWA
PRENONE		
@ MURO	5MG/5ML	N89654 001 JAN 17, 1989 JUL DISC
AA + TEVA	15MG/5ML	N89081 001 FEB 04, 1986 MAY CAHN
AA	15MG/5ML	N89081 001 FEB 04, 1986 JUL CRLD

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

@ ALCON	0.125%	N17468 001 JUN DISC
---------	--------	---------------------

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

@ ALCON	0.25%;10%	N87771 001 AUG 06, 1993 JUN DISC
---------	-----------	----------------------------------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA HI TECH PHARMA EQ 5MG BASE/5ML

N75183 001 MAR 26, 2003 MAR NEWA

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT ALCON EQ 0.23% PHOSPHATE;10%

N73630 001 MAY 27, 1993 APR CAHN

PREDNISONE

TABLET; ORAL

PREDNISONE

AB VINTAGE PHARMS 20MG

N40392 001 FEB 12, 2003 FEB NEWA

PRIMIDONE

TABLET; ORAL

MYSOLINE

AB + XCEL PHARMS 50MG

N09170 003 JUL CRLD

AB 250MG

N09170 002 JUL CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

@ BAXTER HLTHCARE 100MG/ML

N89029 001 APR 17, 1986 AUG CAHN

@ 500MG/ML

N89030 001 APR 17, 1986 AUG CAHN

@ ELKINS SINK 100MG/ML

N89029 001 APR 17, 1986 JUN DISC

@ 500MG/ML

N89030 001 APR 17, 1986 JUN DISC

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCaine HCL

>D	AP	AM PHARM PARTNERS	1%	N80421 001	OCT	DISC
>A		@	1%	N80421 001	OCT	DISC
>D	AP		2%	N80421 002	OCT	DISC
>A		@	2%	N80421 002	OCT	DISC
>D	AP	ELKINS SINK	1%	N83315 001	OCT	DISC
>A		@	1%	N83315 001	OCT	DISC
>D	AP		2%	N83315 002	OCT	DISC
>A		@	2%	N83315 002	OCT	DISC
>D	AP	STERIS	2%	N80658 002	OCT	DISC
>A		@	2%	N80658 002	OCT	DISC

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE

AP BAXTER HLTHCARE EQ 5MG BASE/ML

N87759 001 OCT 01, 1982 AUG CAHN

PROCHLORPERAZINE EDISYLATE

@ BAXTER HLTHCARE EQ 5MG BASE/ML

N89523 001 MAY 03, 1988 AUG CAHN

AP GENsIA SICOR PHARMS EQ 5MG BASE/ML

N40505 001 MAY 30, 2003 MAY NEWA

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

SPARINE

⑥ BAXTER HLTHCARE CORP	25MG/ML	N10349 008	AUG CAHN
⑥	50MG/ML	N10349 006	AUG CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

⑥ WYETH AYERST	25MG/ML	N08857 002	JUN DISC
⑥	50MG/ML	N08857 003	APR DISC

PROMETHAZINE HCL

AP BAXTER HLTHCARE	25MG/ML	N83312 001	JUN CAHN
AP	50MG/ML	N83312 002	JUN CAHN
AP + GENESIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002
AP +	50MG/ML	N40454 002	AUG 22, 2002
AP PHARMAFORCE	25MG/ML	N40515 001	MAR NEWA

SUPPOSITORY; RECTAL

PHENERGAN

AB + WYETH AYERST	50MG	N11689 001	FEB CTEC
AB WYETH PHARMS INC	12.5MG	N10926 002	MAR CAHN
AB +	25MG	N10926 001	MAR CAHN
AB +	50MG	N11689 001	MAR CAHN

PROMETHAZINE HCL

AB ABLE	12.5MG	N40504 001	APR 11, 2003
AB	25MG	N40504 002	APR 11, 2003
AB	50MG	N40449 001	FEB 27, 2003
AB CLAY PARK	12.5MG	N40500 001	JUN 30, 2003
AB	25MG	N40500 002	JUN 30, 2003
AB G AND W LABS	12.5MG	N40428 002	MAR 31, 2003
AB PADDOK	12.5MG	N40479 001	JUN 24, 2003
AB	25MG	N40479 002	JUN 24, 2003

SYRUP; ORAL

PHENERGAN PLAIN

⑥ WYETH AYERST	6.25MG/5ML	N08381 004	APR 18, 1984
PROMETH PLAIN			JUN DISC
AA + ALPHARMA	6.25MG/5ML	N85953 001	
TABLET; ORAL			JUN CRLD
PHENERGAN			
WYETH PHARMS INC	12.5MG	N07935 002	MAR CAHN
BP	25MG	N07935 003	MAR CAHN
BP +	50MG	N07935 004	MAR CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

RYTHMOL SR

ABBOTT	225MG	N21416 001	SEP 04, 2003
	325MG	N21416 002	SEP 04, 2003
+ +	425MG	N21416 003	SEP 04, 2003

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

@ BAXTER HLTHCARE CORP 20MG/ML

N12382 002

MAY CAHN

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DOLENE

@ CLONMEL HLTHCARE 65MG

N80530 001

AUG DISC

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

@ AAIPHARMA LLC 50MG/5ML

N16861 001

JUL DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

WYETH PHARMS INC 60MG

N18553 004 MAR 18, 1987 MAR CAHN

BX 80MG
BX 120MGN18553 002 APR 19, 1983 MAR CTEC
N18553 003 APR 19, 1983 MAR CTEC

+ 160MG

N18553 001 APR 19, 1983 MAR CAHN

INNOPRAN XL

BX RELIANT PHARMS 80MG
BX 120MGN21438 001 MAR 12, 2003 MAR NEWA
N21438 002 MAR 12, 2003 MAR NEWA

INJECTABLE; INJECTION

INDERAL

AP + BAXTER HLTHCARE CORP 1MG/ML
PROPRANOLOL HCLN16419 001 MAY CAHN
N16419 001 AUG CTNA

AP + BAXTER HLTHCARE CORP 1MG/ML

N76400 001 FEB 26, 2003 FEB NEWA

AP SABEX 2002 1MG/ML

TABLET; ORAL

INDERAL

AB + WYETH PHARMS INC 10MG
AB 20MG
AB 40MG
AB 60MG
AB + 80MGN16418 001 MAR CAHN
N16418 003 MAR CAHN
N16418 002 MAR CAHN
N16418 009 OCT 18, 1982 MAR CAHN
N16418 004 MAR CAHN

@ 90MG

N16418 010 OCT 18, 1982 MAR CAHN

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

@ BAXTER HLTHCARE 10MG/ML
@ 10MG/ML
@ ELKINS SINK 10MG/ML
@ 10MG/MLN89474 001 NOV 05, 1986 AUG CAHN
N89475 001 NOV 05, 1986 AUG CAHN
N89474 001 NOV 05, 1986 JUN DISC
N89475 001 NOV 05, 1986 JUN DISCPROTIRELIN

INJECTABLE; INJECTION

THYREL TRH

@ FERRING 0.5MG/ML

N18087 001 JUL DISC

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

REGONOL

>D>	ORGANON	5MG/ML	N17398 001	MAY	DISC		
>D>	SABEX 2002	5MG/ML	N17398 001	OCT	CMFD		
>A>	AP	5MG/ML	N17398 001	OCT	CMFD		
	@	5MG/ML	N17398 001	JUN	CAHN		
	TABLET; ORAL						
	PYRIDOSTIGMINE BROMIDE						
>A>	AB	BARR	60MG	N40512 001	OCT 08, 2003	OCT	NEWA
	AB	IMPAK LABS	60MG	N40502 001	APR 24, 2003	APR	NEWA
		@ US ARMY	30MG	N20414 001	FEB 05, 2003	FEB	NEWA

QUETIAPINE FUMARATE

TABLET; ORAL

SEROQUEL

+ ASTRazeneca

EQ 25MG BASE

N20639 001 SEP 26, 1997 MAR CRLD

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCUPRIL

AB	PFIZER PHARMS	EQ 5MG BASE	N19885 001	NOV 19, 1991	MAY	CFTG
AB		EQ 10MG BASE	N19885 002	NOV 19, 1991	MAY	CFTG
AB		EQ 20MG BASE	N19885 003	NOV 19, 1991	MAY	CFTG
AB +		EQ 40MG BASE	N19885 004	NOV 19, 1991	MAY	CFTG
	QUINAPRIL HCL					
AB	TEVA	EQ 5MG BASE	N75504 001	MAY 30, 2003	MAY	NEWA
AB		EQ 10MG BASE	N75504 002	MAY 30, 2003	MAY	NEWA
AB		EQ 20MG BASE	N75504 003	MAY 30, 2003	MAY	NEWA
AB		EQ 40MG BASE	N75504 004	NOV 20, 1998	MAY	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINAGLUTE

@ BERLEX LABS

324MG

N16647 001

MAR DISC

QUINIDINE GLUCONATE

BX +	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	APR	CRLD
+ +		324MG	N89338 001	FEB 11, 1987	MAY	CTEC
+ +	WATSON LABS	324MG	N87810 001	SEP 29, 1982	MAR	CRLD
BX		324MG	N87810 001	SEP 29, 1982	APR	CRLD
@		324MG	N87810 001	SEP 29, 1982	MAY	DISC

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

AB	CLONMEL HLTHCARE	200MG	N87011 001		JUL	CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	QUININDEX					
AB +	WYETH PHARMS INC	300MG	N12796 002		MAR	CAHN
@		300MG	N12796 002		JUN	DISC
	QUINIDINE SULFATE					
+ +	COPLEY PHARM	300MG	N40045 001	JUN 30, 1994	JUN	CTEC

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HCL

MAY DISC	>A> AB TEVA	EQ 150MG BASE	N75557 001 OCT 31, 2003 OCT NEWA
OCT CMFD	>A> AB	EQ 300MG BASE	N75557 002 OCT 31, 2003 OCT NEWA

OCT CMFD			
JUN CAHN			

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2

OCT NEWA	@ AVENTIS PHARMS	0.1MG;2MG	N12972 001 MAY DISC
APR NEWA			
FEB NEWA	METATENSIN #4		
	@ AVENTIS PHARMS	0.1MG;4MG	N12972 002 MAY DISC

RIBAVIRIN

SOLUTION; ORAL

REBETOL

MAR CRLD	+ SCHERING	40MG/ML	N21546 001 JUL 29, 2003 JUL NEWA
----------	------------	---------	----------------------------------

RILUZOLE

TABLET; ORAL

RILUTEK

MAY CFTG	AB + AVENTIS	50MG	N20599 001 DEC 12, 1995 JAN CFTG
MAY CFTG	RILUZOLE		
MAY CFTG	AB IMPAX LABS	50MG	N76173 001 JAN 29, 2003 JAN NEWA
MAY CFTG			

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HCL

MAY NEWA	AB AMIDE PHARM	100MG	N76375 001 JAN 14, 2003 JAN NEWA
MAY NEWA			
MAY NEWA			
MAY NEWA			

RISPERIDONE

>A> INJECTABLE; INTRAMUSCULAR

>A> RISPERDAL CONSTA

>A> JOHNSON AND JOHNSON 25MG/VIAL

N21346 001 OCT 29, 2003 OCT NEWA

>A> 37.5MG/VIAL

N21346 002 OCT 29, 2003 OCT NEWA

>A> + 50MG/VIAL

N21346 003 OCT 29, 2003 OCT NEWA

MAR DISC			
----------	--	--	--

APR CRLD TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

MAY CTEC			
----------	--	--	--

MAR CRLD JOHNSON AND JOHNSON 0.5MG

N21444 001 APR 02, 2003 APR NEWA

APR CRLD			
----------	--	--	--

MAY CTEC + 1MG

N21444 002 APR 02, 2003 APR NEWA

MAR CRLD			
----------	--	--	--

MAY DISC 2MG

N21444 003 APR 02, 2003 APR NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

JUL CAHN	SB PHARMC	EQ 2MG BASE	N21071 002 MAY 25, 1999 APR CAHN
----------	-----------	-------------	----------------------------------

EQ 4MG BASE

N21071 003 MAY 25, 1999 APR CAHN

+ EQ 8MG BASE

N21071 004 MAY 25, 1999 APR CAHN

MAR CAHN			
----------	--	--	--

JUN DISC			
----------	--	--	--

JUN CTEC			
----------	--	--	--

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

ASTRAZENECA	5MG	N21366 002	AUG 12, 2003	AUG	NEWA
	10MG	N21366 003	AUG 12, 2003	AUG	NEWA
	20MG	N21366 004	AUG 12, 2003	AUG	NEWA
+	40MG	N21366 005	AUG 12, 2003	AUG	NEWA

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+	QOL MEDCL	8,500 IU/ML	N20772 001	APR 09, 1998	MAY	CAHN
---	-----------	-------------	------------	--------------	-----	------

SECOBARBITAL SODIUM

INJECTABLE; INJECTION

SODIUM SECOBARBITAL

@ WYETH AYERST 50MG/ML

N83262 001 JUN DISC

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HCL

AB AAIPHARMA LLC 5MG

N75145 001 SEP 15, 2003 SEP NEWA

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

@ SERONO EQ 0.5MG BASE/VIAL

N20443 001 SEP 26, 1997 JUN DISC

@ EQ 1MG BASE/VIAL

N20443 002 SEP 26, 1997 JUN DISC

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

+ GENZYME 403MG

N20926 001 OCT 30, 1998 APR CAHN

TABLET; ORAL

GENZYME 400MG

N21179 001 JUL 12, 2000 APR CAHN

+ 800MG

N21179 002 JUL 12, 2000 APR CAHN

SILDENAFIL CITRATE

TABLET; ORAL

VIAGRA

>D>	PFIZER	25MG	N20895 001	MAR 27, 1998	OCT	CAHN
>D>		50MG	N20895 002	MAR 27, 1998	OCT	CAHN
>D>	+	100MG	N20895 003	MAR 27, 1998	OCT	CAHN
>A>	PFIZER IRELAND	25MG	N20895 001	MAR 27, 1998	OCT	CAHN
>A>		50MG	N20895 002	MAR 27, 1998	OCT	CAHN
>A>	+	100MG	N20895 003	MAR 27, 1998	OCT	CAHN

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+ WYETH PHARMS INC 1MG/ML

N21083 001 SEP 15, 1999 MAR CAHN

SIROLIMUS

TABLET; ORAL

RAPAMUNE

WYETH PHARMS INC

1MG

N21110 001 AUG 25, 2000 MAR CRLD

+

2MG

N21110 002 AUG 22, 2002 MAR NEWA

AUG NEWA
AUG NEWA
AUG NEWA
AUG NEWASODIUM IODIDE, I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ DRAIMAGE

1-250mCi

N21305 002 JAN 24, 2003 JAN NEWA

+

1-500mCi

N21305 003 JAN 24, 2003 JAN NEWA

SOLUTION; ORAL

SODIUM IODIDE I 131, KIT

+ DRAIMAGE

1-250mCi/0.25ML

N21305 002 JAN 24, 2003 FEB CDFR

+

1-500mCi/0.5ML

N21305 003 JAN 24, 2003 FEB CDFR

MAY CAHN

JUN DISC

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

AP + ABBOTT

50MG/VIAL

N70566 001 JUN 09, 1986 JUN CRLD

+

50MG/VIAL

N70566 001 JUN 09, 1986 AUG CTEC

SEP NEWA

SODIUM NITROPRUSSIDE

@ BAXTER HLTHCARE

50MG/VIAL

N18581 001 JUL 28, 1982 AUG CAHN

@ ELKINS SINK

50MG/VIAL

N18581 001 JUL 28, 1982 JUN DISC

JUN DISC

JUN DISC

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

BIO-TROPIN

@ BIO TECH GEN

4.8MG/VIAL

N19774 001 MAY 25, 1995 MAR DISC

NORDITROPIN

BX NOVO NORDISK

4MG/VIAL

N19721 001 MAY 08, 1995 JUL CMFD

8MG/VIAL

N19721 002 MAY 08, 1995 JUL CMFD

TEV-TROPIN

BX + BIO TECH GEN

5MG/ML

N19774 002 JAN 04, 2002 FEB CTNA

APR CAHN

APR CAHN

APR CAHN

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

AB1 BERLEX LABS

80MG

N19865 001 OCT 30, 1992 AUG CTEC

AB1

120MG

N19865 005 APR 20, 1994 AUG CTEC

AB1 +

160MG

N19865 002 OCT 30, 1992 AUG CTEC

AB1

240MG

N19865 003 OCT 30, 1992 AUG CTEC

BETAPACE AF

@ BERLEX LABS

40MG

N21151 006 APR 02, 2003 MAY DISC

40MG

N21151 006 APR 02, 2003 APR NEWA

@

60MG

N21151 007 APR 02, 2003 MAY DISC

60MG

N21151 007 APR 02, 2003 APR NEWA

AB2

80MG

N21151 001 FEB 22, 2000 AUG CFTG

@

100MG

N21151 005 MAR 14, 2003 MAY DISC

100MG

N21151 005 MAR 14, 2003 MAR NEWA

AB2

120MG

N21151 002 FEB 22, 2000 AUG CFTG

MAR CAHN

AB2 +		160MG	N21151 003	FEB 22, 2000	AUG	CFTG
<u>SORINE</u>						
AB1	UPSHER SMITH	80MG	N75500 001	APR 27, 2001	AUG	CTEC
AB1		120MG	N75500 004	APR 27, 2001	AUG	CTEC
AB1		160MG	N75500 002	APR 27, 2001	AUG	CTEC
AB1		240MG	N75500 003	APR 27, 2001	AUG	CTEC
<u>SOTALOL HCL</u>						
AB1	APOTEX	80MG	N76140 001	SEP 26, 2002	AUG	CTEC
AB1		120MG	N76140 002	SEP 26, 2002	AUG	CTEC
AB1		160MG	N76140 003	SEP 26, 2002	AUG	CTEC
AB1		240MG	N76140 004	SEP 26, 2002	AUG	CTEC
AB1	EON	80MG	N75366 001	MAY 01, 2000	AUG	CTEC
AB1		120MG	N75366 002	MAY 01, 2000	AUG	CTEC
AB1		160MG	N75366 003	MAY 01, 2000	AUG	CTEC
AB1		240MG	N75366 004	MAY 01, 2000	AUG	CTEC
AB1	GENPHARM	80MG	N75237 001	MAY 01, 2000	AUG	CTEC
AB1		120MG	N75237 002	MAY 01, 2000	AUG	CTEC
AB1		160MG	N75237 003	MAY 01, 2000	AUG	CTEC
AB1		240MG	N75237 004	MAY 01, 2000	AUG	CTEC
AB1	IMPAK PHARMS	80MG	N75663 001	NOV 07, 2000	AUG	CTEC
AB1		120MG	N75663 002	NOV 07, 2000	AUG	CTEC
AB1		160MG	N75663 003	NOV 07, 2000	AUG	CTEC
AB1		240MG	N75663 004	NOV 07, 2000	AUG	CTEC
AB1	MUTUAL PHARM	80MG	N75515 001	OCT 15, 2001	AUG	CTEC
AB1		120MG	N75515 004	OCT 15, 2001	AUG	CTEC
AB1		160MG	N75515 002	OCT 15, 2001	AUG	CTEC
AB1		240MG	N75515 003	OCT 15, 2001	AUG	CTEC
AB1	MYLAN	80MG	N75725 001	DEC 19, 2000	AUG	CTEC
AB1		120MG	N75725 002	DEC 19, 2000	AUG	CTEC
AB1		160MG	N75725 003	DEC 19, 2000	AUG	CTEC
AB1		240MG	N75725 004	DEC 19, 2000	AUG	CTEC
AB1	TEVA	80MG	N75429 001	MAY 01, 2000	AUG	CTEC
AB1		120MG	N75429 002	MAY 01, 2000	AUG	CTEC
AB1		160MG	N75429 003	MAY 01, 2000	AUG	CTEC
AB1		240MG	N75429 004	MAY 01, 2000	AUG	CTEC
AB2	TORPHARM	80MG	N76214 001	AUG 27, 2003	AUG	NEWA
AB2		120MG	N76214 002	AUG 27, 2003	AUG	NEWA
AB2		160MG	N76214 003	AUG 27, 2003	AUG	NEWA
AB1	WATSON LABS	80MG	N75238 001	JUL 13, 2000	AUG	CTEC
AB1		120MG	N75238 002	JUL 13, 2000	AUG	CTEC
AB1		160MG	N75238 003	JUL 13, 2000	AUG	CTEC
AB1		240MG	N75238 004	JUL 13, 2000	AUG	CTEC

STANOZOLOL

TABLET; ORAL

WINSTROL

+ OVATION PHARMS

2MG

N12885 001 MAY 14, 1984 JUL CAHN

@ WINSTROL

2MG

N12885 001 MAY 14, 1984 AUG DISC

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+ GENSLA SICOR PHARMS

1GM/VIAL

N50577 001 MAY 07, 1982 JUN CAHN

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

METASTRON

AP + AMERSHAM HLTH	1mCi/ML	N20134 001 JUN 18, 1993 JAN CFTG
STRONTIUM CHLORIDE SR-89		
AP BIO NUCLEONICS	1mCi/ML	N75941 001 JAN 06, 2003 JAN NEWA

SUCCIMER

CAPSULE; ORAL

CHEMET

+ OVATION PHARMS	100MG	N19998 002 JAN 30, 1991 JUL CAHN
------------------	-------	----------------------------------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SEPTRA

@ MONARCH PHARMS	80MG/ML;16MG/ML	N18452 001	MAY DISC
------------------	-----------------	------------	----------

SULFANILAMIDE

SUPPOSITORY; VAGINAL

AVC

@ NOVAVAX	1.05GM	N06530 004 JAN 27, 1987 SEP DISC
-----------	--------	----------------------------------

SULINDAC

TABLET; ORAL

SULINDAC

@ CLONMEL HLTHCARE	150MG	N73261 001 SEP 06, 1991 JUN DISC
@	200MG	N73262 001 SEP 06, 1991 JUN DISC

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

AB ASTRazeneca	EQ 10MG BASE	N17970 001	FEB CTEC
AB +	EQ 20MG BASE	N17970 002 MAR 21, 1994	FEB CTEC
TAMOXIFEN CITRATE			
AB AEGIS PHARMS	EQ 10MG BASE	N76398 001	MAR 31, 2003 MAR NEWA
AB	EQ 20MG BASE	N76398 002	MAR 31, 2003 MAR NEWA
AB ANDRX PHARMS	EQ 10MG BASE	N76179 001	FEB 20, 2003 FEB NEWA
AB	EQ 20MG BASE	N76179 002	FEB 20, 2003 FEB NEWA
AB BARR	EQ 10MG BASE	N70929 001	FEB 20, 2003 FEB NEWA
AB	EQ 20MG BASE	N70929 002	FEB 20, 2003 FEB NEWA
AB IVAX PHARMS	EQ 10MG BASE	N75740 001	FEB 20, 2003 FEB NEWA
AB	EQ 20MG BASE	N75740 002	FEB 20, 2003 FEB NEWA
AB MYLAN	EQ 10MG BASE	N74732 002	FEB 20, 2003 FEB NEWA
AB	EQ 20MG BASE	N74732 001	FEB 20, 2003 FEB NEWA
AB PHARMACHEMIE	EQ 10MG BASE	N74539 001	MAR 31, 2003 APR CAHN
AB	EQ 20MG BASE	N74858 001	FEB 20, 2003 FEB NEWA
AB ROXANE	EQ 10MG BASE	N76027 001	FEB 20, 2003 FEB NEWA
AB	EQ 20MG BASE	N76027 002	FEB 20, 2003 FEB NEWA
AB TEVA	EQ 10MG BASE	N74504 001	APR 28, 2003 APR NEWA
AB	EQ 10MG BASE	N74539 001	MAR 31, 2003 MAR NEWA
AB	EQ 10MG BASE	N75797 001	FEB 20, 2003 FEB NEWA
AB	EQ 20MG BASE	N74504 002	APR 28, 2003 APR NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
TECHNECAN MDP KIT

AP + DRAIMAGE N/A N18035 001 MAR CRLD

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION
PYROLITE
@ CIS

N/A

N17684 001

MAY DISC

TELMISARTAN

TABLET; ORAL
MICARDIS
BOEHRINGER INGELHEIM 20MG

N20850 003 APR 04, 2000 JUL CRLD

TESTOSTERONE

GEL; TOPICAL
ANDROGEL

BX + UNIMED PHARMS 1%
TESTIM

N21015 001 FEB 28, 2000 APR CTEC

BX + AUXILIUM A2 1%
TABLET, EXTENDED RELEASE; Buccal
STRIANT
+ COLUMBIA LABS 30MG

N21454 001 OCT 31, 2002 APR CTEC

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL

>D> @ BTG 200MG/ML
>D> AO + 200MG/ML
>A> @ SAVIENT PHARMS 200MG/ML
>A> AO + 200MG/ML

N09165 001 OCT CAHN

N09165 003 OCT CAHN

N09165 001 OCT CAHN

N09165 003 OCT CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

@ CLONMEL HLTHCARE 250MG
@ 500MG

N50278 003 JUN DISC

N50278 001 JUN DISC

SUMYCIN

AB + APOTHECON 500MG
TETRACYCLINE HCL

N60429 003 JUN CRLD

AB AXIOM PHARM 250MG
AB 500MG

N60736 001 MAY CAHN

N60736 002 MAY CAHN

>D> AB ROXANE 500MG
>A> @ 500MG

N61214 002 OCT DISC

N61214 002 OCT DISC

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

@ ALZA 12.7MG/FIBER

N50653 001 MAR 25, 1994 JUN DISC

THALIDOMIDE

CAPSULE; ORAL

THALOMID

CELGENE

50MG

N20785 001 JUL 16, 1998 AUG CRLD

100MG

N20785 002 JAN 17, 2003 JAN NEWA

+

200MG

N20785 003 JAN 17, 2003 JAN NEWA

THALLOUS CHLORIDE, TL-201

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

>A> + BRISTOL MYERS SQUIBB 2mCi/ML

N17806 002 OCT 09, 1998 OCT NEWA

THEOPHYLLINE

SYRUP; ORAL

SLO-PHYLLIN

@ AVENTIS

80MG/15ML

N85187 001 AUG DISC

TABLET; ORAL

@ AVENTIS

100MG

N85202 001 AUG DISC

@

200MG

N85204 001 AUG DISC

TABLET, EXTENDED RELEASE; ORAL

THEO-DUR

@ SCHERING

100MG

N85328 001 SEP DISC

@

200MG

N86998 001 SEP DISC

@

300MG

N85328 002 SEP DISC

@

450MG

N89131 001 JUN 25, 1986 SEP DISC

THEOPHYLLINE

AB PLIVA

300MG

N89763 001 APR 30, 1990 AUG CRLD

UNI-DUR

@ SCHERING

600MG

N89823 001 JAN 04, 1995 SEP DISC

OCT CAHN

OCT CAHN

OCT CAHN

OCT CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

@ WYETH AYERST

100MG/ML

N80553 001 JUN DISC

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

TORECAN

@ NOVARTIS

10MG

N13247 001 JUN DISC

JUN CRLD

THIOTEP'A

INJECTABLE; INJECTION

THIOPLEX

@ IMMUNEX

15MG/VIAL

N20058 001 DEC 22, 1994 JUL DISC

THIOTEP'A

AP + GENSIA SICOR PHARMS

15MG/VIAL

N75730 001 APR 20, 2001 JUL CRLD

JUN DISC

THIOTHIXENE

CAPSULE; ORAL

NAVANE

AB PFIZER

1MG

N16584 001 FEB CAHN

AB

2MG

N16584 002 FEB CAHN

AB +	5MG	N16584 003	FEB CAHN
AB	10MG	N16584 004	FEB CAHN
	20MG	N16584 005	FEB CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

AA + PFIZER	EQ 5MG BASE/ML	N16758 001	FEB CAHN
INJECTABLE; INJECTION			
@ PFIZER	EQ 2MG BASE/ML	N16904 001	FEB CAHN
+	EQ 10MG BASE/VIAL	N16904 002	FEB CAHN

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

>A> + GUILFORD PHARMS	EQ 0.05MG BASE/ML	N20913 001	MAY 14, 1998	OCT	CAHN
>A> +	EQ 0.25MG BASE/ML	N20912 001	MAY 14, 1998	OCT	CAHN
>D> + MERCK	EQ 0.05MG BASE/ML	N20913 001	MAY 14, 1998	OCT	CAHN
>D> +	EQ 0.25MG BASE/ML	N20912 001	MAY 14, 1998	OCT	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HCL

>A> AB AMIDE PHARM	EQ 2MG BASE	N76281 001	OCT 20, 2003	OCT	NEWA
>A> AB	EQ 4MG BASE	N76281 002	OCT 20, 2003	OCT	NEWA
AB BARR	EQ 2MG BASE	N76371 001	APR 09, 2003	APR	NEWA
AB	EQ 4MG BASE	N76371 002	APR 09, 2003	APR	NEWA
AB CARACO	EQ 2MG BASE	N76416 001	SEP 29, 2003	SEP	NEWA
AB	EQ 4MG BASE	N76416 002	SEP 29, 2003	SEP	NEWA
AB MYLAN	EQ 2MG BASE	N76354 001	MAR 28, 2003	MAR	NEWA
AB	EQ 4MG BASE	N76354 002	MAR 28, 2003	MAR	NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991	AUG	CAHN
@	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	AUG	CAHN
AP	EQ 40MG BASE/ML	N63117 001	APR 26, 1991	AUG	CAHN
AP	EQ 40MG BASE/ML	N63118 001	JUL 29, 1991	AUG	CAHN
@	EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	AUG	CAHN

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

@ CLONMEL HLTHCARE	500MG	N86926 001		JUL	DISC
--------------------	-------	------------	--	-----	------

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

@ PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

N12095 001

JUN DISC

FEB	CAHN		<u>TORSEMIDE</u>					
FEB	CAHN		TABLET; ORAL					
FEB	CAHN		TORSEMIDE					
		AB	PAR PHARM	5MG		N76226 001	MAY 27, 2003	MAY NEWA
		AB		10MG		N76226 002	MAY 27, 2003	MAY NEWA
		AB		20MG		N76226 003	MAY 27, 2003	MAY NEWA
		AB		100MG		N76226 004	MAY 27, 2003	MAY NEWA
FEB	CAHN		AB	PLIVA PHARM IND	5MG	N76346 001	MAY 30, 2003	MAY NEWA
		AB		10MG		N76346 002	MAY 30, 2003	MAY NEWA
		AB		20MG		N76346 003	MAY 30, 2003	MAY NEWA
			<u>TRAMADOL HYDROCHLORIDE</u>					
			TABLET; ORAL					
			TRAMADOL HCL					
MAY 14, 1998	OCT	CAHN	AB	IVAX PHARMS	50MG	N75963 001	JUL 03, 2002	MAR CAHN
MAY 14, 1998	OCT	CAHN						
MAY 14, 1998	OCT	CAHN						
MAY 14, 1998	OCT	CAHN						
			<u>TRIAMCINOLONE ACETONIDE</u>					
			AEROSOL, METERED; NASAL					
			NASACORT					
		@ AVENTIS		0.055MG/INH		N19798 001	JUL 11, 1991	JUL DISC
		LOTION; TOPICAL						
			TRIAMCINOLONE ACETONIDE					
OCT 20, 2003	OCT	NEWA	AT	ALTANA	0.025%	N40467 001	APR 21, 2003	APR NEWA
OCT 20, 2003	OCT	NEWA	AT		0.1%	N40467 002	APR 21, 2003	APR NEWA
APR 09, 2003	APR	NEWA						
APR 09, 2003	APR	NEWA						
SEP 29, 2003	SEP	NEWA						
SEP 29, 2003	SEP	NEWA						
MAR 28, 2003	MAR	NEWA						
MAR 28, 2003	MAR	NEWA						
			<u>TRICHLORMETHIAZIDE</u>					
			TABLET; ORAL					
			METAHYDRIN					
		@ AVENTIS PHARMS		2MG		N12594 001	JUN 16, 1988	MAY DISC
		@		4MG		N12594 002	JUN 16, 1988	MAY DISC
			<u>TRIHEXYPHENIDYL HYDROCHLORIDE</u>					
			ELIXIR; ORAL					
			ARTANE					
		@ LEDERLE		2MG/5ML		N06773 009		JUN DISC
			TRIHEXYPHENIDYL HCL					
		AA + PHARM VENTURES		2MG/5ML		N89514 001	APR 07, 1989	JUN CRLD
			TABLET; ORAL					
			ARTANE					
		@ LEDERLE		2MG		N06773 005		JUN DISC
		@		5MG		N06773 003		JUN DISC
			TRIHEXYPHENIDYL HCL					
		AA + WATSON LABS		2MG		N84363 001		JUN CRLD
		AA +		5MG		N84364 001		JUN CRLD
JUN	DISC		<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>					
			CAPSULE; ORAL					
			TIGAN					
		AB + KING PHARMS		300MG		N17531 006	DEC 13, 2001	AUG CFTG

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TRIMETHOBENZAMIDE HCL

AB	AMIDE PHARM	300MG
AB	MUTUAL PHARMA	300MG

N76546 001	AUG 20, 2003	AUG	NEWA
N76570 001	AUG 28, 2003	AUG	NEWA

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

@ MONARCH PHARMS	200MG
TRIMETHOPRIM	
+ TEVA	200MG

N17943 003	JUL 14, 1982	MAY	DISC
N71259 001	JUN 18, 1987	MAY	CRLD

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

>D>	GYNE-SULF					
>D>	AT G AND W LABS	3.7%;2.86%;3.42%	N88607 001	JUN 09, 1986	OCT	DISC
>A>	@	3.7%;2.86%;3.42%	N88607 001	JUN 09, 1986	OCT	DISC
	SULTRIN					
	@ ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%	N05794 001		AUG	DISC
	TRIPLE SULFA					
>D>	AT ALPHARMA	3.7%;2.86%;3.42%	N87864 001	SEP 01, 1982	OCT	WDAG
>A>	@	3.7%;2.86%;3.42%	N87864 001	SEP 01, 1982	OCT	WDAG
>D>	AT CLAY PARK	3.7%;2.86%;3.42%	N87285 001	NOV 15, 1982	OCT	DISC
>A>	@	3.7%;2.86%;3.42%	N87285 001	NOV 15, 1982	OCT	DISC
>D>	TRYSL					
>D>	AT SAVAGE LABS	3.7%;2.86%;3.42%	N87887 001	JUL 23, 1982	OCT	DISC
>A>	@	3.7%;2.86%;3.42%	N87887 001	JUL 23, 1982	OCT	DISC

UREA, C-13

FOR SOLUTION; ORAL

HELCOSOL

@ METABOLIC SOLUTIONS 125MG/VIAL

N21092 001 DEC 17, 1999 MAY DISC

PYLORI-CHEK BREATH TEST

@ DKS DEVICES 100MG/VIAL

N20900 001 FEB 04, 1999 MAR CAHN

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

AP	AM PHARM	EQ 100MG BASE/ML
----	----------	------------------

N76539 001 JUN 26, 2003 JUN NEWA

VALSARTAN

TABLET; ORAL

DIOVAN

NOVARTIS 40MG

N21283 004 AUG 14, 2002 JUL NEWA

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HCL

+ LILLY	EQ 250MG BASE/5ML
---------	-------------------

N61667 002 JUL 13, 1983 JUN CTEC

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOLED

@ LEDERLE

EQ 250MG BASE/5ML

N63321 002 OCT 15, 1993 JUN DISC

INJECTABLE; INJECTION

AP + BAXTER HLTHCARE

EQ 500MG BASE/VIAL

N62682 001 JUL 22, 1986 AUG CAHN

AP +

EQ 1GM BASE/VIAL

N62682 002 MAR 30, 1988 AUG CAHN

+

EQ 2GM BASE/VIAL

N62682 003 MAY 11, 1988 AUG CAHN

AP +

EQ 5GM BASE/VIAL

N62682 004 MAY 11, 1988 AUG CAHN

AP +

EQ 10GM BASE/VIAL

N62682 005 MAY 11, 1988 AUG CAHN

VANCOMYCIN HCL

@ BAXTER HLTHCARE

EQ 500MG BASE/VIAL

N62879 001 AUG 02, 1988 AUG CAHN

@

EQ 1GM BASE/VIAL

N62879 002 AUG 02, 1988 AUG CAHN

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

BAYER PHARMS

2.5MG

N21400 003 AUG 19, 2003 AUG NEWA

5MG

N21400 001 AUG 19, 2003 AUG NEWA

10MG

N21400 002 AUG 19, 2003 AUG NEWA

+

20MG

N21400 004 AUG 19, 2003 AUG NEWA

OCT DISC

OCT DISC

AUG DISC

OCT WDAG

OCT WDAG

OCT DISC

OCT DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

@ ORGANON

10MG/VIAL

N18776 002 APR 30, 1984 MAY DISC

VECURONIUM BROMIDE

AP BAXTER HLTHCARE

10MG/VIAL

N75218 001 AUG 23, 1999 AUG CAHN

AP 20MG/VIAL

N75218 002 AUG 23, 1999 AUG CAHN

AP + BEDFORD

10MG/VIAL

N75549 001 JUN 13, 2000 MAY CRLD

VENLAFAKINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC

EQ 37.5MG BASE

N20699 001 OCT 20, 1997 MAR CAHN

EQ 75MG BASE

N20699 002 OCT 20, 1997 MAR CRLD

@

EQ 100MG BASE

N20699 003 OCT 20, 1997 MAR CAHN

+

EQ 150MG BASE

N20699 004 OCT 20, 1997 MAR CRLD

TABLET; ORAL

EFFEXOR

@ WYETH PHARMS INC

EQ 12.5MG BASE

N20151 001 DEC 28, 1993 MAR CAHN

EQ 25MG BASE

N20151 002 DEC 28, 1993 MAR CRLD

EQ 37.5MG BASE

N20151 006 DEC 28, 1993 MAR CAHN

EQ 50MG BASE

N20151 003 DEC 28, 1993 MAR CAHN

EQ 75MG BASE

N20151 004 DEC 28, 1993 MAR CAHN

+

EQ 100MG BASE

N20151 005 DEC 28, 1993 MAR CAHN

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HCL

@ CLONMEL HLTHCARE

80MG

N71880 001 APR 05, 1988 JUL DISC

JUN NEWA

JUL NEWA

JUN CTEC

@	120MG	N71881 001 APR 05, 1988 JUL DISC
---	-------	----------------------------------

VIDARABINE

OINTMENT; OPHTHALMIC

VIRA-A

@ PARKEDALE

3%

N50486 001

MAY DISC

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCASAR PFS

AP GENSIA SICOR PHARMS

1MG/ML

N71426 001 JUL 17, 1987 JUL CAHN

VINCRISTINE SULFATE

>A> AP AM PHARM

1MG/ML

N76401 001 OCT 28, 2003 OCT NEWA

>D> + AM PHARM PARTNERS

1MG/ML

N76296 001 DEC 20, 2002 OCT CTEC

>A> AP +

1MG/ML

N76296 001 DEC 20, 2002 OCT CTEC

VINCRISTINE SULFATE PFS

AP SICOR PHARMS

1MG/ML

N75493 001 SEP 01, 1999 JUL CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

AP + GLAXOSMITHKLINE

EQ 10MG BASE/ML

N20388 001 DEC 23, 1994 FEB CFTG

VINORELBINE TARTRATE

AP ESI LEDERLE

EQ 10MG BASE/ML

N75992 001 JUN 10, 2003 JUN NEWA

AP GENSIA SICOR PHARMS

EQ 10MG BASE/ML

N76028 001 FEB 03, 2003 FEB NEWA

WARFARIN SODIUM

TABLET; ORAL

>A> JANTOVEN

>A> AB USL PHARMA

1MG

N40416 001 OCT 02, 2003 OCT NEWA

>A> AB

2MG

N40416 002 OCT 02, 2003 OCT NEWA

>A> AB

2.5MG

N40416 003 OCT 02, 2003 OCT NEWA

>A> AB

3MG

N40416 004 OCT 02, 2003 OCT NEWA

>A> AB

4MG

N40416 005 OCT 02, 2003 OCT NEWA

>A> AB

5MG

N40416 006 OCT 02, 2003 OCT NEWA

>A> AB

6MG

N40416 007 OCT 02, 2003 OCT NEWA

>A> AB

7.5MG

N40416 008 OCT 02, 2003 OCT NEWA

>A> AB

10MG

N40416 009 OCT 02, 2003 OCT NEWA

XENON, XE-133

GAS; INHALATION

XENON XE 133

GEN ELECTRIC

5-100 CI/CYLINDER

N17550 001

JUL CPOT

0.25-5 CI/AMP

N17550 003

JUL CPOT

ZALEPLON

CAPSULE; ORAL

SONATA

JONES PHARMA

5MG

N20859 001 AUG 13, 1999 JUN CAHN

+

10MG

N20859 002 AUG 13, 1999 JUN CAHN

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

+ NOVARTIS

EQ 4MG BASE/5ML

N21223 002 MAR 07, 2003 MAR NEWA

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

+ ASTRazeneca

5MG/SPRAY

N21450 004 SEP 30, 2003 SEP NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

DAINIPPON

25MG

50MG

N20789 003 AUG 22, 2003 AUG NEWA

N20789 002 AUG 22, 2003 AUG NEWA

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL					
TYLENOL (CAPLET)					
+ MCNEIL CONS SPECLT	650MG		N19872 001	JUN 08, 1994	JUN CTNA
TYLENOL (GELTAB)					
+ MCNEIL CONS SPECLT	650MG		N19872 002	JAN 11, 2001	JUN NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL					
FOAMICON					
>D>	NOVARTIS	80MG;20MG	N72687 001	JUN 28, 1989	OCT WDAG
>A>	@	80MG;20MG	N72687 001	JUN 28, 1989	OCT WDAG
		80MG;20MG	N72687 001	JUN 28, 1989	MAR CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE					
@ CENT PHARMS	8MG;120MG		N19428 001	AUG 02, 1988	MAR DISC

CIMETIDINE

TABLET; ORAL					
CIMETIDINE					
@ LEK PHARMS	100MG		N75122 001	JUN 19, 1998	MAR CAHN
	200MG		N75122 002	JUN 19, 1998	MAR CAHN

EPINEPHRINE

AEROSOL, METERED; INHALATION					
BRONKAID MIST					
@ STERLING	0.25MG/INH		N16803 001		MAY DISC

FAMOTIDINE

TABLET; ORAL					
PEPCID AC					
MERCK	10MG		N20325 001	APR 28, 1995	SEP CRLD
+	20MG		N20325 002	SEP 23, 2003	SEP NEWA
PEPCID AC (GELTAB)					
MERCK	10MG		N20902 001	AUG 05, 1999	AUG CTNA
TABLET, CHEWABLE; ORAL					
FAMOTIDINE					
PERRIGO	10MG		N75715 001	AUG 22, 2003	AUG NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL					
MUCINEX					
ADAMS LABS	600MG		N21282 001	JUL 12, 2002	JAN CRLD
+	1.2GM		N21282 002	DEC 18, 2002	JAN NEWA

IBUPROFEN

TABLET; ORAL					
JUNIOR STRENGTH MOTRIN					
MCNEIL	100MG		N20602 001	JUN 10, 1996	JUN CRLD

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

LOPERAMIDE HCL

LNK

2MG

N76497 001 JUN 10, 2003 JUN NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM ADVANCED

+ MCNEIL CONS SPECLT

2MG;125MG

N21140 001 NOV 30, 2000 JAN CRLD

LORATADINE

SYRUP; ORAL

CLARITIN

+ SCHERING

1MG/ML

N20641 002 NOV 27, 2002 APR CRLD

>A>

1MG/ML

N20641 002 NOV 27, 2002 MAR NEWA

>A>

TABLET; ORAL

+ SCHERING

10MG

N19658 002 NOV 27, 2002 APR CRLD

>D>

10MG

N19658 002 NOV 27, 2002 MAR NEWA

>D>

LORATADINE

GENEVA PHARMS

10MG

N75209 001 JAN 21, 2003 JAN NEWA

>A>

GENPHARM

10MG

N76154 001 AUG 20, 2003 AUG NEWA

>D>

RANBAXY

10MG

N76134 001 AUG 18, 2003 AUG NEWA

>A>

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

WYETH CONS

10MG

N21375 001 DEC 19, 2002 APR CRLD

>A>

CLARITIN REDITABS

+ SCHERING

10MG

N20704 002 NOV 27, 2002 APR CRLD

>D>

10MG

N20704 002 NOV 27, 2002 MAR NEWA

>A>

LORATADINE

IMPAK LABS

10MG

N76011 001 SEP 29, 2003 SEP NEWA

>D>

WYETH CONS

10MG

N75822 001 FEB 10, 2003 FEB NEWA

>A>

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ SCHERING

5MG;120MG

N19670 002 NOV 27, 2002 APR CRLD

>A>

5MG;120MG

N19670 002 NOV 27, 2002 MAR NEWA

>D>

CLARITIN-D 24 HOUR

+ SCHERING

10MG;240MG

N20470 002 NOV 27, 2002 APR CRLD

>A>

10MG;240MG

N20470 002 NOV 27, 2002 MAR NEWA

>D>

LORATADINE AND PSEUDOEPHEDRINE HCL

>D>

ANDRX PHARMS

10MG;240MG

N75706 001 FEB 21, 2003 OCT CTNA

>A>

10MG;240MG

N75706 001 FEB 21, 2003 FEB NEWA

>A>

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ANDRX PHARMS

10MG;240MG

N75706 001 FEB 21, 2003 OCT CTNA

>D>

IMPAX LABS

5MG;120MG

N76050 001 JAN 30, 2003 JAN NEWA

>A>

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+ PERSONAL PRODS

2%,4%

N21261 003 JUN 17, 2003 JUN NEWA

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL
 MONISTAT 3 COMBINATION PACK (PREFILLED)
 + PERSONAL PRODS 2%,4%

N21261 001 FEB 02, 2001 JUN CTNA

MINOXIDIL

SOLUTION; TOPICAL
 MINOXIDIL EXTRA STRENGTH (FOR MEN)
 MORTON GROVE 5%

N75438 001 FEB 27, 2003 FEB NEWA

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

PROSTEP

>A>	+	AVEVA	11MG/24HR	N19983 003	DEC 23, 1998	OCT	CAHN
>A>	+		22MG/24HR	N19983 004	DEC 23, 1998	OCT	CAHN
>D>	+	ELAN PHARM	11MG/24HR	N19983 003	DEC 23, 1998	OCT	CAHN
>D>	+		22MG/24HR	N19983 004	DEC 23, 1998	OCT	CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL
 COMMIT
 GLAXOSMITHKLINE CONS EQ 2MG BASE
 + EQ 4MG BASE

N21330 001 OCT 31, 2002 SEP CPOT
 N21330 002 OCT 31, 2002 SEP CPOT

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE; ORAL
 PRILOSEC
 + ASTRazeneca EQ 20MG BASE

N21229 001 JUN 20, 2003 JUN NEWA

PERMETHRIN

LOTION; TOPICAL
 NIX
 + INSIGHT PHARMS 1%

N19918 001 MAY 02, 1990 MAR CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER '03

NO OCTOBER 2003 APPROVALS

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

**Orphan Products Designations and Approvals List
October 2003**

Generic Name/ Trade Name (if present):	Date Designated = DD Date Approved= MA Indication Designated:	Sponsor and Address
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	DD: 3/31/2003 Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy MA:	BioMedicines, Inc. 2000 Powell Street Suite 1640 Emeryville CA 94608
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3-yl)propyl]acetamide	DD: 7/3/2003 Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients MA:	Phase 2 Discovery, Inc. 3130 Highland Ave. Third Floor Cincinnati OH 45219
1,1'-[1,4-phenylenebis(methylene)-b-is-1,4,8,11-tetraazacyclotetradecan	DD: 7/10/2003 For combination use with filgrastim to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy MA:	AnorMED Inc. 200-20353 64th Avenue Langley, BC, V2Y 1N5
2',3',5'-tri-o-acetyluridine	DD: 1/13/2003 Treatment of mitochondrial disease MA:	Repligen Corporation 41 Seyon Street Building 1, Suite 100 Waltham MA 02453
2-O-Butyryl-1-O-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	DD: 8/15/2003 Treatment of cystic fibrosis MA:	Inologic, Inc. 101 Elliott Ave., West Seattle WA 98119
4,5-dibromorhodamine 123 Theralux Irradiation Device	DD: 4/10/2003 Treatment of chronic myelogenous leukemia MA:	Celmed BioSciences Inc. 2310 boul Alfred-Nobel Saint-Laurent, Quebec
5,5',5"-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylhelidoninium]trihydroide hexahydrochloride	DD: 8/20/2003 Treatment of pancreatic cancer MA:	Now Pharm AG 241, route d'Arlon L-1150
a-(3-aminophthalimido) Actimid	DD: 1/15/2003 Treatment of multiple myeloma MA: MA:	Celgene Corporation 7 Powder Horn Drive Warren NJ 07059

Orphan Products Designations and Approvals List

October 2003

a-Galactosidase A Corporation Plant-Produced Human a-Galactosidase	DD: 1/21/2003 Treatment of Fabry's disease MA:	Large Scale Biology 3333 Vacaville Parkway Suite 1000 Vacaville CA 95688
alendronate	DD: 3/31/2003 Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older MA:	Merck & Co., Inc. 126 East Lincoln Ave. 126 East Lincoln Ave. Rahway NJ 07065-0900
Fosamax	MA:	Daniel F. Hanley, MD Johns Hopkins Johns Hopkins 600 N. Wolfe St.,
alteplase	DD: 1/27/2003 Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage MA:	Baltimore MD 21287 Amgen, Inc. One Amgen Center Thousand Oaks CA IDEC Pharmaceuticals, 3030 Callan Road San Diego CA 92121 KS Biomedix Ltd Ground Floor, 1 Occam
University Activase University		
Jefferson 1-109		
AMG 531	DD: 3/27/2003 Treatment of immune thrombocytopenic purpura. MA:	Surrey Research Park Lorus Therapeutics, Inc 2 Meridian Road Toronto, Ontario
Drive		
91320-1799		
anti-CD23 IgG1, kappa monoclonal Inc. antibody	DD: 2/12/2003 Treatment of chronic lymphocytic leukemia MA:	Cell Therapeutics, Inc. 501 Elliott avenue West Suite 400 Seattle WA 98119
Anti-CEA Sheep-human chimeric monoclonal antibody labeled Court w/iodine-131 (KAb201)	DD: 5/21/2003 Treatment of pancreatic cancer MA:	
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] GTI-2040	DD: 3/12/2003 Treatment for renal cell carcinoma MA: MA:	
arsenic trioxide Trisenox	DD: 5/13/2003 Treatment of chronic lymphocytic leukemia MA:	

Orphan Products Designations and Approvals List
October 2003

arsenic trioxide Trisenox	DD: 6/13/2003 Treatment of liver cancer MA:	Cell Therapeutics, Inc. 501 Elliott Avenue West Suite 400 Seattle WA 98119
Atomoxetine hydrochloride STRATTERA	DD: 8/26/2003 Treatment of Tourette's Syndrome MA:	ELI LILLY & Company Lilly Corporate Center Indianapolis IN 46285
bifidobacterium longum infantis Limited 35624	DD: 1/16/2003 Treatment of pediatric Crohn's disease MA:	Alimentary Health Guardwell, Kinsale
bortezomib Pharmaceuticals, Inc. VELCADE	DD: 1/15/2003 To treat multiple myeloma MA:	Millennium 75 Sidney Street Cambridge MA 02139
Capsaicin Park 4117	DD: 5/2/2003 Treatment of painful HIV-associated neuropathy MA:	NeurogesX, Inc. San Carlos Business 981F Industrial Road San Carols CA 94070-
Carboxypeptidase G2 Suite 405	DD: 8/19/2003 Treatment of patients at risk of methotrexate toxicity MA:	Protherics, Inc. 5214 Maryland Way, Brentwood TN 37027
cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanolic acid) Falkochol	DD: 7/18/2003 Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism MA: MA:	Dr. Falk Pharma GmbH Leinenweberstrasse 5 Postfach 6529
cinacalcet Drive 91320-1799	DD: 5/12/2003 Treatment of hypercalcemia in patients with parathyroid carcinoma MA:	Amgen, Inc. One Amgen Center Thousand Oaks CA
Combretastatin A4 Phosphate	DD: 7/23/2003 Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer MA: MA:	OXiGENE, Inc 321 Arsenal Street Watertown MA 02472

Orphan Products Designations and Approvals List

October 2003

conjugated bile acids	DD: 7/18/2003 Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc. 1824 S. Robertson Blvd. 1824 S. Robertson Blvd. Los Angeles CA 90035-
COBARTin	MA:	
4317		
cultured, partially T-Cell depleted, Center allogenic thymic tissue for Allergy & transplantation	DD: 8/15/2003 As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Division of Pediatric Immunology Erwin Road Durham NC 27710
	MA:	
debrase	DD: 8/20/2003 Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd. 3, Azrieli Center 3, Azrieli Center Triangular Tower 45th
Debridase	MA:	
Floor		
Defibrotide	DD: 5/21/2003 For the treatment of hepatic veno-occlusive disease	Gentium SpA Piazza XX Settembre, 2 22079 Villa Guardia
(CO)	MA:	
Dehydroepiandrosterone (DHEA)	DD: 8/19/2003 Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc. 6111 Royalmount
Avenue Suite	MA:	6111 Royalmount
Fidelin		
Avenue Suite		Montreal, Quebec
dextran 1	DD: 3/21/2003 Treatment of cystic fibrosis	BCY LifeSciences Inc. 160 Eglinton Ave. East Suite 600
	MA:	
DHA-paclitaxel	DD: 5/1/2003 Treatment of adenocarcinoma of the stomach or lower esophagus	Protarga, Inc. 2200 Renaissance
Boulevard Taxoprexin	MA:	2200 Renaissance
Boulevard		
19406		Suite 450 King of Prussia PA
diferuloylmethane	DD: 6/13/2003 Treatment of cystic fibrosis	Seer Pharmaceuticals, LLC P. O. Box 138 Southport CT 06890
	MA:	

Orphan Products Designations and Approvals List
October 2003

diphenylcyclopentone	DD: 6/13/2003 MA: MA:	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis) [AT]/Alopecia Universalis [AU]	Lloyd E. King, Jr. 1900 Patterson Street Suite 104
eculizumab Pharmaceuticals, Inc.	DD: 8/20/2003 MA:	Treatment of paroxysmal nocturnal hemoglobinuria	Nashville TN 37203 Alexion
Erlotinib Hydrochloride Tarceva	DD: 7/18/2003 MA:	Treatment of malignant gliomas	Genentech, Inc 1 DNA Way South San Francisco CA
94080-4990	DD: 5/21/2003 MA:	Treatment of congenital FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue Seattle WA 98102
Factor XIII [A2] homodimer, recombinant DNA origin East	DD: 6/26/2003 MA:	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG Weissfrauenstr.9 D-60287 Frankfurt
HepeX-B Biopharmaceuticals, Ltd.	DD: 7/15/2003 MA: MA:	For the prevention of hepatitis B virus (HBV) XTL reinfection in patients who have received a liver transplantation	Kiryat Weizmann Science Park Bldg 3
Human Anti-tumor Necrosis factor alpha monoclonal antibody Parkway	DD: 1/16/2003 MA:	Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy	Centocor, Inc. 200 Great Valley Malvern PA 19355-
1307	DD: MA:	Treatment of idiopathic inflammatory myopathies	Protein Therapeutics, 2761 N. Country Club Suite 202 Tucson AZ 85716
human gammaglobulin Inc. Road	DD: MA:	Treatment of patients undergoing solid organ transplantation.	Idun Pharmaceuticals, 9380 Judicial drive
IDN 6556 Inc. San Diego CA 92121	DD: 8/19/2003 MA:	Treatment of patients undergoing solid organ transplantation.	

Orphan Products Designations and Approvals List
October 2003

infliximab Remicade Parkway 1307	DD: 5/6/2003 Treatment of giant cell arteritis MA:	Centocor, Inc. 200 Great Valley Malvern PA 19355-
infliximab Remicade Parkway 1307	DD: 5/21/2003 Treatment of chronic sarcoidosis MA:	Centocor, Inc. 200 Great Valley Malvern PA 19355-
infliximab Parkway REMICADE Parkway 1307	DD: Treatment of pediatric (0 to 16 years of age) Crohn's Disease MA:	Centocor, Inc. 200 Great Valley 200 Great Valley Malvern PA 19355-
infliximab Parkway REMICADE Parkway 1307	DD: Treatment of pediatric (0 to 16 years of age) ulcerative colitis MA:	Centocor, Inc. 200 Great Valley 200 Great Valley Malvern PA 19355-
INGN 201 Inc. ADVEXIN	DD: 1/27/2003 Treatment of head and neck cancer MA: MA:	Introgen Therapeutics, 2250 Holcombe Blvd Houston TX 77030
iron(III)-hexacyanoferrate(II) Pharmazeutische KG	DD: 5/1/2003 Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or	Heyl Chemisch- Fabrik GMBH & Co, Goerzallee 253
Radiogardase Republic of	MA: thallium MA:	Goerzallee 253 D-14167 Berlin, Federal Germany
Lactoferrin alpha	DD: 8/20/2003 For the treatment of graft versus host disease MA:	Agennix, Inc. Greenway Plaza Suite 910 Houston TX 77046
Lactoferrin alpha	DD: 8/20/2003 For the prevention of graft-versus-host disease MA:	Agennix, Inc. 8 Greenway Plaza Suite 910 Houston TX 77046

Orphan Products Designations and Approvals List
October 2003

Mafosfamide (formerly Oncology)	DD: 1/21/2003 Treatment of neoplastic meningitis MA:	Baxter Oncology GmbH ASTA Medica Daimlerstrasse 40 60314 franfurt/Main
MaxAdFVIII Corporation 1113	DD: 3/3/2003 Treatment of Hemophilia A MA:	GenStar Therapeutics 10865 Altman Row Suite 200 San Diego CA 92121-
monarsen B, 10th Floor	DD: Treatment of Myasthenia Gravis MA:	Medica Venture Partners Ackerstein Towers, Bldg ISRAEL
motexafin gadolinium Xcytrin 4521	DD: 1/27/2003 For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors MA: MA:	Pharmacyclics, Inc. 999 East Arques Avenue 999 East Arques Avenue Sunnyvale CA 94085-
Mx-dnG1 or Rexin-G retroviral Corporation REXIN-G 1803W	DD: 8/15/2003 Treatment of pancreatic cancer MA:	Epeius Biotechnologies 345 Pioneer Drive, Glendale CA 91203
myristoylated recombinant SCR1-3 of human complement reseptor Pk, type I APT070 Saffron Walden,	DD: 5/21/2003 Prevention of delayed graft function in solid organ transplant MA: MA:	Adprotech, Ltd. Chesterford Research Little Chesterford,
niprasan Inc. Hemoxin Technology Center Building B, Suite 08901	DD: 8/15/2003 Treatment of sickle cell disease MA:	Xechem International, New Brunswick 100 Jersey Avenue, 310 New Brunswick NJ

Orphan Products Designations and Approvals List
October 2003

polyinosinic-polycytidilic acid NW Poly-ICLC NW 3450	DD: 3/3/2003 MA: MA:	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Ribopharm, Inc. 3203 Cleveland Ave., 3203 Cleveland Ave., Washington DC 20008-
Protaxel Court	DD: 5/21/2003 MA:	Treatment of ovarian cancer	Biophysica, Inc. 3333 North Torrey Pines Suite 100 La Jolla CA 92037
recombinant adeno-associated Technologies Corp. virus alpha 1-antitrypsin vector rAAV-AAT	DD: 1/27/2003 MA: MA:	Treatment of alpha1-antitrypsin deficiency	Applied Genetic 12085 Research Drive Suite 110 Alachua FL 32615
recombinant inhibitor of human plasma kallikrein	DD: 2/4/2003 MA:	Treatment of angioedema	Dyax Corp 300 Technology Square Cambridge MA 02139
Recombinant T-cell receptor Square Road	DD: 5/2/2003 MA: MA:	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive residues 35-55 to myelin oligodendrocyte glycoprotein	Virogenomics, Inc. 9020 SW Washington Suite 380 Tigard, OR 97223-4332
repertaxin	DD: 1/27/2003 MA:	Prevention of delayed graft function in solid organ transplant	Dompe s.p.a. Via Campo di Pile 67100 - L'Aquila
repository corticotropin or Pharmaceuticals, Inc. adrenocorticotrophic hormone H.P. Acthar Gel 1217	DD: 5/21/2003 MA: MA:	Treatment of infantile spasms	Questcor 3260 Whipple Road Union City CA 94587-
resiniferatoxin	DD: 5/13/2003 MA: DASS/PPCS/NIDCR/NIH	Treatment of intractable pain at end-stage disease	Andrew J. Mannes, Md Bldg 10/Rm 2N236 - 10 Convent Drive Bethesda MD 20892

Orphan Products Designations and Approvals List
October 2003

ribavirin	DD: 4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation 2000 Galloping Hill
Road REBETOL Road	MA:		2000 Galloping Hill Kenilworth NJ 07033
SC-1 monoclonal antibody	DD:	Treatment of patients with CD55 (sc-1) positive gastric tumors	H3 Pharma, Inc. 666 Sherbrooke Street
West, Suite	MA:		1400 Montreal, Quebec
SGN-30 (anti-CD30 mAb)	DD: 7/18/2003	Treatment of Hodgkin's disease	Seattle Genetics, Inc 21823 30th Drive,
Southeast	MA:		Bothell WA 98021
sipilizumab Inc.	DD: 7/15/2003	Treatment of T-cell lymphomas	MedImmune Oncology, 35 W. Watkins Mill
Road	MA:		Gaithersburg Md 20878
sodium dichloroacetate	DD: 7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group 6120 Paseo del Norte Suite J2 Carlsbad CA 92009
MA:			
Sodium pyruvate	DD: 3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc. 84 Park Avenue P. O. Box 968 Flemington NJ 08822
	MA:		
suberoylanilide hydroxamic acid	DD: 6/12/2003	Treatment of multiple myeloma	Aton Pharma, Inc. 777 Old Saw Mill River
Road	MA:		Tarrytown NY 10591-
6717			
Tezacicabine	DD: 1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Chiron Corporation 4560 Horton Street Emeryville CA 94608-
2916	MA:		

Orphan Products Designations and Approvals List October 2003

Tinidazole Inc.	DD: 8/20/2003 For the treatment of amebiasis	Presutti Laboratories,
60004	MA:	1607 N. Douglas Avenue Arlington Heights IL
Tretinoïn ATRA-IV	DD: 4/11/2003 Treatment of T-cell non-Hodgkin's lymphoma MA:	Antigenics, Inc. 34 Commerce Way 34 Commerce Way Woburn MA 01801

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2003 ADDITIONS

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 # represents patent information submitted prior to 08/18/03 * PED and PED represent Pediatric Exclusivity

APPL / PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020977 001	ABACAVIR SULFATE; ZiAGEN	#5034394 #5034394* PED	DEC 18, 2011 JUN 18, 2012			
020978 001	ABACAVIR SULFATE; ZiAGEN	#5034394 #5034394* PED	DEC 18, 2011 JUN 18, 2012			
020213 001	ACETYLCHOLINE CHLORIDE; MIOPHOL-E	#6261546 #4963555	JUN 18, 2012 APR 29, 2019			
021478 001	ACYCLOVIR; ZOVIRAX	#5573751	OCT 16, 2007			
020899 001	ALBUMIN HUMAN; OPTISON	#5529786 #5558094	APR 25, 2012 FEB 28, 2012			
>ADD>	ALBUTEROL SULFATE; DUONEB	6632842 #5358941	DEC 28, 2011 DEC 02, 2012		U-532	SEP 29, 2003
020950 001	ALENDRONATE SODIUM; FOSAMAX	#4621077 #5358941* PED	FEB 06, 2008			MAR 29, 2004
020560 001		#5681590 #5849726	AUG 06, 2007 JUN 06, 2015		U-114	
020560 002	ALENDRONATE SODIUM; FOSAMAX	#6008207 #6090410	JUN 06, 2015 DEC 02, 2012			
		#6194004 #4621077* PED	DEC 02, 2012			
		#5358941* PED	FEB 06, 2008			
		#5681590* PED	JUN 02, 2013			
		#5849726* PED	JUN 02, 2013			
		#6008207* PED	DEC 06, 2015			
		#6090410* PED	JUN 02, 2013			
		#6194004* PED	JUN 02, 2013			
		#5358941* PED	DEC 02, 2012			
		#4621077	AUG 06, 2007			
		#5681590	DEC 02, 2012			
		#5849726	JUN 06, 2015			
		#6008207	JUN 06, 2015			
		#6090410	DEC 02, 2012			
		#4621077* PED	FEB 06, 2008			
		#5358941* PED	JUN 02, 2013			
		#5681590* PED	JUN 02, 2013			
		#5849726* PED	JUN 06, 2015			
		#6008207* PED	JUN 02, 2013			
		#6090410* PED	DEC 02, 2012			
		#4621077	AUG 06, 2007			
		#5681590	DEC 02, 2012			
		#5849726	JUN 06, 2015			
		#6008207	JUN 06, 2015			
		#6090410	DEC 02, 2012			
		#4621077* PED	FEB 06, 2008			
		#5358941* PED	JUN 02, 2013			
		#5681590* PED	JUN 02, 2013			
		#5849726* PED	JUN 06, 2015			
		#6008207* PED	JUN 02, 2013			
		#6090410* PED	DEC 06, 2015			
		#6090410* PED	JUN 02, 2013			

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 # represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020560 004	ALENDRONATE SODIUM; FOSAMAX	#6015801 #4621077 #5358941 #5681590 #5849726 #6008207 #6090410 #5994329 #6225294	JUL 17, 2018 AUG 06, 2007 DEC 02, 2012 DEC 02, 2012 JUN 06, 2015 JUN 06, 2015 DEC 02, 2012 JUL 17, 2018 FEB 06, 2008	U-353 U-114 D-61 D-62 PED PED PED	NS OCT 20, 2003 OCT 20, 2003 OCT 20, 2003 APR 20, 2004 APR 20, 2004 APR 20, 2004	OCT 20, 2003 OCT 20, 2003 OCT 20, 2003 APR 20, 2004 APR 20, 2004 APR 20, 2004
020560 005	ALENDRONATE SODIUM; FOSAMAX	#6015801 #6090410* PED #6225294* PED #6015801 #4621077 #5358941 #5681590 #5849726 #5994329 #6008207 #6090410 #6225294 #4621077* PED #5358941* PED #5681590* PED #5849726* PED #5994329* PED #6008207* PED #6090410* PED #6225294* PED #4621077	JAN 17, 2019 JUN 02, 2013 JUN 02, 2013 DEC 16, 2015 JAN 17, 2019 DEC 06, 2015 JAN 17, 2019 JUN 02, 2013 JUN 02, 2013 JUN 06, 2015 JUL 17, 2018 AUG 06, 2007 DEC 02, 2012 DEC 02, 2012 JUN 06, 2015 JUL 17, 2018 JUN 06, 2015 DEC 02, 2012 JUL 17, 2018 FEB 06, 2008	U-353 U-114 D-61 D-62 PED PED PED	NS OCT 20, 2003 OCT 20, 2003 OCT 20, 2003 APR 20, 2004 APR 20, 2004 APR 20, 2004	OCT 20, 2003 OCT 20, 2003 OCT 20, 2003 APR 20, 2004 APR 20, 2004 APR 20, 2004
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021575 001	ALENDRONATE SODIUM; FOSAMAX	JAN 17, 2019 JUN 02, 2013 JUN 02, 2013 JUN 06, 2015 JUL 17, 2018 JUN 06, 2015 DEC 02, 2012 JUL 17, 2018 AUG 06, 2007 FEB 06, 2008 MAY 17, 2014 JUL 17, 2018 JAN 17, 2019 JUL 17, 2018 JAN 17, 2019 JUL 17, 2018 JAN 17, 2019 JUL 17, 2018 JAN 17, 2019	U-353 U-114 D-61 D-62 PED PED PED	I-309 MAR 29, OCT 20, APR 20,	SEP 29, MAR 29, OCT 20, APR 20,

A-4

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021436 001	ARIPRAZOLE; ABILIFY	#4734416 #5006528 #4734416 #5006528	MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2009	I-401	AUG 28, 2006	
021436 002	ARIPRAZOLE; ABILIFY	#4734416 #5006528 #4734416 #5006528	MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2009	I-401	AUG 28, 2006	
021436 003	ARIPRAZOLE; ABILIFY	#4734416 #5006528 #4734416 #5006528	MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2009	I-401	AUG 28, 2006	
021436 004	ARIPRAZOLE; ABILIFY	#4734416 #5006528 #4734416 #5006528	MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2009	I-401	AUG 28, 2006	
021436 005	ARIPRAZOLE; ABILIFY	#4734416 #5006528 #4734416 #5006528	MAR 29, 2005 OCT 20, 2009 MAR 29, 2005 OCT 20, 2009	I-401	AUG 28, 2006	
021436 006	ARIPRAZOLE; ABILIFY	#4734416 #5006528 #4346227 #5030447	OCT 20, 2009 MAR 29, 2005 OCT 20, 2009 APR 20, 2006	I-401	AUG 28, 2006	
021387 001	ASPIRIN; PRAVIGARD PAC (COPAC	#4346227* PED #5030447* PED #5180589 #5180589* PED	OCT 20, 2009 JUL 09, 2008 JUL 09, 2009 JAN 09, 2009			
021387 002	ASPIRIN; PRAVIGARD PAC (COPAC	#5622985 #5622985* PED #4346227 #4346227* PED #5030447 #5030447* PED	APR 22, 2014 OCT 22, 2014 OCT 22, 2014 APR 20, 2006 JUL 09, 2008 JUL 09, 2008 JAN 09, 2009	U-335 U-335 U-335 U-335 JAN 09, 2009 JUL 09, 2008 JUL 09, 2008 JAN 09, 2009		
021387 003	ASPIRIN; PRAVIGARD PAC (COPAC	#5622985 #5030447 #5180589 #5180589* PED	APR 22, 2014 OCT 22, 2014 JUL 09, 2008 JUL 09, 2008	U-335 U-335 U-335 U-335		
021387 004	ASPIRIN; PRAVIGARD PAC (COPAC	#5030447* PED #5180589 #4346227 #4346227* PED #5030447 #5030447* PED	JUL 09, 2008 JUL 09, 2008 APR 20, 2006 JUL 09, 2008 JUL 09, 2008 JUL 09, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
represents patent information submitted prior to 08/18/03 * PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020259 001	ATOVAQUONE;MEPRON	#4981874 #5053432 #5053432*PED 4981874*PED	AUG 15, 2009 OCT 01, 2008 APR 01, 2009 FEB 15, 2010	U-69	JAN 05, 2006 JUL 05, 2006	ODE PED
020500 001	ATOVAQUONE;MEPRON	#4981874 #5053432 #5053432*PED 4981874*PED	AUG 15, 2009 OCT 01, 2008 APR 01, 2009 FEB 15, 2010	U-69	JAN 05, 2006 JUL 05, 2006	ODE PED
021470 001 019851 001	AZELAIC ACID;FINACEA BENAZEPRIL HYDROCHLORIDE;LOTENSIN	#6534070 #4410520 #4410520*PED #4410520*PED	NOV 18, 2018 AUG 11, 2003 FEB 11, 2004 AUG 11, 2003	U-69		
019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	#4410520 #4410520*PED	FEB 11, 2004			
019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	#4410520 #4410520*PED	FEB 11, 2004			
019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	#4410520*PED #4410520 #4410520*PED	AUG 11, 2003 AUG 11, 2003 FEB 11, 2004	U-69		
020033 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	#4410520 #4410520*PED	FEB 11, 2004			
020033 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	#4410520 #4410520*PED	FEB 11, 2004			
020033 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	#4410520*PED #4410520 #4410520*PED	AUG 11, 2003 FEB 11, 2004 AUG 11, 2003	U-69		
020033 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	#4410520 #4410520*PED	FEB 11, 2004			
021055 001	BEXAROTENE;TARGETRETIN	#4410520*PED	FEB 11, 2003			
021056 001	BEXAROTENE;TARGETRETIN	#5780676	JUL 14, 2004	U-509		
021602 001	BORTEZOMIB;VELCADE	#5780676 #5780454 #6083903	JUL 14, 2015 OCT 28, 2014 OCT 28, 2014	U-510	NCE ODE	MAY 13, 2008 MAY 13, 2010
021290 001 021290 002 021262 001	BOSENTAN;TRACLEER BOSENTAN;TRACLEER BRIMONIDINE TARTRATE;ALPHAGAN P	#6297217 #6617317 #5292740 #6627210*PED	OCT 28, 2014 OCT 28, 2014 NOV 20, 2015 JUL 18, 2021	U-515 U-515 JUL 10, 2021		
>ADD> >ADD>		6641834*PED #6562873*PED #6562873*PED #6598603*PED #6598603*PED #6598603	JAN 28, 2022 JUL 28, 2021 JAN 28, 2022 JUL 18, 2021 JAN 18, 2022			
>ADD>	076260 001	BRIMONIDINE TARTRATE;BRIMONIDINE TARTRATE	JUN 23, 2019	PC	SEP 16, 2003	
>ADD>	020929 001	BUDESONIDE;PULMICORT RESPULES	DEC 23, 2018			
>ADD>	020929 002	BUDESONIDE;PULMICORT RESPULES	JUN 23, 2019			
		U-529	DEC 23, 2018			

PREScription AND oTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
represents patent information submitted prior to 08/18/03 * PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020774 001	CHLORHEXIDINE GLUCONATE; PERIOCHIP	#5002769 #5023082	MAR 16, 2006 MAR 30, 2005		NDF	FEB 28, 2006
021159 001	CICLOPIROX; LOPROX	#4670444	DEC 09, 2003		NDF	DEC 13, 2005
021473 001	CIPROFLOXACIN; CIPRO XR	#4844902	FEB 11, 2008		NDF	DEC 13, 2005
021473 002	CIPROFLOXACIN; CIPRO XR	#6284804	AUG 10, 2020		NC	JUL 18, 2006
021537 001	CIPROFLOXACIN; CIPRODEX	#6359016	AUG 10, 2020		NCE	JUL 17, 2003
020822 004	CITALOPRAM HYDROBROMIDE; CELEXA			PED	JAN 17, 2004	
021535 001	CLOBETASOL PROTIONATE; CLOBEX	#6106848	SEP 22, 2017		NDF	JUL 24, 2006
020839 001	CLOPIDOGREL BISULFATE; PLAVIX	#6504030	JUN 10, 2019		NCE	SEP 12, 2008
019758 001	CLOZAPINE; CLOZARTIL			I-380	DEC 18, 2005	
019758 002	CLOZAPINE; CLOZARIL			I-380	DEC 18, 2005	
021141 001	COLESEVELAM HYDROCHLORIDE; WELCHOL	#6066678	JUN 10, 2014		NCE	JAN 17, 2004
021176 001	COLESEVELAM HYDROCHLORIDE; WELCHOL	#6066678	JUN 10, 2014		NCE	JUL 24, 2006
017821 001	CYCLOBENZAPRINE HYDROCHLORIDE; FLEXERIL	#5912226	JUN 15, 2016		D-78	FEB 03, 2006
021572 001	DAPTONYCIN; CUBICIN	#6468967	SEP 24, 2019		NCE	SEP 12, 2008
>ADD>	DAPTONYCIN; CUBICIN	#5912226	JUN 15, 2016		NCE	SEP 12, 2008
>ADD>	021572 002	#6468967	SEP 24, 2019		NCE	SEP 12, 2008
>ADD>	020705 002	#5563142	OCT 08, 2013		NCE	SEP 12, 2008
>ADD>	DELAVIDRINE MESYLATE; RESSCRIPTOR	#6177101	JUN 11, 2018		NCE	SEP 12, 2008
021271 001	DESTRUDIN; IPRIVASK	#4745177	MAY 17, 2005		NCE	SEP 12, 2008
021165 001	DESLORATADINE; CLARINEX	#4801576	JAN 31, 2006		NCE	SEP 12, 2008
021165 001	DESLORATADINE; CLARINEX	#5733874	MAR 31, 2015		NCE	SEP 12, 2008
021312 001	DESLORATADINE; CLARINEX	#4659716	APR 21, 2004		U-427	DEC 21, 2006
021312 001	DESLORATADINE; CLARINEX	#4863931	SEP 15, 2008		PED	JUN 21, 2007
021312 001	DESLORATADINE; CLARINEX	#4804666	FEB 14, 2006		U-428	
021312 001	DESLORATADINE; CLARINEX	#5595997	DEC 30, 2014		U-429	
021312 001	DESLORATADINE; CLARINEX	#6100274	JAN 07, 2020		NCE	DEC 21, 2006
021312 001	DESLORATADINE; CLARINEX	#6100274	JUL 07, 2019		PED	JUN 21, 2007
021312 001	DESLORATADINE; CLARINEX	#4659716*PED	OCT 21, 2004		U-427	
021312 001	DESLORATADINE; CLARINEX	#4804666*PED	AUG 14, 2006		U-428	
021312 001	DESLORATADINE; CLARINEX	#4863931*PED	MAR 15, 2009		U-429	
021312 001	DESLORATADINE; CLARINEX	#5595997*PED	JUN 30, 2015		U-429	
021312 001	DESLORATADINE; CLARINEX	#6100274*PED	JAN 07, 2020		NCE	DEC 21, 2006
021312 001	DESLORATADINE; CLARINEX	#4659716	APR 21, 2004		U-427	JUN 21, 2007
021312 001	DESLORATADINE; CLARINEX	#4659716*PED	OCT 21, 2004		U-427	
021312 001	DESLORATADINE; CLARINEX	#4863931	SEP 15, 2008		U-428	
021312 001	DESLORATADINE; CLARINEX	#4863931*PED	MAR 15, 2009		U-429	
021312 001	DESLORATADINE; CLARINEX	#4804666	FEB 14, 2006		U-428	
021312 001	DESLORATADINE; CLARINEX	#5595997	DEC 30, 2014		U-429	
021312 001	DESLORATADINE; CLARINEX	#5595997*PED	JUN 30, 2015		U-429	
021312 001	DESLORATADINE; CLARINEX	#6100274	JUL 07, 2019		NCE	DEC 21, 2006
021312 001	DESLORATADINE; CLARINEX	#6100274*PED	JAN 07, 2020		PED	JUN 21, 2007

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 # represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020648 001	DIAZEPAM; DIASTAT	#5462740	SEP 17, 2013			
020648 002	DIAZEPAM; DIASTAT	#5462740	SEP 17, 2013			
020648 003	DIAZEPAM; DIASTAT	#5462740	SEP 17, 2013			
020648 004	DIAZEPAM; DIASTAT	#5462740	SEP 17, 2013			
020648 005	DIAZEPAM; DIASTAT	#5288505	JUN 26, 2013	NDF	FEB 06, 2006	
021392 001	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	#5329791	JUN 25, 2013	NDF	FEB 06, 2006	
021392 002	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	#5288505	JUN 25, 2013	NDF	FEB 06, 2006	
021392 003	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	#5288505	JUN 25, 2013	NDF	FEB 06, 2006	
021392 004	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	#5529791	JUN 25, 2013	NDF	FEB 06, 2006	
021392 005	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	#5288505	JUN 26, 2013	NDF	FEB 06, 2006	
021392 006	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	#5529791	JUN 25, 2013	NDF	FEB 06, 2006	
020401 006	DILTAZEM HYDROCHLORIDE; TIAZAC	#5288505	JUN 25, 2013	NDF	FEB 06, 2006	
021168 001	DIVALPROEX SODIUM; DEPAKOTE ER	#6511678	DEC 18, 2018			
021168 002	DIVALPROEX SODIUM; DEPAKOTE ER	#6511678	DEC 18, 2018			
020941 001	DOCOSANOL; AREVA	#4874794	APR 28, 2014			
020624 002	DOLASITRON MESYLATE MONOHYDRATE; ANZEMET	#4906755	JUL 02, 2011			
020624 003	DOLASITRON MESYLATE MONOHYDRATE; ANZEMET	#4906755	JUL 02, 2011			
020972 001	EFAVIRENZ; SUSTIVA	#6555133	APR 06, 2019			
020972 002	EFAVIRENZ; SUSTIVA	#6555133	APR 06, 2019			
020972 003	EFAVIRENZ; SUSTIVA	#6555133	APR 06, 2019			
021360 001	EFAVIRENZ; SUSTIVA	#5663169	SEP 02, 2014	NCE	JUL 02, 2008	
021500 001	EMTRICITABINE; EMTRIVA	#5210085	MAY 1, 2010			
		#5814639	SEP 29, 2015			
		#5914331	SEP 29, 2015			
		#5464933	—			
021481 001	ENFUVIRTIDE; FUZEON	#6133418	JUN 07, 2013			
		#6475491	JUN 07, 2015			
			U-248			
020164 007	ENOXAPARIN SODIUM; LOVENOX	#4692435	DEC 24, 2004			
020164 008	ENOXAPARIN SODIUM; LOVENOX	#4692435	FEB 14, 2012			
020164 009	ENOXAPARIN SODIUM; LOVENOX	#5399530	SEP 14, 2018			
>ADD>						
>ADD>	020796 001	ENTACAPONE; COMTAN				
>ADD>	021565 001	EPINASTINE HYDROCHLORIDE; ELESTAT	#4559132	APR 09, 2004	U-537	OCT 15, 2008
>ADD>	021437 001	EPERENONE; INSPIRA	6558707	DEC 08, 2009	I-407	OCT 07, 2006
>ADD>			#6534093	DEC 08, 2019	I-315	NCE
>ADD>			#6410054	DEC 08, 2019	I-537	
>ADD>			#6495165	DEC 08, 2019	U-537	
>ADD>			#6534093	DEC 18, 2019	U-3	

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA * PED and PED represent Pediatric Exclusivity
 # represents patent information submitted prior to 08/18/03

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	EPLERENONE; INSPRA	#4559332 #6558707 #6495165 #6410054 #6534093 #6534093	APR 09, 2004 DEC 08, 2009 DEC 08, 2019 DEC 08, 2019 DEC 08, 2019 APR 09, 2004	I-407 U-537 U-537 U-537 U-537 I-407	OCT 07, 2006 OCT 07, 2006 OCT 07, 2006 OCT 07, 2006 OCT 07, 2006 OCT 07, 2006	
021437 002	EPLERENONE; INSPRA	#6558707 #6495165 #6410054 #6534093 #6534093	DEC 08, 2019 DEC 08, 2019 DEC 08, 2019 DEC 08, 2019 DEC 08, 2019	I-407 U-537 U-537 U-537 U-537	OCT 07, 2006 OCT 07, 2006 OCT 07, 2006 OCT 07, 2006 OCT 07, 2006	
021437 003	EPLERENONE; INSPRA	#4559332 #6558707 #6410054 #6534093 #6495165 #6534093	APR 09, 2004 DEC 08, 2009 DEC 08, 2019 DEC 08, 2019 DEC 08, 2019 DEC 08, 2019	I-407 U-537 U-537 U-537 U-537 I-407	OCT 07, 2006 OCT 07, 2006 OCT 07, 2006 OCT 07, 2006 OCT 07, 2006 OCT 07, 2006	
021365 001	ESCITALOPRAM OXALATE; LEXAPRO	#RE34712 * PED #4593119	JUN 08, 2009 JUN 03, 2003	DEC 08, DEC 08,	2009 2009	
019386 002	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#5017609 #5017609 * PED #4593119 * PED #5017609 #4593119	MAY 21, 2008 NOV 21, 2008 DEC 03, 2003 MAY 21, 2008 JUN 03, 2003	DEC 08, DEC 08, DEC 08, DEC 08, DEC 08,	2008 2008 2003 2008 2003	
019386 003	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#5017609 * PED #4593119 * PED #6528540 #4593119	NOV 21, 2008 NOV 21, 2008 JUN 03, 2003 JUN 03, 2003	DEC 03, DEC 03, DEC 03, DEC 03,	2003 2003 2003 2003	
019386 004	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#6528540 #6528540 * PED #4593119 * PED #6528540 #4593119	JAN 12, 2021 JUL 12, 2021 JUN 03, 2003 JUN 03, 2003	DEC 03, DEC 03, DEC 03, DEC 03,	2021 2021 2003 2003	
019386 005	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#6310094 #6310094 * PED #6528540 #4593119 * PED #6528540 #4593119	JUL 12, 2021 JUL 12, 2021 JUN 03, 2003 JUN 03, 2003 JUN 03, 2003	DEC 03, DEC 03, DEC 03, DEC 03, DEC 03,	2021 2021 2003 2003 2003	
019386 006	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#6528540 #6528540 * PED #6310094 * PED #4593119 * PED #6528540 #4593119	JAN 12, 2021 JUL 12, 2021 JUL 12, 2021 DEC 03, JAN 12, JUN 03,	DEC 03, DEC 03, DEC 03, DEC 03, DEC 03, JUN 03,	2021 2021 2021 2003 2003 2003	
019386 007	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#6310094 #6310094 * PED #6528540 #4593119 * PED #6310094 #6528540 #4593119	JAN 12, 2021 JUL 12, 2021 JUL 12, 2021 DEC 03, JAN 12, JAN 12, JUN 03,	DEC 03, DEC 03, DEC 03, DEC 03, DEC 03, DEC 03, JUN 03,	2021 2021 2021 2003 2003 2003 2003	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA			*PED and PED represent Pediatric Exclusivity		
APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE
021367 001	ESTRADIOL ACETATE; FEMRING	#5855906	DEC 19, 2015	U-508	MAR 20, 2006
021367 002	ESTRADIOL ACETATE; FEMRING	#5855906	DEC 19, 2015	U-508	MAR 20, 2006
020375 005	ESTRADIOL; CLIMARA	#5223261	JUN 29, 2010	D-82	JUL 16, 2006
020375 006	ESTRADIOL; CLIMARA	#5223261	JUN 29, 2010	D-82	JUL 16, 2006
004782 003	ESTROGENS, CONJUGATED; PREMARIN	#RE36247	MAY 02, 2006	D-79	MAR 12, 2006
004782 006	ESTROGENS, CONJUGATED; PREMARIN	#RE36247	MAY 02, 2006	D-79	MAR 12, 2006
020527 002	ESTROGENS, CONJUGATED; PREMPRO	#RE36247	MAY 02, 2006	D-79	MAR 12, 2006
020527 001	ESTROGENS, CONJUGATED; PREMPRO	#RE36247	MAY 02, 2006	D-79	MAR 12, 2006
020527 003	ESTROGENS, CONJUGATED; PREMPRO	#5210081	FEB 26, 2012	D-81	JUN 04, 2006
020527 004	ESTROGENS, CONJUGATED; PREMPRO	#5210081	FEB 26, 2012	NS	JUN 04, 2006
020527 005	ESTROGENS, CONJUGATED; PREMPRO	#RE36247	MAY 02, 2006	D-81	JUN 04, 2006
021180 001	ETHINYL ESTRADIOL; ORTHO EVRA	#5547948	JAN 17, 2015	U-514	SEP 05, 2006
>ADD>	021544 001	ETHINYL ESTRADIOL; SEASONALE	#5547948	U-514	SEP 05, 2006
>ADD>	020325 002	FAMOTIDINE; PEPCID AC	#6589552	JAN 09, 2018	NP
021203 001	FENOFLIBRATE; TRICOR	#6589552	JAN 09, 2018	NP	
021203 003	FENOFLIBRATE; TRICOR	#4863737	SEP 05, 2006	NP	
020747 001	FENTANYL CITRATE; ACTIQ	#5785989	SEP 05, 2006	NP	
020747 002	FENTANYL CITRATE; ACTIQ	#4863737	SEP 05, 2006	NP	
020747 003	FENTANYL CITRATE; ACTIQ	#4863737	SEP 05, 2006	NP	
020747 004	FENTANYL CITRATE; ACTIQ	#5785989	SEP 05, 2006	NP	
020747 005	FENTANYL CITRATE; ACTIQ	#4863737	SEP 05, 2006	NP	
020747 006	FENTANYL CITRATE; ACTIQ	#5785989	SEP 05, 2006	NP	
019813 001	FENTANYL; DURAGESIC	#4588580 * PED	JUL 23, 2004	U-43	NPP
019813 002	FENTANYL; DURAGESIC	#4588580 * PED	JUL 23, 2004	U-43	PED
019813 003	FENTANYL; DURAGESIC	#4588580 * PED	JUL 23, 2004	U-43	PED
019813 004	FENTANYL; DURAGESIC	#4588580 * PED	JUL 23, 2004	U-43	PED
>ADD>	021626 001	FERRIC HEXACYANOIRONFERRATE (II); RADIOGARDASE (PRUSSI	#5538610	NOV 26, 2013	U-192
>ADD>	020625 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	#585512	FEB 28, 2015	M-25

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
represents patent information submitted prior to 08/18/03 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019958 001	FLUTICASONE PROPIONATE; CULTIVATE	#4335121 #4335121*PED #4335121 #4335121*PED	NOV 14, 2003 MAY 14, 2004 NOV 14, 2003 MAY 14, 2004	D-76 PED M-24	MAY 23, 2005 NOV 23, 2005 MAY 01, 2006 PED	MAY 23, 2005 NOV 23, 2005 MAY 01, 2006 NOV 01, 2006
020121 001	FLUTICASONE PROPIONATE; FLONASE					
020548 001	FLUTICASONE PROPIONATE; FLOVENT					
020548 002	FLUTICASONE PROPIONATE; FLOVENT					
020548 003	FLUTICASONE PROPIONATE; FLOVENT					
020549 001	FLUTICASONE PROPIONATE; FLOVENT					
020549 002	FLUTICASONE PROPIONATE; FLOVENT					
020549 003	FLUTICASONE PROPIONATE; FLOVENT					
020833 001	FLUTICASONE PROPIONATE; FLOVENT DISKUS 50					
020833 002	FLUTICASONE PROPIONATE; FLOVENT DISKUS 100					
020833 003	FLUTICASONE PROPIONATE; FLOVENT DISKUS 250					
020261 001	FLUVASTATIN SODIUM; LESCOL					
020261 002	FLUVASTATIN SODIUM; LESCOL					
021192 001	FLUVASTATIN SODIUM; LESCOL XL					
020961 001	FOMIVIRSEN SODIUM; VITRAVENE PRESERVATI					
021345 001	FONDAPARINUX SODIUM; ARIXTRA					
020831 001	FORMOTEROL FUMARATE; FORADIL					
>ADD>	021548 001 FOSAMPRENAVIR CALCIUM; LEXIVA	#6488027	DEC 08, 2019			
>ADD>	019915 002 FOSINOPRIL SODIUM; MONOPRIL	#6436989 #6514953 #4337201 #5006344 #4337201	JUL 15, 2019 DEC 04, 2002 JUL 10, 2009 JAN 10, 2010 JUN 04, 2003	U-257 U-257 NPP NPP NPP	I-397 I-342 SEP 25, 2004 JUN 27, 2006	JUN 17, 2006 MAY 27, 2006 NOV 27, 2006

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA * PED and PED represent Pediatric Exclusivity
represents patent information submitted prior to 08/18/03

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES		USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			PATENT	PED			
019915 003	FOSINOPRIL SODIUM; MONOPRIL	#4337201 #5006344 #5006344*PED #4337201*PED	DEC 04, 2002 JUL 10, 2009 JAN 10, 2010 JUN 04, 2003	DEC 04, 2002 JUL 10, 2009 JAN 10, 2010 JUN 04, 2003	NPP NPP NPP NPP	MAY 27, NOV 27, MAY 27, NOV 27,	2006 2006 2006 2006
019915 004	FOSINOPRIL SODIUM; MONOPRIL	#4337201 #5006344 #5006344*PED #4337201*PED	DEC 04, 2002 JUL 10, 2009 JAN 10, 2010 JUN 04, 2003	DEC 04, 2002 JUL 10, 2009 JAN 10, 2010 JUN 04, 2003	NPP NPP NPP NPP	MAY 27, NOV 27, MAY 27, NOV 27,	2006 2006 2006 2006
020286 001	FOSINOPRIL SODIUM; MONOPRIL-HCT	#4337201 #5006344 #5006344*PED #4337201*PED	DEC 04, 2002 JUL 10, 2009 JAN 10, 2010 JUN 04, 2003	DEC 04, 2002 JUL 10, 2009 JAN 10, 2010 JUN 04, 2003	PC PC PC PC	FEB 16, FEB 16, OCT 17, OCT 17,	2004 2004 2005 2005
020286 002	FOSINOPRIL SODIUM; MONOPRIL-HCT	#4337201 #5006344 #5006344*PED #4337201*PED	DEC 04, 2002 JUL 10, 2009 JAN 10, 2010 JUN 04, 2003	DEC 04, 2002 JUL 10, 2009 JAN 10, 2010 JUN 04, 2003	PC PC PC PC	FEB 16, FEB 16, OCT 17, OCT 17,	2004 2004 2005 2005
>ADD>	0211489 001	GADOTERIDOL; PROHANCE MULTIPACK	#5474756 #6143274 #4885363 #5846519	DEC 12, 2012 DEC 12, 2012 DEC 05, 2006 DEC 08,	U-536 U-536		
>ADD>	076457 001	GANCICLOVIR; GANCICLOVIR					
076457 002	GANCICLOVIR; GANCICLOVIR						
021061 001	GATIFLOXACIN; TEQUIN						
021061 002	GATIFLOXACIN; TEQUIN						
021062 001	GATIFLOXACIN; TEQUIN						
021062 002	GATIFLOXACIN; TEQUIN						
021062 003	GATIFLOXACIN; TEQUIN						
021062 004	GATIFLOXACIN; TEQUIN						
021493 001	GATIFLOXACIN; ZYMAR						
021399 001	GEFITINTIB; IRESSA						
021158 001	GEMIFLOXACIN MESYLATE; FACTIVE						
>ADD>	0206622 001	GLATIRMER ACETATE; COPAXONE					
>ADD>	0206622 002	GLATIRMER ACETATE; COPAXONE					

represents patent information submitted prior to 08/18/03
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
078467 001 020329 001	GLIPIZIDE; GLIPIZIDE GLIPIZIDE; GLUCOTROL XL	#5091190 #5545413 #5091190 #5545413 #4612008 #502843 #5082668 #5091190	SEP 05, 2009 JUL 21, 2008 SEP 05, 2009 JUL 21, 2008 SEP 16, 2003 SEP 05, 2009 SEP 16, 2003 SEP 05, 2003	PC	OCT 19, 2003	
020329 002 020329 003	GLIPIZIDE; GLUCOTROL XL GLIPIZIDE; GLUCOTROL XL	#5091190 #5545413 #5091190 #5545413 #4612008 #502843 #5082668 #5091190	U-111 U-111 U-111 U-111 U-111 U-111 U-111 U-111			
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021178 001 GLYBURIDE; GLUCOVANCE	#5545413 #5591454 #6303146 #6303146* PED	JUL 21, 2008 JAN 07, 2014 JUL 14, 2019 JAN 14, 2020	U-111 U-111 U-111 U-111		
>ADD> >ADD> >ADD> >ADD>	021178 003 GLYBURIDE; GLUCOVANCE	#6303146* PED 6303146* PED	JUL 14, 2019 JAN 14, 2020	U-412 U-412	NC	JUL 31, 2003 SEP 30, 2005
>ADD> >ADD> >ADD> >ADD>	021178 002 GLYBURIDE; GLUCOVANCE	#6303146 #6303146* PED	JUL 14, 2019 JAN 14, 2020	U-412 U-412	NC	JAN 31, 2004 MAR 30, 2006
>ADD> >ADD> >ADD>	020239 001 GRANISETRON HYDROCHLORIDE; KYTRIL GUAIFENESTIN; MUCINEX	#5952340 #5952340 #6312252 #4619921 #5616599	SEP 14, 2016 SEP 14, 2016 APR 28, 2020 DEC 16, 2004 APR 01, 2014	U-412 U-412	NC	JUL 31, 2003 SEP 30, 2005 JAN 31, 2004 MAR 30, 2006
020239 002 021282 002	HALOBETASOL PROPIONATE; ULTRAVATE	#6312252 #4619921	U-519 U-519			
0219968 001 021532 002	HYDROCHLOROTHIAZIDE; BENICAR HCT	#5616599	U-489			
021532 003 021532 005	HYDROCHLOROTHIAZIDE; BENICAR HCT HYDROCHLOROTHIAZIDE; BENICAR HCT	#5616599 #5616599	U-500		NC	JUN 05, 2006 JUN 05, 2006
020818 003 >ADD>	HYDROCHLOROTHIAZIDE; DIOVAN HCT HYDROCHLOROTHIAZIDE; HYZAAR	#5616599 #5399578 #6294197 #5153197* PED	APR 01, 2014 MAR 21, 2012 JUN 18, 2017 APR 06, 2010	U-500 U-3 U-3 U-3	NC NC NCE NCE	JUN 05, 2006 APR 25, 2007 JUN 05, 2006 APR 25, 2007
020387 001 >ADD>	HYDROCHLOROTHIAZIDE; HYZAAR	#5153197 #5153197* PED	OCT 06, 2009 APR 06, 2010	OCT 06, 2009 APR 06, 2010	U-538 U-538	
020387 002 >ADD>	HYDROCHLOROTHIAZIDE; HYZAAR	#6358986 #6599531	JAN 10, 2020 JUN 10, 2017	JAN 10, 2020 JUN 10, 2017	U-538 U-538	
021162 001 021162 002	HYDROCHLOROTHIAZIDE; MICARDIS HCT HYDROCOdone BITARTRATE; MICARDIS HCT	#4794106 #4927814 #6143326 #6294196	AUG 28, 2006 JUL 09, 2007 APR 21, 2017 OCT 07, 2019	U-520 U-520 U-520 U-520	NCE	MAY 16, 2008
020716 001 020453 001 021455 001	HYDROCOFTISONE PROBUTATE; PAMEL IBANDRONATE SODIUM; BONIVA					

represents patent information submitted prior to 08/18/03
 PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021472 001 021321 001	IBUPROFEN; IBUPROFEN ICODEXTRIN; EXTRANEAL	#6251426 #6248726 #4761237 #4886789 #6077836	JUN 25, 2018 JUN 19, 2018 AUG 02, 2005 DEC 12, 2006 JUN 20, 2017	U-495 U-495 U-495 U-495 U-495	ODE	DEC 20, 2009
021335 001 021335 002 021588 001	IMATINIB MESYLATE; GLEEVEC IMATINIB MESYLATE; GLEEVEC IMATINIB MESYLATE; GLEEVEC	#5521184	MAY 28, 2013	I-392 I-392 I-392	NCE NCE NCE	MAY 20, 2006 MAY 20, 2006 MAY 10, 2006
021588 002	IMATINIB MESYLATE; GLEEVEC	#5521184	MAY 28, 2013	I-392 I-376	NCE ODE	MAY 20, 2006 FEB 01, 2009
>ADD> >ADD> >ADD> >ADD>	IMIGLUCERASE; CEREZYME INSULIN GLARGINE; LANTUS INSULIN LISPRO; HUMALOG INSULIN LISPRO; HUMALOG PEN	#5474978 #5514646 #5474978 #5514646 #4364921 #4364921 #5110493 #5110493 #5047407*PED #5047407 #5047407 #5047407 #5047407*PED #5047407*PED	AUG 27, 2013 JUN 16, 2014 MAY 07, 2013 JUN 16, 2014 MAY 07, 2013 MAR 06, 2005 MAR 06, 2005 MAY 05, 2009 NOV 05, 2009 MAY 17, 2010 NOV 17, 2009 NOV 17, 2009 MAY 17, 2010 NOV 17, 2009 MAY 17, 2010	U-252 U-252 D-80	MAY 01, 2006 I-392 MAY 20, 2006	MAY 01, 2006 MAY 10, 2008 MAY 20, 2006
021081 001 020563 001	KETOROLAC TROMETHAMINE; ACULAR LS					
021425 001 021425 002 021528 001	TOPROMIDE; ULTRAVIST (PHARMACY TOPROMIDE; ULTRAVIST (PHARMACY KETOROLAC TROMETHAMINE; ACULAR LS					
020857 001	LAMIVUDINE; COMBIVIR					
021003 001	LAMIVUDINE; EPIVIR-HEV					
021004 001	LAMIVUDINE; EPIVIR-HEV					
020241 001	LAMOTRIGINE; LAMICTAL					
020241 002	LAMOTRIGINE; LAMICTAL					
020241 003	LAMOTRIGINE; LAMICTAL					
020241 004	LAMOTRIGINE; LAMICTAL					
020241 005	LAMOTRIGINE; LAMICTAL					
020241 006	LAMOTRIGINE; LAMICTAL					

PRESCRIPTION AND OTC DRUG PRODUCT™
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020764 001	LAMOTRIGINE; LAMICTAL CD				I-387	JAN 17, 2006
020764 002	LAMOTRIGINE; LAMICTAL CD	#5013743	JUL 29, 2005 FEB 12, 2010	U-126 U-452	I-404	JUN 20, 2006
020764 003	LAMOTRIGINE; LAMICTAL CD	#5026560	JUN 25, 2008		I-387	JAN 17, 2006
020764 004	LAMOTRIGINE; LAMICTAL CD	#5093132	SEP 03, 2008		I-404	JUN 20, 2006
021281 001	LANSOPRAZOLE; PREVACID	#545321	SEP 03, 2008		I-387	JAN 17, 2006
		#5433959	SEP 03, 2008		I-404	JUN 20, 2006
021281 002	LANSOPRAZOLE; PREVACID	#4628098	MAY 10, 2009		I-395	JUN 13, 2006
		#4689333	JUL 29, 2005 FEB 12, 2010	U-452	I-395	JUN 13, 2006
		#5013743	JUN 25, 2008		I-395	JUN 13, 2006
		#5026560	SEP 03, 2008		I-395	JUN 13, 2006
		#5093132	SEP 03, 2008		I-395	JUN 13, 2006
		#545321	SEP 03, 2008		I-395	JUN 13, 2006
		#5433959	SEP 03, 2008		I-395	JUN 13, 2006
020905 001	LEFLUNOMIDE; ARAVA	#4938763	OCT 03, 2008	OCT 03, 2008	I-395	JUN 13, 2006
020905 002	LEFLUNOMIDE; ARAVA	#5278201	JAN 11, 2011	OCT 20, 2011	I-395	JUN 13, 2006
020905 003	LEFLUNOMIDE; ARAVA	#5324519	FEB 04, 2014	OCT 03, 2008	I-395	JUN 13, 2006
021488 001	LEUPROLIDE ACETATE; ELIGARD	#5599552	OCT 03, 2008	OCT 03, 2008	I-395	JUN 13, 2006
		#5733950	NOV 08, 2011	NOV 08, 2011	I-395	FEB 13, 2006
		#5739176	OCT 03, 2008	OCT 03, 2008	I-395	
		#5362755	JUN 06, 2006	JUN 06, 2006	I-395	
		#4943639	JUN 06, 2006	JUN 06, 2006	I-395	
		#4943639	JUN 06, 2006	JUN 06, 2006	I-395	
		#4443639	JUN 06, 2006	JUN 06, 2006	I-395	
		#4837223	JUN 06, 2006	JUN 06, 2006	I-395	
020837 001	LEVALBUTEROL HYDROCHLORIDE; XOPENEX				I-393	MAY 23, 2006
021035 001	LEVETIRACETAM; KEPRA	#5739176	OCT 03, 2008	OCT 03, 2008	D-83	OCT 23, 2006
021035 002	LEVETIRACETAM; KEPRA	#5362755	NOV 08, 2011	NOV 08, 2011	I-393	MAY 23, 2006
021035 003	LEVETIRACETAM; KEPRA	#4943639	JUN 06, 2006	JUN 06, 2006	D-83	OCT 23, 2006
021505 001	LEVETIRACETAM; KEPRA	#4943639	JUN 06, 2006	JUN 06, 2006	I-393	MAY 23, 2006
020634 001	LEVOFLOXACIN; LEVAQUIN	#4837223	JUN 06, 2006	JUN 06, 2006	D-83	OCT 23, 2006
>ADD>					I-393	MAY 23, 2006
>ADD>	020634 002	LEVOFLOXACIN; LEVAQUIN			D-83	OCT 23, 2006
>ADD>	020634 003	LEVOFLOXACIN; LEVAQUIN			I-393	MAY 23, 2006
>ADD>	020635 001	LEVOFLOXACIN; LEVAQUIN			D-83	OCT 23, 2006
>ADD>					I-393	OCT 23, 2006

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03

* PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020635 004	LEVOFLOXACIN; LEVAQUIN	#5053407	DEC 20, 2010		I-393	MAY 23, 2006
>ADD> 020635 002	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				D-83	OCT 23, 2006
>ADD> 020635 003	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				I-393	MAY 23, 2006
>ADD> 020635 005	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE				D-83	OCT 23, 2006
>ADD> 021199 001	LEVOFLOXACIN; QUIXIN	#5053407	DEC 20, 2010		I-393	MAY 23, 2006
>ADD> 021301 001	LEVOTHYROXINE SODIUM; LEVOXYL	#5053407	DEC 20, 2010		D-83	OCT 23, 2006
>ADD> 021301 002	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		I-393	MAY 23, 2006
>ADD> 021301 003	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		D-83	OCT 23, 2006
>ADD> 021301 004	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		I-393	MAY 23, 2006
>ADD> 021301 005	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		D-83	OCT 23, 2006
>ADD> 021301 006	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		I-393	MAY 23, 2006
>ADD> 021301 007	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		D-83	OCT 23, 2006
>ADD> 021301 008	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		I-393	MAY 23, 2006
>ADD> 021301 009	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		D-83	OCT 23, 2006
>ADD> 021301 010	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		I-393	MAY 23, 2006
>ADD> 021301 011	LEVOTHYROXINE SODIUM; LEVOXYL	#6555581	FEB 15, 2022		D-83	OCT 23, 2006
>ADD> 021301 012	LEVOTHYROXINE SODIUM; LEVOXYL	#5589180	MAR 17, 2009	U-485	I-402	JUL 22, 2005
020612 001	LIDOCaine; LIDODERM	#5411738	MAY 02, 2012		NPP	DEC 19, 2005
		#58217529	OCT 27, 2015		I-402	JUL 22, 2005
		#5709869	MAR 17, 2009		NPP	DEC 19, 2005
		#55601838	MAY 02, 2012		NPP	DEC 19, 2005
		#66559305	JAN 29, 2021		NPP	DEC 19, 2005
		#66559305	JAN 29, 2021		NPP	DEC 19, 2005
		#66559305	JAN 29, 2021		NPP	DEC 19, 2005
021130 001	LINEZOLID; ZYVOX	#6559305	JAN 29, 2021		NPP	DEC 19, 2005
021130 002	LINEZOLID; ZYVOX	#6559305	JAN 29, 2021		NPP	DEC 19, 2005
021131 001	LINEZOLID; ZYVOX	#6559305	JAN 29, 2021		NPP	DEC 19, 2005
021132 001	LINEZOLID; ZYVOX	#6559305	JAN 29, 2021		NPP	DEC 19, 2005
019558 001	LISINOPRIL; PRINIVIL				PED	NOV 29, 2006
019558 002	LISINOPRIL; PRINIVIL				NPP	MAY 29, 2006
019558 003	LISINOPRIL; PRINIVIL				PED	NOV 29, 2006
019558 004	LISINOPRIL; PRINIVIL				NPP	MAY 29, 2006
019558 006	LISINOPRIL; PRINIVIL				NPP	MAY 29, 2006
019777 001	LISINOPRIL; ZESTRIL				PED	NOV 29, 2006
					NPP	MAY 29, 2006

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL / PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT / PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019777 002	LISINOPRIL;ZESTRIL				PED	NOV 29, 2006
019777 003	LISINOPRIL;ZESTRIL			NPP	MAY 29, 2006	
019777 004	LISINOPRIL;ZESTRIL			PED	NOV 29, 2006	
019777 005	LISINOPRIL;ZESTRIL			NPP	MAY 29, 2006	
019777 006	LISINOPRIL;ZESTRIL			PED	NOV 29, 2006	
021226 001	LOPINAVIR;KALETRA LORATADINE;CLARITIN	#6521651 #4659716 #4659716*PED	NOV 01, 2017 APR 21, 2004 OCT 21, 2004	U-142 U-142		
019658 002	LORATADINE;CLARITIN	#4863931 #4863931*PED	SEP 15, 2008 MAR 15, 2009			
020641 002	LORATADINE;CLARITIN REDDITABS	#4659716 #4863931 #4863931*PED	APR 21, 2004 OCT 21, 2004 SEP 15, 2008	U-142 U-142 U-142		
020704 002	LORATADINE;CLARITIN-D	#61124758 #4659716 #4659716*PED	JUN 01, 2018 APR 21, 2004 OCT 21, 2004	U-142 U-142 U-142		
019670 002	LORATADINE;CLARITIN-D	#4659716 #4863931 #4863931*PED	MAR 15, 2009 APR 21, 2004 OCT 21, 2004	U-142 U-142 U-142		
020470 002	LORATADINE;CLARITIN-D 24 HOUR	#4863931 #4659716 #4659716*PED	SEP 15, 2008 APR 21, 2004 OCT 21, 2004	U-142 U-142 U-142		
075209 001	LORATADINE;LORATADINE LORATADINE;LORATADINE AND PSEUD LORATADINE;LORATADINE AND PSEUD LOSARTAN POTASSIUM;COZAAR	#5314697 #5314697*PED	OCT 23, 2012 APR 23, 2013		PC	JUL 21, 2003
075822 001					PC	AUG 09, 2003
075706 001					PC	NOV 29, 2003
076050 001					PC	JUL 30, 2003
020386 001					I-383	SEP 17, 2005
020386 002	LOSARTAN POTASSIUM;COZAAR	#5210079 #5210079*PED	MAY 11, 2010 NOV 11, 2010	U-496 U-496	I-383	SEP 17, 2005
020386 003	LOSARTAN POTASSIUM;COZAAR	#5210079 #5210079*PED	MAY 11, 2010 NOV 11, 2010	U-496 U-496	I-383	SEP 17, 2005
		#5210079*PED	NOV 11, 2010	U-496		

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APL / PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT / PED EXPLIES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
021487 001	MEMANTINE HYDROCHLORIDE; NAMENDA	NCE	OCT 16,	2008	NCE	OCT 16,
>ADD>	MEMANTINE HYDROCHLORIDE; NAMENDA					
021487 002	MEMANTINE HYDROCHLORIDE; NAMENDA	NCE	OCT 16,	2008	NCE	OCT 16,
>ADD>	MEMANTINE HYDROCHLORIDE; NAMENDA					
021487 003	MEMANTINE HYDROCHLORIDE; NAMENDA	NCE	OCT 16,	2008	NCE	OCT 16,
>ADD>	MEMANTINE HYDROCHLORIDE; NAMENDA					
021487 004	MEMANTINE HYDROCHLORIDE; NAMENDA	NCE	OCT 16,	2008	NCE	OCT 16,
021410 001	METFORMIN HYDROCHLORIDE; AVANDAMET	NCE	MAY 25,	2004	NCE	MAY 25,
021410 002	METFORMIN HYDROCHLORIDE; AVANDAMET	NCE	MAY 25,	2004	NCE	MAY 25,
021410 003	METFORMIN HYDROCHLORIDE; AVANDAMET	NCE	MAY 25,	2004	NCE	MAY 25,
021410 004	METFORMIN HYDROCHLORIDE; AVANDAMET	NCE	MAY 25,	2004	NCE	MAY 25,
021410 005	METFORMIN HYDROCHLORIDE; AVANDAMET	NDF	OCT 13,	2003	NDF	APR 03,
021202 004	METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	#6475521	MAR 19,	2018	NDF	OCT 27,
021259 002	METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	#6344215	OCT 27,	2020	NDF	OCT 27,
021259 003	METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	#6344215	MAY 22,	2007	NDF	MAY 22,
019962 003	METOPROLOL SUCCINATE; TOPROL-XL	#4927640	MAY 13,	2013	NCE	JUL 31,
021348 001	MIGLUSTAT; ZAVESCA	#5472999	MAY 13,	2013	ODE	JUL 31,
		#5525616	JUN 11,	2013	PC	JUN 16,
076119 001	MIRTAZAPINE; MIRTAZAPINE					
076119 002	MIRTAZAPINE; MIRTAZAPINE					
076204 001	MOXIPRIL HYDROCHLORIDE; MOXIPRIL HCL					
076204 002	MOXIPRIL HYDROCHLORIDE; MOXIPRIL HCL					
021085 001	MOXIFLOXACIN HYDROCHLORIDE; AVELOX	#4990517	JUN 30,	2009	U-298	U-298
021277 001	MOXIFLOXACIN HYDROCHLORIDE; AVELOX IN SODIUM CHL	#5607942	MAR 04,	2014	U-298	U-298
		#5849752	DEC 05,	2016		
021598 001	MOXIFLOXACIN HYDROCHLORIDE; VIGAMOX	#4990517	JUN 30,	2009	NDF	APR 15,
		#4990517	MAR 04,	2014	PED	OCT 15,
		#5607942	MAR 04,	2014		
		#5849752	MAR 04,	2014		
		#5849752	DEC 05,	2016		
		#4990517* PED	DEC 30,	2009		
		#5607942* PED	DEC 30,	2009		
		#5849752* PED	DEC 30,	2009		
021204 001	NATEGLINIDE; STARLIX	#5849752	JUN 05,	2017		
021204 002	NATEGLINIDE; STARLIX	#6559188	SEP 17,	2019		
020778 001	NELFINAVIR MESYLATE; VIRACEPT	#6559188	SEP 17,	2019		
		#5484926	OCT 07,	2013		
		#5484926	OCT 07,	2013		
		#5952343	OCT 07,	2013		
		#6162812	OCT 07,	2013		
		#6162812	OCT 07,	2013		
		5952343* PED	APR 07,	2014		
		5484926* PED	APR 07,	2014		
		6162812* PED	APR 07,	2014		
		6162812* PED	APR 07,	2014		
		#5484926	OCT 07,	2013		
		#5952343	OCT 07,	2013		
		#6162812	OCT 07,	2013		
		5484926* PED	APR 07,	2014		
		5952343* PED	APR 07,	2014		
		6162812	APR 07,	2014		
		6162812* PED	APR 07,	2014		
020779 001	NELFINAVIR MESYLATE; VIRACEPT	#5484926	OCT 07,	2013		
021503 001	NELFINAVIR MESYLATE; VIRACEPT	#5484926	OCT 07,	2013		
		#5484926	OCT 07,	2013		
		#5484926	OCT 07,	2013		
		#5952343	OCT 07,	2013		
		#5952343	OCT 07,	2013		
		5952343* PED	APR 07,	2014		
		6162812	APR 07,	2014		
		6162812* PED	APR 07,	2014		

PRESCRITION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL / PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020636 001	NEVTRAPINE; VIRAMUNE	#5366972	NOV 22, 2011			U-167
020933 001	NEVTRAPINE; VIRAMUNE	#5366972* PED	MAY 22, 2012			
021330 001	NICOTINE POLACRILEX; COMMIT	#5366972	NOV 22, 2011			
021330 002	NICOTINE POLACRILEX; COMMIT	#5366972* PED	MAY 22, 2012			
020076 004	NICOTINE; HABITROL	#5110605	AUG 21, 2010			
020076 005	NICOTINE; HABITROL	#5110605	AUG 21, 2010			
020076 006	NICOTINE; HABITROL	#4597961	JAN 23, 2005			U-56
019983 003	NICOTINE; PROSTEP	#5016652	MAY 21, 2008			
019983 004	NICOTINE; PROSTEP	#4597961	JAN 23, 2005			U-56
021498 001	NITAZOXANIDE; ALINTA	#5016652	MAY 21, 2008			
021232 001	NITISINONE; ORFADIN	#4597961	JAN 23, 2005			U-56
021232 002	NITISINONE; ORFADIN	#5016652	MAY 21, 2008			
021232 003	NITISINONE; ORFADIN	#4944853	AUG 07, 2007			U-56
020845 002	NITRIC OXIDE; INOMAX	#4944853	AUG 07, 2007			
020845 003	NITRIC OXIDE; INOMAX	#4946853	FEB 07, 2012			U-524
020799 001	OFLOXACIN; FLOXIN	#5387598	SEP 08, 2014			U-525
>ADD>	OFLOXACIN; OCUFLOX	#5578621	JUL 03, 2017			
020592 001	OLANZAPINE; ZYPREXA	#5966590				
020592 002	OLANZAPINE; ZYPREXA	#59888961	MAY 07, 2017			
020592 003	OLANZAPINE; ZYPREXA	#6020353	SEP 08, 2014			
020592 004	OLANZAPINE; ZYPREXA	#6117894	MAY 07, 2017			
020592 005	OLANZAPINE; ZYPREXA	#5006158	APR 09, 2008			
020592 006	OLANZAPINE; ZYPREXA	#550165	AUG 27, 2013			
021286 001	OLMESARTAN MEDOXMIL; BENEVAS	#5006158	APR 09, 2008			
021286 003	OLMESARTAN MEDOXMIL; BENICAR	#550165	AUG 27, 2013			
021286 004	OLMESARTAN MEDOXMIL; BENICAR	#5871359	AUG 27, 2013			
021229 001	OMEPRAZOLE MAGNESTUM; PRILOSEC	#5871359	JAN 23, 2013			
020592 001	OLANZAPINE; ZYPREXA	#4382892	SEP 02, 2003			
020592 002	OLANZAPINE; ZYPREXA	#4551456	NOV 14, 2003			
020592 003	OLANZAPINE; ZYPREXA	#4382892* PED	MAR 02, 2004			
020592 004	OLANZAPINE; ZYPREXA	#4551456* PED	MAY 14, 2004			
020592 005	OLANZAPINE; ZYPREXA					
021286 002	OLMESARTAN MEDOXMIL; BENEVAS					
021286 003	OLMESARTAN MEDOXMIL; BENICAR					
021286 004	OLMESARTAN MEDOXMIL; BENICAR					
021229 001	OMEPRAZOLE MAGNESTUM; PRILOSEC					
020592 001	OLANZAPINE; ZYPREXA	#5616599	APR 01, 2014			
020592 002	OLANZAPINE; ZYPREXA	#5616599	APR 01, 2014			
020592 003	OLANZAPINE; ZYPREXA	#5616599	APR 01, 2014			
020592 004	OLANZAPINE; ZYPREXA	#4738974	APR 19, 2005			
020592 005	OLANZAPINE; ZYPREXA	#5900424	MAY 04, 2016			
021286 001	OLMESARTAN MEDOXMIL; BENEVAS	#4786505	APR 20, 2007			
021286 003	OLMESARTAN MEDOXMIL; BENICAR	#4853230	APR 20, 2007			
021286 004	OLMESARTAN MEDOXMIL; BENICAR	#5690960	NOV 05, 2014			
021229 001	OMEPRAZOLE MAGNESTUM; PRILOSEC	#5753265	OCT 06, 2015			
020592 001	OLANZAPINE; ZYPREXA	#603616	JUN 07, 2015			
021286 001	OLMESARTAN MEDOXMIL; BENEVAS	#6428810	NOV 15, 2019			
021286 003	OLMESARTAN MEDOXMIL; BENICAR	#4786505* PED	NOV 03, 2019			
021229 001	OMEPRAZOLE MAGNESTUM; PRILOSEC	#4853230* PED	OCT 20, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020007 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN PRESERVATIVE	#4695578 #4753789 #4598089 #6004996*PED 4598089*PED #6030643	JAN 25, 2005 JUN 24, 2006 JUN 18, 2009 JAN 06, 2018 DEC 18, 2009 JUL 06, 2018 MAY 16, 2017	U-44 NCE PED	APR 23, 2004 OCT 23, 2004	NCE PED
020766 001	ORLISTAT; XENICAL					
020776 001	OXaprozin potassium chloride; DAYPRO ALTA					
017577 001	OXYBUTYNIN CHLORIDE; DITROPAN					
018211 001	OXYBUTYNIN CHLORIDE; DITROPAN XL					
020897 001	OXYBUTYNIN CHLORIDE; DITROPAN XL					
020897 002	OXYBUTYNIN CHLORIDE; DITROPAN XL					
020897 003	OXYBUTYNIN CHLORIDE; DITROPAN XL					
021351 002	OXYBUTYNIN; OXYTROL					
021372 001	PALONOSETRON HYDROCHLORIDE; ALOXI					
020987 001	PANTOPRAZOLE SODIUM; PROTONIX					
020987 002	PANTOPRAZOLE SODIUM; PROTONIX					
020988 001	PANTOPRAZOLE SODIUM; PROTONIX IV					
075356 001	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL					
075356 002	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL					
075356 003	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL					
075356 004	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL					
>ADD>	020936 001	PAROXETINE HYDROCHLORIDE; PAXIL CR				
>ADD>	020936 002	PAROXETINE HYDROCHLORIDE; PAXIL CR				
>ADD>	020936 003	PAROXETINE HYDROCHLORIDE; PAXIL CR				
021299 001	PAROXETINE MESYLATE; PAROXETINE MESYLATE					
021299 002	PAROXETINE MESYLATE; PAROXETINE MESYLATE					
021299 003	PAROXETINE MESYLATE; PAROXETINE MESYLATE					
021299 004	PAROXETINE MESYLATE; PAROXETINE MESYLATE					

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020413 001	STAVUDINE; ZERIT	#4978655 #4978655 * PED	JUN 24, 2008 DEC 24, 2008			
021453 001	STAVUDINE; ZERIT XR	#4978655 #4978655 * PED	JUN 24, 2008 DEC 24, 2008	U-248 U-248	NDF NDF	DEC 31, 2005 JUL 01, 2006
021453 002	STAVUDINE; ZERIT XR	#4978655 #4978655 * PED	JUN 24, 2008 DEC 24, 2008	U-248 U-248	PED NDF	DEC 31, 2005 JUL 01, 2006
021453 003	STAVUDINE; ZERIT XR	#4978655 #4978655 * PED	JUN 24, 2008 DEC 24, 2008	U-248 U-248	PED NDF	DEC 31, 2005 JUL 01, 2006
021453 004	STAVUDINE; ZERIT XR	#4978655 #4978655 * PED	JUN 24, 2008 DEC 24, 2008	U-248 U-248	PED NDF	DEC 31, 2005 JUL 01, 2006
020600 001	TAZAROTENE; TAZORAC	#5914334 #6258830	JUN 07, 2014 JUN 07, 2014	U-248 U-517	PED JUL 01, 2005	JUL 01, 2005
020600 002	TAZAROTENE; TAZORAC	#5914334 #6258830	JUN 07, 2014 JUN 07, 2014	U-517 U-517		
020372 001	TECHNETIUM TC-99M TETRASFOSMIN KIT; MYOVIEW	#6358986 #6358986 #5591762	JAN 10, 2020 JAN 10, 2020 JAN 07, 2014	U-3	NCE	NOV 10, 2003
020850 001	TELmisartan; MICARDIS	#6358986	JAN 10, 2020			
020850 002	TELmisartan; MICARDIS	#5591762	JAN 07, 2014			
020850 003	TELmisartan; MICARDIS	#6358986	JAN 10, 2020			
021356 001	TENOFOVIR DISOPROXIL FUMARATE; VIREAD	#6121314 #6121314 #4863970	MAY 18, 2012 MAY 18, 2012 NOV 14, 2006	U-502 U-504	NPP	AUG 15, 2006
020749 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	#5152997	NOV 12, 2007			
021124 001	TERBINAFINE HYDROCHLORIDE; LAMISIL AT	#5164190	DEC 11, 2010			
020489 001	TESTOSTERONE; ANDRODERM	#4849224 #4855294 #4849224	NOV 12, 2007 SEP 06, 2008 NOV 12, 2007	U-490		
020489 002	TESTOSTERONE; ANDRODERM	#4855294 #4863970 #4983395	SEP 06, 2008 NOV 14, 2006 NOV 12, 2007			
021543 001	TESTOSTERONE; STRIANT	#5152997 #5164190 #4615697	DEC 11, 2010 DEC 11, 2010 OCT 07, 2003	U-490		
021454 001	TESTOSTERONE; TESTIM	#6248358	AUG 23, 2019	U-527	NP	JUN 19, 2006
020785 001	THALIDOMIDE; THALOMID	#6561977 #6561976 #6045501	OCT 23, 2020 AUG 28, 2018 AUG 28, 2018	U-371 U-371 U-371	NP	OCT 31, 2005
020785 002	THALIDOMIDE; THALOMID	#6315720 #6561977 #6561976 #6045501	OCT 23, 2020 AUG 23, 2020 AUG 28, 2018 AUG 28, 2018	U-442 U-371 U-371 U-371	ODE NCE ODE NCE	JUL 16, 2005 JUL 16, 2003
020785 003	THALIDOMIDE; THALOMID	#6315720 #6561977 #6561976 #6045501	OCT 23, 2020 AUG 23, 2020 AUG 28, 2018 AUG 28, 2018	U-442 U-371 U-371 U-371	ODE NCE ODE NCE	JUL 16, 2005 JUL 16, 2003

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
represents patent information submitted prior to 08/18/03 *PED and PED represent pediatric exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPRES
>ADD> >ADD>	020699 003 VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	#6444708 #6444708*PED #6419958 #6419958*PED #6403120 #6403120*PED #6444708 #6444708*PED #6419958 #6419958*PED #6403120 #6403120*PED #4612008 #6146662 #4612008 #6146662 #5116844 #5366938 #5567817 #5773443 #5116844 #5366938 #5567817 #5773443 #5773443 #5116844 #5364938 #5567817 #5773443 #4626538 #4626538 #4777163 #4939130	JUN 28, 2013 DEC 28, 2013 MAR 20, 2017 SEP 20, MAR 20, 2017 SEP 20, JUN 28, 2013 DEC 28, 2013 MAR 20, 2017 SEP 20, MAR 20, 2017 SEP 20, JUN 28, 2013 DEC 28, 2013 MAR 20, 2017 SEP 20, MAR 20, 2017 SEP 20, SEP 16, 2003 AUG 14, AUG 14, AUG 14, AUG 11, NOV 15, OCT 22, JAN 25, JAN 25, AUG 11, NOV 15, OCT 22, JAN 25, JAN 25, JUN 06, JUN 06, JUL 24, NOV 13,	I-261 U-398 U-398 U-535 U-535 U-535 I-261 U-398 U-398 U-535 U-535 U-535 U-535 U-535 U-535 U-535 U-535 U-535 U-366 U-366 U-366 U-366	FEB 11, 2006	
>ADD> >ADD>	020699 004 VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR					
>ADD> >ADD>	020552 001 VERAPAMIL HYDROCHLORIDE; COVERA-HS					
>ADD> >ADD>	020552 002 VERAPAMIL HYDROCHLORIDE; COVERA-HS					
>ADD> >ADD>	021266 001 VORTICONAZOLE; VFEND					
>ADD>	021266 002 VORTICONAZOLE; VFEND					
>ADD>	021266 001 VORTICONAZOLE; VFEND					
>ADD>	021267 001 VORTICONAZOLE; VFEND					
>ADD>	020859 001 ZALEPLON; SONATA					
>ADD>	020859 002 ZALEPLON; SONATA					
>ADD>	021223 002 ZOLEDRONIC ACID; ZOMETA					
>ADD>	021450 004 ZOLMITRIPTAN; ZOMIG					
>ADD>	021231 002 ZOLMITRIPTAN; ZOMIG-ZMT					
>ADD>	020789 002 ZONISAMIDE; ZONEGRAN					
>ADD>	020789 003 ZONISAMIDE; ZONEGRAN					

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 23RD EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

PATENT & EXCLUSIVITY ABBREVIATIONS

RTO RX TO OTC SWITCH OR OTC USE

EXCLUSIVITY DOSING SCHEDULE

- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS

EXCLUSIVITY INDICATION

- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN \geq 2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
- I-391 INTENTIONALLY LEFT BLANK
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS

- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
 I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
 I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
 I-398 IDIOPATHIC SHORT STATURE
 I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
 I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
 I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
 I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
 I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
 I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
 I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
 I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPositive/RECIPIENT CMV SERONEgative)
 I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
 I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)

EXCLUSIVITY MISCELLANEOUS

- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
 M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
 M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
 M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
 M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY

PATENT USE

- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
 U-495 PERITONEAL DIALYSIS SOLUTION
 U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
 U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
 U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
 U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
 U-500 USE AS AN ANTIHYPERTENSIVE AGENT
 U-501 TREATMENT OF RECURRENT HERPES LABialis (COLD SORES) IN ADULTS
 U-502 PITYRIASIS VERSICOLOR
 U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
 U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
 U-505 ULTRASOUND CONTRAST AGENT
 U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM

- ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
- U-518 OBSESSIVE COMPULSIVE DISORDER
- U-519 POST OPERATIVE NAUSEA AND VOMITING
- U-520 PREMENOPAUSAL OSTEOPOROSIS
- U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
- U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED
- U-524 METHOD OF TREATING DIARRHEA
- U-525 METHOD OF TREATING PARASITIC INFECTIONS
- U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
- U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
- U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
- U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
- U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
- U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
- U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
- U-533 ERECTILE DYSFUNCTION
- U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
- U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
- U-536 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
- U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
- U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
- U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE



United States Government
INFORMATION
PUBLICATIONS • PERIODICALS • ELECTRONIC PRODUCTS

Order Processing
Code: **8392**

YES, enter my subscription(s) as follows:

____ subscription(s) of the **Approved Drug products with Therapeutic Equivalence Evaluations, ADP**, and the monthly Cumulative Supplements, for \$108.00 per year. The total cost of my order is \$ _____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.



Personal name _____
(Please type or print)

Company name _____

Street address _____

Daytime phone including area code _____

Purchase Order Number _____

Authorizing signature _____

02/03

Approved Drug Products, ADP SUBSCRIPTION ORDER FORM



Easy Secure Internet:
bookstore.gpo.gov

Toll Free: 866 512-1800
Phone: 202 512-1800
Fax: 202 512-2250

Mail: Superintendent of Documents

PO Box 371954

Pittsburgh, PA 15250-7954



- Check method of payment:
- Check payable to Superintendent of Documents
 - SOD Deposit Account —
 - VISA MasterCard Discover/NOVUS American Express



(expiration date)

Thank you for your order!